

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/12, C07K 14/47, 16/18, C12Q 1/68, G01N 33/53, 33/574, A61K 38/17, 39/395, 48/00, A61P 35/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/50595</b> <b>(43) International Publication Date:</b> 31 August 2000 (31.08.00)
<b>(21) International Application Number:</b> PCT/US00/04929 <b>(22) International Filing Date:</b> 25 February 2000 (25.02.00)  <b>(30) Priority Data:</b> 09/257,417      25 February 1999 (25.02.99)      US  <b>(71)(72) Applicants and Inventors:</b> GOUT, Ivan [UA/GB]; Ludwig Institute for Cancer Research, Coutauld Building, 91 Riding House St., London W2 1PG (GB). RÖDNIN, Nikolay [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). FILONENKO, Valery [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). MATSUKA, Genadiy [UA/UA]; Institute of Molecular Biology and Genetics, 150 Zabolotny St., Kyiv, 143 (UA). SCANLAN, Matthew [US/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US). OLD, Lloyd [US/US]; Ludwig Institute for Cancer Research, 605 3rd Avenue, 33rd Floor, New York, NY 10158 (US). BILYNSKY, Boris [UA/UA]; Lviv State Medical University, Dept. of Oncology, 69 Pekarska St., Lviv, 290010 (UA).	<b>(74) Agents:</b> DIGIGLIO, Frank, S. et al.; Scully, Scott, Murphy & Presser, 400 Garden City Plaza, Garden City, NY 11530 (US).  <b>(81) Designated States:</b> AU, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> NUCLEIC ACID MOLECULES ASSOCIATED WITH MELANOMA AND THYROID TUMORS  <b>(57) Abstract</b>  The present invention relates to isolated nucleic acid molecules associated with melanoma or thyroid tumors and compositions derived therefrom. The present invention further relates to methods for diagnosing and treating melanoma, thyroid tumors and other related pathological conditions such as rectal cancer, lung cancer, breast cancer and colon cancer, by employing such nucleic acid molecules and compositions.		

Best Available Copy

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NUCLEIC ACID MOLECULES ASSOCIATED  
WITH MELANOMA AND THYROID TUMORS

**FIELD OF THE INVENTION**

5           This invention relates to isolated nucleic acid molecules associated with melanoma and thyroid tumors as well as uses thereof for diagnosing and treating melanoma and thyroid tumors.

10          **BACKGROUND OF THE INVENTION**

          Recent advances in the understanding of the molecular mechanisms of antigen recognition have led to many novel immunotherapy approaches for the treatment of human cancer. One approach is by stimulating a  
15       patient's immune system with antigens that are specifically expressed by cancerous cells, i.e., tumor vaccines. Specific tumor vaccines require pre-identification of tumor associated antigens, i.e., molecules that are either specifically expressed or  
20       overexpressed in tumor cells.

          Extensive efforts have been made to identify tumor associated antigens in humans by using two approaches which are referred to as the genetic approach and the biochemical approach. The genetic  
25       approach is exemplified by dePlaen et al., *Proc. Natl. Sci. USA* 85: 2275 (1988), incorporated herein by reference. In this approach, cDNA libraries prepared from antigen-positive tumor-cell lines are transfected into antigen-negative recipient cells, such as COS  
30       cells or variants of tumor cell lines. The transfectants are subsequently screened for the expression of tumor antigens which are recognized by tumor-specific cytolytic T-Lymphocyte clones ("CTLs"). The biochemical approach, exemplified by Mandelblom et

al. *Nature* 369: 69 (1994) which is incorporated herein by reference, is based on acidic elution of peptides which are bound to MHC-class I molecules at the surface of tumor cells. Such elution produces  
5 pools of peptides which are subsequently fractionated by reverse-phase high performance liquid chromatography (HPLC). Tumor specific antigenic peptides are subsequently identified based on their ability to activate tumor-specific CTL clones.

10 Application of these two approaches has led to the molecular identification of new human antigens in human tumors, most notably in malignant melanoma, such as MAGE-1, Tyrosinase and MART-1. See, e.g., van der Bruggen et al., *Science* 254: 1643-1647 (1991);  
15 Brichard et al., *J. Exp. Med.* 178: 489-495 (1993); Kawakami et al., *Proc. Natl. Acad. Sci. USA* 91: 3515-3519; Cox et al., *Science* 264: 716-719 (1994).

However, these two approaches have the following disadvantages. First, such methods are  
20 enormously cumbersome, time-consuming and expensive. Second, these methods depend on the establishment of autologous tumor cells in culture and isolation of stable autologous CTL clones that recognize antigens on the cultured tumor cells. It is difficult to establish  
25 cell lines from certain types of tumors, as shown by, e.g., Oettgen, et al., *Immunol. Allerg. Clin. North. Am.* 10:607-637 (1990). In addition, malignant cell lines established from a patient which are capable of growing *in vitro* may not express the complete spectrum  
30 of tumor associated antigens of the patient's original tumor. It is also known that some epithelial cell type cancers are poorly susceptible to CTLs *in vitro*, precluding routine analysis. Third, the relevance of

an identified tumor associated antigen to the respective tumor *in vivo* remains to be proven, as the respective CTLs can be obtained not only from patients with the respective tumor, but also from healthy individuals.

These problems have stimulated the art to develop alternative methodologies. One such methodology is described by Sahin et al., *Proc. Natl. Acad. Sci. USA* 92: 11810-11913 (1995), incorporated herein by reference. Also, see U.S. Patent No. 5,698,396 and International Application WO 96/40209, both of which are incorporated herein by reference. According to this method, a cDNA library is prepared from a pathological sample of a patient, e.g., tumor cells. The library is expressed in host cells, and screened with diluted serum from a patient which has been pre-treated to remove interfering binding partners. Host cells expressing the antigens are identified by their strong reactivity toward the antibodies in the serum in a binding assay. This method is also known as the SEREX method ("Serological Identification of Antigens by Recombinant Expression Cloning").

Application of the SEREX methodology has confirmed the expression of previously identified tumor associated antigens that are associated with melanoma, renal cell carcinoma and Hodgkins' disease. Application of the SEREX methodology has also led to the identification of novel genes encoding tumor-associated antigens, such as HOM-RCC-3.11, HOM-HD-21 and NY-ESO-1. See Sahin et al. (1995); Türeci et al. (1997a), *J. Biol. Chem.* 272: 6416- 6422; Crew et al. (1995), *EMBO J.* 144: 2333-2340; Chen et al. (1997),

*Proc Natl. Acad. Sci. USA* 94: 1914-1918, review by  
Türeci et al. (1997b) *Molecular Medicine Today* 3(8):  
342-349 and review by Sahin et al. (1997) *Current*  
*Opinion in Immunology* 9: 709-716 . Since the  
5 molecular identification of immunogenic proteins by the  
SEREX methodology is based on the reactivity of such  
proteins with patients' sera, immunogenic proteins  
which can be identified by SEREX are not restricted to  
cell-surface antigens and include a more complete  
10 repertoire of proteins expressed by a tumor. In fact,  
the SEREX methodology permits the identification of  
proteins which are abnormally expressed by cells of any  
pathological condition that are capable of eliciting a  
strong antibody immune response in the patient.

15           The antigens identified by SEREX can be  
classified into different categories based on the  
expression patterns of these antigens, as described by  
Türeci et al. (1997b), *Molecular Medicine Today* 3(8):  
342- 349. One category of the SEREX-detected antigens  
20 are tumor-specific antigens derived from  
transcriptionally activated genes which are not  
expressed in normal tissues, such as HOM-MEL-40.  
Another category of the SEREX-detected antigens are  
differentiation antigens which are expressed in tumor  
25 cells as well as in normal cells developed from the  
same precursor origin, e.g., Tyrosinase. Yet another  
category of the SEREX-detected antigens are derived  
from mutated genes, such as a mutated tumor suppressor  
gene p53. Still another category of the SEREX-detected  
30 antigens are products of alternative splicing, e.g.,  
the splice variant of restin (associated with Hodgkin's  
disease). The majority of the SEREX-detected antigens

are encoded by genes which are expressed in normal tissues and are overexpressed in tumors, e.g., HOM-HD-21 (associated with Hodgkin's disease) and carbonic anhydrase (associated with renal cancer). SEREX has also identified antigens encoded by genes which are expressed at similar levels in normal tissues and in tumors, such as CCAAT enhancer-binding protein HOM-MEL-2.4. It is proposed that this category of tumor associated antigens are detected by SEREX perhaps due to unusual protein processing, and therefore, unusual presentation of antigens in tumors. SEREX has also identified non-cancer-related autoantigens involved in, e.g., autoimmune diseases, such as NY-ESO-2' (encoding U1 snRNP).

In accordance with the present invention, the SEREX methodology has been applied to melanoma samples and thyroid tumor samples. A number of nucleic acid molecules have been isolated and sequenced. These results are the subject of this invention, which are elaborated upon the disclosure which follows.

#### SUMMARY OF THE INVENTION

The present invention is directed to isolation and identification of nucleic acid molecules which are associated with melanoma and thyroid tumors. In particular, ten nucleic acid molecules have been isolated by applying the SEREX methodology to melanoma samples, and ten nucleic acid molecules have been isolated by applying the SEREX methodology to thyroid tumor samples.

Accordingly, one embodiment of the present invention is directed to newly isolated nucleic acid

molecules, MEL 3, MEL7, Thy5, Thy6, Thy 11, Thy14 and Thy 15 (SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20). The present invention also contemplates nucleic acid molecules, the complement sequences of which hybridize under stringent conditions to at least one of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20.

The present invention further contemplates vectors containing any one of the above nucleic acid molecules, as well as host cells transformed with such vectors. In a preferred embodiment, the present invention provides an antigen presenting cell transformed with one of such expression vectors, having an HLA/peptide complex at the cell surface.

In another embodiment, the present invention provides proteins encoded by the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20 or parts thereof.

Still another embodiment of the present invention provides antibodies directed towards a protein encoded by any one of the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20 or parts thereof.

The present invention is also directed to isolated HLA/peptide complexes, wherein the peptide is encoded by a fragment of any one of the nucleic acid molecules of SEQ ID NOS: 3, 7, 14, 15, 17 and 19-20.

A further aspect of the present invention is directed to methods for diagnosing pathological conditions characterized by an abnormal expression of at least one of the nucleic acid molecules encompassing SEQ ID NOS: 1-20. The pathological condition includes melanoma, the presence of a thyroid tumor, rectal



cancer, lung cancer, breast cancer or colon cancer. According to the present invention, the determination of the abnormal expression of a nucleic acid molecule can be made by assaying a component manifesting the expression of such molecule, such as mRNA, protein(s), antibodies in the serum, presence of specific CTLs, or cells presenting an antigenic peptide.

Another aspect of the present invention is directed to pharmaceutical compositions. The pharmaceutical compositions of the present invention can include an antisense molecule of one or more of the nucleic acid molecules encompassing any one of SEQ ID NOS: 1-20, a protein encoded by a nucleic acid molecule encompassing any one of SEQ ID NOS: 1-20 or parts of such protein, an antibody directed to such a protein, a cell presenting an antigenic peptide at the surface, a CTL generated *ex vivo* against such cell, or combinations thereof.

The subject therapeutic compositions of the present invention may be administered to a subject for treating a pathological condition in the subject, which is characterized by an abnormal expression of at least one of the nucleic acid molecules encompassing SEQ ID NOS: 1-20. Accordingly, methods of treatment are also provided by the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to isolated nucleic acid molecules that are associated with melanoma or thyroid tumors. The present invention further relates to proteins encoded by such nucleic acid molecules, antibodies directed against such proteins and cells expressing such nucleic acid

molecules. The present invention also provides pharmaceutical compositions as well as methods for diagnosing and treating melanoma, thyroid tumors and other related pathological conditions.

5           Nucleic acid molecules encoding tumor associated antigens have been identified by employing the SEREX methodology as described by Sahin et al. (1995). According to SEREX, samples of suspected abnormality, e.g., tumor cells, can be obtained from  
10 patients via routine clinical procedures. RNAs are purified from the freshly isolated samples for preparing a cDNA library, which is subsequently cloned into an appropriate expression vector. The choice of vectors may vary, depending on the host cells. When  
15 the host cell is a eukaryotic cell, yeast, viral or baculoviral vectors are preferred. When the host cell is a prokaryotic cell, then phage vectors are preferred, such as a  $\lambda$  phage vector. The resulting vector-carried library is then transformed into a host  
20 cell. The skilled artisan is familiar with the choice of host cells, including bacteria cells such as strains of *E. coli*, strains of *Pseudomonas* such as *Pseudomonas aeruginosa* or strains of *Bacillus*, yeast cells such as strains of *Saccharomyces* or *Pichia pastoris*, CHO cells  
25 such as CHO-1, COS cells such as COS-7 and insect host cells such as *Spodoptera frugiperda*. Once the host cells receive the vectors, the cells are cultivated and induced so as to express the proteins encoded by the nucleic acid molecules of the cDNA library.

30           The expressed proteins as well as derivatives thereof, such as posttranslationally-modified products (e.g., glycoproteins or lipoproteins) and polypeptide or peptide fragments processed therefrom, are then

5 contacted with a sample secured from a patient for  
identifying the clones of interest. A preferred sample  
is the patient's body fluid, such as serum. The serum  
may be obtained via routine clinical procedures from  
both autologous and non-autologous patients afflicted  
with the relevant pathological condition such as a  
tumor. Such serum is treated prior to use in order to  
remove components in the serum which recognize either  
the host cell or molecules derived from the vector  
10 other than the specific target molecule. Such  
pretreatment procedure is described by, e.g., Sahin et  
al. (1995).

When the expressed proteins and derivatives  
thereof are contacted with the pretreated patient's  
15 sample, the immune components present in the patient's  
sample, e.g., IgG, which are specific for a protein or  
derivative thereof will bind thereto. Preferably, the  
proteins and derivatives can be immobilized to a solid  
material, e.g., nitrocellulose, to facilitate the  
20 binding. The binding can be detected by a variety of  
assays, for example, assays using anti-human IgG  
conjugated with an identifiable label, such as an  
enzyme, a dye, or a radiolabel. Once positive clones  
are identified, i.e., clones expressing proteins or  
25 derivatives which are bound by the immune components  
from the patient's sample, the corresponding cDNA can  
be isolated and sequenced via routine procedures.

The SEREX methodology permits the  
identification of not only cell surface antigens, but  
30 any molecules which are abnormally expressed by cells  
that are capable of eliciting a strong antibody immune  
response in the patient. See, e.g., Türeci et al.  
(1997b).

By applying the SEREX methodology to human melanoma samples and thyroid tumor samples, the present invention provides the isolation and identification of nucleic acid molecules associated with melanoma (MEL 1-10) and nucleic acid molecules associated with thyroid tumors (Thy 1-3, 5-6, 9, 11-12 and 14-15), respectively (SEQ ID NOS: 1-20). These nucleic acid molecules have been compared with sequences in the databases and are resolved into both known and unknown sequences. Table II summarizes the results. Whether previously known or unknown, these isolated nucleic acid molecules have been identified by the instant invention to be associated with either melanoma or thyroid tumors.

Accordingly, one embodiment of the present invention is directed to newly isolated nucleic acid molecules that are associated with melanoma (MEL3 and MEL7) or thyroid tumors (Thy 5-6, 11 and 14-15). In particular, the present invention contemplates isolated nucleic acid molecules having a sequence as set forth in any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

The term "associated" or "association" is used herein to indicate that a relevant nucleic acid molecule is abnormally expressed in melanoma or thyroid tumors. These nucleic acid molecules may also be expressed by cells other than melanoma cells or thyroid tumor cells, e.g., cells of other types of tumors, or cells of other disorders such as an autoimmune disorder. For example, the present invention has also shown that the isolated nucleic acid molecules scored positive in the SEREX screening assay using sera from patients having rectal, lung, breast or colon cancer, indicating that an abnormal expression of these nucleic

acid molecules is also present in rectal, lung, breast or colon cancer.

5           The term "abnormal expression" as used herein refers to an expression that is not present in normal cells or an expression that is present in normal cells at a lower level. In the present invention, "an abnormal expression" can also be used to refer to an unusual processing of the protein expressed from a nucleic acid, which is not present in normal cells and  
10           which results in unusual presentation of antigenic peptides at the cell surface.

          Another embodiment of the present invention is directed to nucleic acid molecules, the complement sequences of which hybridize under stringent conditions  
15           to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

          "Stringent conditions" as used herein refer to conditions such as those specified in US Patent No. 5,342,774, i.e., 18 hours of hybridization at 65°C, followed by four one-hour washes with 2x SSC, 0.1% SDS,  
20           and a final wash with 0.2x SSC, more preferably 0.1x SSC, and 0.1% SDS for 30 minutes, as well as alternate conditions which afford the same level of stringency, and more stringent conditions.

          In accordance with the present invention,  
25           molecules having a sequence, the complementary sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20, can include nucleic acid molecules having substantial homology to any one of SEQ ID NOS: 3, 7, 14-15, 17 and  
30           19-20; parts of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20; degenerate sequences; and modified forms of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20, such as mutant forms with base pair substitutions, deletions or insertions. In

the event that SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 are fragments of full-length genes, such genes are also contemplated by the present invention as nucleic acid molecules having a sequence, the complementary sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

As used herein, "a part" of a nucleic acid molecule refers to a fragment of the nucleic acid molecule having sufficient length to encode an antigenic peptide of at least 8 or 9 amino acids. In particular, the present invention contemplates "unique" fragments of nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20. A unique fragment is one that is a "signature" for the larger nucleic acid molecule. It is, for example, long enough to selectively distinguish the sequence of interest from others. As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 will require longer segments to be unique while others will require only shorter segments, typically between 12 and 32 nucleotides. Those skilled in the art are well versed in methods for selecting such sequences, e.g., by comparing the sequence of the fragment to those in known databases. *In vitro* confirmatory hybridization and sequencing analysis may also be used. According to the present invention, the unique fragments do not include sequences present in the prior art, such as ESTs and the like. Further according to the present invention, a unique fragment can be a functional fragment. A functional fragment of a nucleic acid molecule of the present invention is a fragment which

retains some functional property of the larger nucleic acid molecule, such as a fragment that encodes an antigenic epitope associated with melanoma or thyroid tumors.

5           The skilled artisan is fully capable of making, by following routine procedures, a nucleic acid molecule, the complement sequence of which hybridizes under stringent conditions to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20. The skilled artisan can  
10 determine, for example, whether SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 encompasses a complete open reading frame, and if not, can isolate the full length molecules that encompass a complete open reading frame by following standard procedures, e.g., DNA  
15 hybridization-based cloning. See, e.g., Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, New York.

20           The skilled artisan is also able to make fragments of these isolated nucleic acid molecules by using standard recombinant cloning techniques. The skilled artisan can further determine whether a fragment of an isolated nucleic acid molecule encodes the antigen(s) responsible for the immune response  
25 elicited in the patient and the resulting hyper-immunoreactive serum. This can be accomplished by following a number of well-known methods. For example, various portions of a nucleic acid molecule can be cloned into an appropriate expression vector which can  
30 be subsequently introduced into a desired host cell. Afterwards, polypeptides or peptides expressed from the respective DNA fragments can be tested for antigenicity by, e.g., using the patient's serum in a binding assay

5 routinely used in the SEREX methodology as described hereinabove; or using CTL clones with pre-defined specificity. Alternatively, one skilled in the art can chemically synthesize polypeptide or peptide fragments directly based on the nucleotide sequence of a fragment, and the antigenicity of the peptide can be determined by the reactivity toward the patient's serum in a binding assay, for example.

10 The skilled artisan is also able to isolate nucleic acid molecules having substantial homology to any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 by following standard procedures, e.g., DNA hybridization-based cloning procedure. See, e.g., Sambrook et al. (1989).

15 In another embodiment, the nucleic acid molecules of the present invention or parts thereof have been inserted into expression vectors. The choice of vectors can be determined by those skilled in the art. When the host cell is a eukaryotic cell, viral (e.g., retroviral, adenoviral or pox), yeast or baculoviral vectors are preferred. When the host cell is a prokaryotic, then phage vectors are preferred, such as a  $\lambda$  phage vector. It is routine for those skilled in the art to construct expression vectors in which a nucleic acid molecule of interest is placed in operable linkage to a desired promoter so as to effect the expression of the polypeptide or peptide encoded by such nucleic acid molecule in host cells. See, e.g., Sambrook et al. (1989).

25 30 The present invention also provides expression vectors which include nucleic acid molecules encoding a series of epitopes, known as "polytopes" (Thompson et al. (1995) in *Proc. Natl. Acad. Sci. USA*



92: 5845-5849; Gilbert et al., *Nature Biotechnol.* 15:  
1280- 1284, 1997). The epitopes can be arranged in  
sequential or overlapping fashion, with or without the  
natural flanking sequences, and can be separated by  
5 unrelated linker sequences if desired. The polytope is  
processed in host cells to generate individual epitopes  
which can be recognized by the immune system. Thus,  
for example, peptides derived from the polypeptide  
having an amino acid sequence encoded by any one of the  
10 nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17  
and 19-20 of the instant invention, which are presented  
by MHC molecules and recognized by CTL or T helper  
lymphocytes can be combined with peptides from other  
tumor rejection antigens (e.g., by preparation of  
15 hybrid nucleic acids or polypeptides) to form  
"polytopes". Exemplary tumor associated peptide  
antigens that can be administered to induce or enhance  
an immune response are derived from tumor associated  
genes and encoded proteins including MAGE-1, MAGE-2,  
20 MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9,  
MAGE-10, MAGE-11, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-  
5, GAGE-6, BAGE-1, RAGE-1, LB33/MUM-1, DAGE, NAG, MAGE-  
Xp2, MAGE-Xp3, MAGE-Xp4, tyrosinase, brain glycogen  
phosphorylase, Melan-A, and MAGE-C1. For example,  
25 antigenic peptides characteristic of tumors include  
those listed in Table I below.

Table I: Exemplary Antigens

Gene	MHC	Peptide	Position	SEQ ID NO:
MAGE-1	HLA-A1	EADPTGHSY	161-169	21
	HLA-Cw16	SAYGEPRKL	230-238	22
MAGE-3	HLA-A1	EVDPIGHLY	168-176	23
	HLA-A2	FLWGPRLV	271-279	24
	HLA-B44	MEVDPIGHLY	167-176	25
BAGE	HLA-Cw16	AARAVFLAL	2-10	26
GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	27
RAGE	HLA-B7	SPSSNRIRNT	11-20	28
GnT-V	HLA-A2	VLPDVFIRC(V)	2-10/11	29
MUM-1	HLA-B44	EEKLIVVLF	exon 2/ intron	30
		EEKLSVVLF (wild type)		31
CDK4	HLA-A2	ACDPHSGHFV	23-32	32
		ARDPHSGHFV (wild type)		33
$\beta$ -catenin	HLA-A24	SYLDSGIHF	29-37	34
		SYLDSGIHS (wild type)		35
Tyrosinase	HLA-A2	MLLAVLYCL	1-9	36
	HLA-A2	YMNGTMSQV	369-377	37
	HLA-A2	YMDGTMSQV	369-377	38
	HLA-A24	AFLPWHRLF	206-214	39
	HLA-B44	SEIWRDIDF	192-200	40
	HLA-B44	YEIWRDIDF	192-200	41
	HLA-DR4	QNILLSNAPLGP QFP	56-70	42
	HLA-DR4	DYSYLQSDPDPS FQD	448-462	43
Melan-A <sup>MART-1</sup>	HLA-A2	(E)AAGIGILTV	26/27-35	44
	HLA-A2	ILTVILGVL	32-40	45
gp100 <sup>Pmel117</sup>	HLA-A2	KTWGQYWQV	154-162	46
	HLA-A2	ITDQVPFSV	209-217	47
	HLA-A2	YLEPGPVTA	280-288	48
	HLA-A2	LLDGTATLRL	457-466	49
	HLA-A2	VLYRYGSFSV	476-485	50
DAGE	HLA-A24	LYVDSLFFL	301-309	51
MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	52

The peptides of SEQ ID NOS: 41, 51 and 52 are presented in U.S. Application Serial No. 08/724,774, PCT Application Publication No. WO96/10577 and U.S. Application Serial No. 08/713,354, respectively. Other exemplary peptides include those listed in U.S. Patent

Applications 08/672,351, 08/669,590, 08/487,135,  
08/530,569 and 08/880,693. Other examples are known to  
one of ordinary skill in the art (for example, see  
Coulie, *Stem Cells* 13: 393-403, 1995), and can be used  
5 in the invention in a like manner as those disclosed  
herein.

It is known that tumors express a set of  
tumor antigens, of which only certain subsets may be  
expressed in the tumor of any given patient. Polytopes  
10 can be prepared which correspond to the different  
combination of epitopes representing the subset of  
tumor rejection antigens expressed in a particular  
patient. Polytopes also can be prepared to reflect a  
broader spectrum of tumor rejection antigens known to  
15 be expressed by a tumor type.

The present invention further contemplates  
host cells for propagating and/or expressing the  
nucleic acid molecules of the present invention. Those  
skilled in the art are equally familiar with the choice  
20 of cell lines and the procedures to transform or  
transfect such cell lines. Examples of the cell lines  
include, but are not limited to, eukaryotic cells such  
as COS cells (e.g., COS-7), CHO cells (e.g., CHO-1),  
NIH 3T3 cells, yeast cells (e.g., strains of  
25 *Saccharomyces* or *Pichia pastoris*), insect cells (e.g.,  
*Spodoptera frugiperda*); and prokaryotic cells such as  
strains of *E. coli*, strains of *Pseudomonas* (e.g.,  
*Pseudomonas aeruginosa*) or strains of *Bacillus*.

In a preferred embodiment, the present  
30 invention provides an antigen presenting cell  
transformed with an expression vector as described  
hereinabove.

"Antigen presenting cells" as used herein refer to cells expressing at least one MHC class I or class II molecule, which include, but are not limited to, professional antigen presenting cells such as B cells, monocytes, macrophages, dendritic cells and T cells; and facultative antigen presenting cells such as fibroblasts and endothelium cells. Antigen presenting cells can be isolated from tissue or blood samples. Both normal and malignant cells can be employed. Cell lines established in tissue culture from such samples can also be used. Many such cell lines are available from American Type Culture Collection (ATCC), Rockville, Maryland. Those skilled in the art can determine whether a chosen antigen presenting cell expresses at least one MHC molecule that is capable of presenting a peptide derived from a particular nucleic acid molecule. See, e.g., Coligan et al. (1994). Such cell can then be transfected with an expression vector which, under appropriate conditions, leads to the expression on the cell surface of one or more antigenic peptides encoded by fragments of the nucleic acid molecule of interest, complexed with appropriate MHC molecules,.

Another embodiment of the present invention is directed to proteins encoded by the isolated nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 or parts thereof.

The term "protein" used herein refers to both the unmodified forms (precursors) and post-translationally modified forms of a protein. Eukaryotic cells are well known for their ability to post-translationally modify proteins, so as to produce glycoproteins and lipoproteins, for example. According

to the present invention, the term "protein" also encompasses polypeptides and peptides.

The term "polypeptide" as used herein refers to a chain of at least 10 contiguous amino acids. The  
5 term "peptide" used herein refers to a chain of at least 8 or 9 amino acids.

The protein encoded by a nucleic acid molecule can be produced by routine recombinant expression in a desired host cell and subsequently  
10 purified by various known procedures, such as chromatography. A polypeptide or peptide can also be chemically synthesized according to its coding sequence in a standard peptide synthesizer. Those skilled in the art can also isolate antigenic peptides directly  
15 from the MHC/peptide complexes of antigen-expressing cells by, e.g., a method disclosed by Mandelblom et al. (1994). According to such method, peptides are eluted from the MHC-peptide complexes at the surface of antigen-expressing cells. The resulting pools of  
20 peptides are fractionated by HPLC and screened with antigen-specific CTL clones. Specific antigenic peptides can be identified and isolated based upon their ability to provoke specific CTL clones.

Purified proteins can be used as immunogens,  
25 either alone or in combination with an adjuvant such as saponins, GM-CSF, or interleukins. Immunogens such as these may be used, for example, to generate antibodies.

Accordingly, the present invention also contemplates antibodies directed against the proteins  
30 encoded by the nucleic acid molecules of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20 or parts thereof.

There are a variety of ways to obtain specific antibodies. Antibodies can be generated by

administering a protein of interest, either alone or in combination with an adjuvant, to various hosts, such as a rabbit, a mouse, or a sheep. Both monoclonal or polyclonal antibodies can be obtained using such immunized host. The methods for generating polyclonal and monoclonal antibodies are well known in the art. See, e.g., Coligan et al. *Current Protocols in Immunology*, John Wiley & Sons Inc., New York, New York (1994). Fragments of antibodies, such as Fab, F(ab)<sub>2</sub>, and the like, as well as recombinantly produced antibodies, are also contemplated by the present invention.

Another embodiment of the present invention is directed to isolated peptide/HLA complexes. Preferably, the peptide in such isolated peptide/HLA complexes is encoded by a fragment of any one of SEQ ID NOS: 3, 7, 14-15, 17 and 19-20.

According to this embodiment, once the type of the HLA molecule capable of presenting a peptide is ascertained, such HLA molecule can be produced by any appropriate recombinant expression system, e.g., an *E. coli*-based expression system. As described above, peptides can be obtained by a number of ways, such as chemical synthesis or recombinant expression. The peptides and the presenting HLA molecules can then be mixed *in vitro* under conditions that favor the formation of HLA/peptide complexes. Such conditions are well known in the art. See, e.g., Garboczi et al. (*Proc. Natl. Acad. Sci. USA* 89: 3429-3433, 1992 and Altman et al. (*Science* 274: 94-96, 1996).

In another embodiment, the present invention provides methods of diagnosing a pathological condition

characterized by an abnormal expression of one or more of the nucleic acid molecules of the present invention.

The term "diagnosing" as used herein encompasses determining or monitoring the onset of, the progression of, the regression of, or the efficacy of a therapeutic regime for, a pathological condition.

Pathological conditions characterized by an abnormal expression of one or more of the nucleic acid molecules SEQ ID NOS: 1-30 of the present invention include, but are not limited to melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

Diagnosis of a pathological condition can be accomplished by determining an abnormal expression of at least one, i.e., one or more, nucleic acid molecule that is associated with such pathological condition. By comparing the expression in a sample from a patient suffering a pathological condition, with the expression in a normal sample, the skilled artisan can readily determine whether a relevant nucleic acid molecule is abnormally expressed in such pathological condition.

The abnormal expression of a nucleic acid molecule can manifest as an abnormal level of the mRNA of such nucleic acid molecule, the protein or peptide fragments encoded by such nucleic acid molecule, serum antibodies against such protein or peptide fragments, peptide/MHC complexes at the cell surface, or CTLs specific for certain peptide/MHC complexes. Accordingly, there are various assays which can be employed to detect the abnormal expression of a subject nucleic acid molecule.

A sample of suspected abnormality can be taken from a patient, such as a tissue biopsy sample,

or body fluid sample such as serum. The expression of a protein of interest in such sample can be determined by a variety of diagnostic assays.

One type of diagnostic assay is based on  
5 determination of the level of mRNA of a nucleic acid molecule associated with the pathological condition in question. Thus, for example, diagnosis of melanoma can be based on assaying the level of mRNA of, preferably, the repressor protein-encoding gene (SEQ ID NO: 21),  
10 the KIAA0201 gene (SEQ ID NO: 22), the Ki-67-encoding gene (SEQ ID NOS: 23 and 24), the CENP-B-encoding gene (SEQ ID NO: 25), or nucleic acid sequences encompassing SEQ ID NO: 3 or 7. Diagnosis of thyroid tumors can be based on assaying the level of mRNA of, preferably, the  
15 TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), or nucleic acid sequences encompassing  
20 one of SEQ ID NOS: 14-15, 17 and 19-20. Similarly, diagnosis of rectal, lung, breast, colon cancer or any other pathological condition can be based on assaying the level of the mRNA of one or more of SEQ ID NOS: 3, 7, 14-15, 17, 19-30 that are associated with the  
25 relevant pathological condition. For example, diagnosis of rectal cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21-24, 26, or 30, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID NOS: 14-15 or  
30 20. Diagnosis of lung cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21 and 23-25, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID



NOS: 14-15 or 20. Diagnosis of breast cancer can be based on determining the level of, preferably, the mRNA of any one of SEQ ID NOS: 23 or 24, or the mRNA of a nucleic acid molecule encompassing SEQ ID NOS: 15.

5 Diagnosis of colon cancer can be based on determining the level of preferably, the mRNA of one or more of SEQ ID NOS: 21-24, 26 or 29-30, or the mRNA of a nucleic acid molecule encompassing any one of SEQ ID NOS: 14-15 or 19-20. The methods for determining the level of  
10 mRNA are well within the ken of those skilled in the art, such as Northern Blot analysis or PCR analysis.

Another type of diagnostic assay is based on determination of the amount of protein expressed from the nucleic acid molecules associated with the  
15 pathological condition in question, or parts of such proteins. For example, for diagnosing melanoma, the protein to be examined can be the repressor protein encoded by SEQ ID NO: 21, the protein encoded by KIAA0201 (SEQ ID NO: 22), Ki-67 antigen (encoded by SEQ  
20 ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25) or the protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7. Preferably, diagnosis of melanoma is based on detecting proteins encoded by any one of SEQ ID NOS: 1-10. For diagnosing  
25 thyroid tumors, the protein to be examined can be TAFII68 (encoded by SEQ ID NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceramidase (encoded by SEQ ID NO: 30), or a  
30 protein encoded by any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20. Preferably, diagnosis of the presence of a thyroid tumor is based on detecting proteins encoded by

any one of SEQ ID NOS: 11-20. Similarly, diagnosis of rectal, lung, breast or colon cancer, or any other pathological condition can be based on assaying one or more proteins encoded by any one, i.e., one or more, of SEQ ID NOS: 1-30, that is associated with the relevant cancer. One skilled in the art can use various assays including, e.g., SDS-gels or 2D gels, Western Blot Analysis, ELISA and immunofluorescence flow-cytometry.

Still another type of diagnostic assay is based on detection of antibodies in the serum that are specific for a protein associated with a pathological condition in question or parts of such protein. Thus, in this type of assay, antibodies are detected by using the specific antigens in assays such as Western Blot or affinity chromatography, or a SEREX screening assay described herein. Antibodies specific for an antigenic peptide can also be detected by using cells which express and present the antigenic peptide at the surface in the context of an MHC molecule via assays such as FACS.

Another type of diagnostic assay is based on detection of cells in the patient's sample, which cells have at their surface, a peptide encoded by a fragment of a nucleic acid molecule associated with the pathological condition in question. For example, for diagnosing melanoma, such nucleic acid molecule includes the gene encoding the repressor protein (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B-encoding gene (SEQ ID NO: 25), or the nucleic acid sequences encompassing SEQ ID NO: 3, or 7; and preferably, such nucleic acid molecule is any one of SEQ ID NOS: 1-10. For diagnosing thyroid tumors, such

nucleic acid molecule includes genes encoding TAFII68 (SEQ ID NO: 26), lipocortin II (SEQ ID NO: 27), thyroglobulin (SEQ ID NO: 28), thymosin (SEQ ID NO: 29), or the acid ceramidase-encoding gene (SEQ ID NO: 30), or any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20; and preferably, such nucleic acid molecule is any one of SEQ ID NOS: 11-20. Likewise, for diagnosing rectal, lung, breast or colon cancer, the nucleic acid molecule can include any one of SEQ ID Nos: 1-30 that is associated with the relevant cancer. To determine the presence of such cell in a patient's sample, cellular-immuno assays can be employed, e.g., FACS analysis using antibodies raised against such peptide, or cytotoxic assays using pre-established CTLs specific for such peptide.

Another type of diagnostic assay is based on detection of CTLs in the patient's sample that are specific for a peptide of a protein associated with the pathological condition in question. Methods for detecting CTLs specific for an antigen are known in the art and are described hereinabove, such as assays for <sup>51</sup>Cr release, TNF production or IFN-gamma production.

According to the present invention, the present methods of diagnosis are applicable not only to the pathological conditions exemplified, such as melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer or colon cancer, but also to pathological conditions in general that are characterized by an abnormal expression of one or more of the subject nucleic acid molecules of the present invention. The isolated nucleic acid molecules of the present invention are clearly expressed in an abnormal

manner in patients having melanoma, thyroid tumor, rectal, lung, breast or colon cancer. These molecules may also be expressed abnormally in other tumors or in cells associated with other pathological disorders.

5 Thus, the techniques described hereinabove can be employed for diagnosing a pathological condition characterized by an abnormal expression of one of the nucleic acid molecules having a sequence encompassing one or more of SEQ ID NOS: 1-20.

10 In another embodiment, the present invention provides pharmaceutical compositions. The pharmaceutical compositions of the present invention are useful for treating pathological conditions characterized by an abnormal expression of one or more  
15 of the instant nucleic acid molecules of the present invention.

One pharmaceutical composition of the present invention includes an antisense molecule of one of the repressor protein-encoding gene (SEQ ID NO: 21), the  
20 KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the  
25 thyroglobulin -encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of such nucleic acid molecules.  
30 Preferably the antisense molecule is about 10-100 nucleotides in length and is carried by a suitable vector, such as a retroviral vector or a viral vector. The choice of vectors for such purpose is well-known in

the art, e.g., Vaccinia. The use of antisense molecules for inhibiting gene expression is known in the art.

Another pharmaceutical composition of the present invention includes a protein encoded by one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of such nucleic acid molecules. Preferably, the protein is encoded by one of SEQ ID NOS: 1-20 or parts thereof. Such proteins can be administered to a subject to provoke or augment an immune response in the subject against the abnormally expressed proteins.

Still another pharmaceutical composition of the present invention includes an antibody specific for a protein encoded by one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25) and nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAF 1168-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences

encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of these nucleic acid molecules. Preferably, the antibody is specific for a protein encoded by any one of SEQ ID NOS: 1-20 or parts of such proteins. Both polyclonal antibodies and monoclonal antibodies can be used. Monoclonal antibodies are preferred.

Another pharmaceutical composition of the present invention includes an antigen-presenting cell having at the cell surface, in the context of MHC molecules, one or more antigenic peptides encoded by a fragment(s) of one of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25) and nucleic acid sequences encompassing SEQ ID NO: 3, or 7, the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II - encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20. The antigen presenting cells to be used in the pharmaceutical composition of the present invention express MHC molecules that are compatible with the MHC molecules of the patient being treated. At least one of the MHC molecules expressed by such cells is capable of presenting a peptide encoded by a fragment of a subject nucleic acid molecule. The choice of antigen presenting cells is described hereinabove.

In accordance with the present invention, antigen presenting cells can be further modified to express other molecules for augmenting immunogenicity. A number of immune response potentiating molecules can

be used, including lymphokines, costimulatory molecules such as B7-1 (CD80), B7-2(CD86), LFA-3, LFA-1 and CD40. B7 molecules, by interacting with CD28 or CTLA-4 molecules on T cells, potentiate T cell proliferation and effector function such as antitumor activity. See, 5 e.g., Zheng et al., *Proc. Natl. Acad. Sci. USA* 95: 6284-6289 (1998); Wang et al., *J. Immunol.* 19: 1-8 (1996). The interaction of LFA-3 on antigen presenting cells with CD2 on T cells induces T cell to produce IL- 10 2 and IFN-gamma (Fenton et al., *J. Immunol.* 21(2): 95-108, 1998). Complete CTL activation and effector function requires Th cell help through the interaction between the CD40 ligand expressed on Th cells and the CD40 molecules expressed on antigen presenting cells 15 (Ridge et al., *Nature* 393:474, 1998; Bennett et al., *Nature* 393: 478, 1998; and Achenberger et al., *Nature* 393: 480, 1998). These additional immune-potentiating molecules can be included in any of the expression vectors (such as retroviral, adenoviral, or pox 20 vectors) and introduced into antigen presenting cells by, e.g., transfection.

The pharmaceutical compositions of the present invention can also include a pharmaceutical acceptable carrier. As used herein, a pharmaceutically 25 acceptable carrier includes any and all solvents, including water, dispersion media, culture from cell media, isotonic agents and the like that are non-toxic to the patient. Preferably, it is an aqueous isotonic buffered solution with a pH of around 7.0. The use of 30 such media and agents in therapeutic compositions is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutical compositions of the present invention,

use of such conventional media or agents in the pharmaceutical compositions are contemplated. Supplementary active ingredients can also be incorporated into the compositions.

5           In a further embodiment, the pharmaceutical compositions of the present invention are used to treat pathological conditions characterized by an abnormal expression of one or more of the instant nucleic acid molecules of the present invention. Accordingly, the  
10           present invention provides methods of treating a subject suffering a pathological condition characterized by an abnormal expression of one or more of the instant nucleic acid molecules, by administering to such subject a therapeutically effective amount of a  
15           pharmaceutical composition of the present invention.

          The term "treating" means delaying the onset of a pathological condition or alleviating a pathological condition by controlling the expression of the nucleic acid molecule being abnormally expressed  
20           under such pathological condition. "Alleviating" is indicated by, in the case of tumor, inhibition of tumor growth, reduction in tumor size, inhibition of tumor metastasis and the like.

          "A pathological condition" as defined  
25           hereinabove, includes, but is not limited to, melanoma the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer or colon cancer. For treating melanoma, pharmaceutical compositions derived from melanoma-associated nucleic acid molecules (such as  
30           antisense molecules, proteins, antibodies or cells) are preferred. For treating thyroid tumors, pharmaceutical compositions derived from thyroid tumor-associated nucleic acid molecules are preferred. Likewise, for



treating any other pathological condition, such as rectal cancer, lung cancer, breast cancer or colon cancer, preferred pharmaceutical compositions to be used in the treatment are those derived from the nucleic acid molecules associated with that condition.

One method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, an antisense molecule of such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by administering to the subject, one or more of an antisense molecule of the repressor protein-encoding gene (SEQ ID NO: 21), the KIAA0201 gene (SEQ ID NO: 22), the Ki-67 encoding gene (SEQ ID NO: 23 and 24), the CENP-B encoding gene (SEQ ID NO: 25), or nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts of these nucleic acid molecules; a subject having thyroid tumors can be treated by administering to the subject one or more of an antisense molecule of the TAFII68-encoding gene (SEQ ID NO: 26), lipocortin II-encoding gene (SEQ ID NO: 27), the thyroglobulin-encoding gene (SEQ ID NO: 28), the thymosin-encoding gene (SEQ ID NO: 29), the acid ceramidase-encoding gene (SEQ ID NO: 30), and nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts of these nucleic acid molecules.

Preferably, the antisense molecule is contained in a vector suitable for expression in the subject being treated. The choice of vectors for such purpose is well-known in the art and can be viral or retroviral vectors, e.g., a Vaccinia vector. A vector carrying the antisense DNA can be administered to a

subject in an amount sufficient to inhibit the expression of the protein. Such vector can be administered alone or with a carrier, such as a liposome, which facilitates the incorporation of the vector into a cell.

Another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, a protein encoded by such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by administering to the subject, the repressor protein (encoded by SEQ ID NO: 21), the protein encoded by KIAA0201 (SEQ ID NO: 22), Ki-67 (encoded by SEQ ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25), a protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts or combinations thereof. A subject having thyroid tumors can be treated by administering to the subject, TAF II68 (encoded by SEQ ID NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceradimase encoded by SEQ ID NO: 30), a protein encoded by any one of the nucleic acid sequences encompassing one of SEQ ID NOS: 14-15, 17 and 19-20, or parts or combinations thereof.

The proteins are administered in an amount sufficient to provoke or augment an immune response in the subject which eliminate the abnormally expressed proteins. The proteins can be combined with one or more of the known immune adjuvants, such as saponins, GM-CSF, interleukins and so forth. Small peptides may

also be coupled to the well-known conjugates to achieve the desired immunogenicity.

5 Still another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject, an antibody directed against the protein encoded by such nucleic acid molecule or parts thereof. For example, a subject having melanoma can be treated by  
10 administering to the subject, one or more of an antibody directed against the repressor protein (encoded by SEQ ID NO: 21), the protein encoded by the KIAA0201 (SEQ ID NO: 22), Ki-67 (encoded by SEQ ID NO: 23 or 24), CENP-B (encoded by SEQ ID NO: 25), or a  
15 protein encoded by any one of the nucleic acid sequences encompassing SEQ ID NO: 3, or 7, or parts of these proteins. A subject having thyroid tumors can be treated by administering to the subject, one or more of an antibody directed against TAFII68 (encoded by SEQ ID  
20 NO: 26), lipocortin II (encoded by SEQ ID NO: 27), thyroglobulin (encoded by SEQ ID NO: 28), thymosin (encoded by SEQ ID NO: 29), the acid ceramidase (encoded by SEQ ID NO: 30), or a protein encoded by any one of the nucleic acid sequences encompassing one of  
25 SEQ ID NOS: 14-15, 17 and 19-20, or parts of these proteins. The antibodies can be administered alone or with pharmaceutically acceptable carriers in an amount sufficient to inhibit the function of the protein or proteins.

30 Still another method of treating a subject having a pathological condition characterized by an abnormal expression of a nucleic acid molecule of the present invention is by administering to the subject,

an antigen presenting cell having one or more antigenic peptides complexed with MHC molecules, which peptides are encoded by fragments of such nucleic acid molecule.

5 The cells are preferably treated to be rendered non-proliferative before the administration to the subject suffering a relevant pathological condition. The cells are administered to a patient in an amount sufficient to stimulate an immune response against the protein that is abnormally expressed in the  
10 patient. Such cells may present epitopes to T cells and/or B cells, leading to a cellular immune response and/or a humoral immune response in the subject. According to the present invention, the induced immune response can alleviate the pathological condition by  
15 cytotoxic killing and/or antibody-mediated killing of the cells of abnormality.

In addition to direct administration to a subject for treatment, antigen presenting cells expressing an MHC/peptide complex of interest can be  
20 used in an ex vivo regime to generate cytolytic T cells specific for the peptide being presented. The procedure to develop such specific CTLs *in vitro* is known in the art, e.g., as disclosed by the United States Patent No. 5,342,774. Briefly, a blood sample  
25 containing T cell precursors is taken from a subject, preferably, the autologous patient. PBLs are purified from such blood sample and are incubated with stimulator cells, in this case, the antigen presenting cells expressing a MHC/peptide complex. Specific CTLs  
30 are thus produced which can be detected by standard assays, such as Cr<sup>51</sup> release or secretion of IFN-gamma. CTL cells generated as such can be reperfused to the patient and alleviate the pathological condition by

lysing the cells abnormally expressing the peptide/MHC complex. See related teachings by Greenberg (1986) *J. Immunol.* 136 (5): 1917; Riddell et al. (1992) *Science* 257: 238; Lynch et al. (1991) *Eur. J. Immunol.* 21: 1403; and Kast et al. (1989) *Cell* 59: 603.

For practicing the treatment methods of the present invention, a pharmaceutical composition as described hereinabove can be administered to a patient in need thereof in any convenient manner, e.g., by subcutaneous (s.c.), intraperitoneal (i.p.), intra-arterial (i.a.), or intravenous (i.v.) injection..

The precise amount of a pharmaceutical composition to be administered so as to be therapeutically effective, can be determined those skilled in the art with consideration of individual differences in age, weight, tumor size, severity of the pathological condition and so forth.

All the publications mentioned in the present disclosure are incorporated herein by reference. The terms and expressions which have been employed in the present disclosure are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

The present invention is further illustrated but not limited by the following examples.

### Example 1

#### Isolation of cDNA clones using the SEREX methodology.

5 Two thyroid tumor cDNA libraries and one  
melanoma cDNA library were prepared, using standard  
techniques. See Sambrook et al., 1989, *Molecular  
Cloning: A Laboratory Manual*, Second Edition, Cold  
Spring Harbor Laboratory Press, New York. The  
10 libraries were screened using the SEREX methodology as  
described supra and set forth by Sahin et al. (1995)  
and by Chen et al., *Proc. Natl. Acad. Sci. USA* 94:  
1914 (1997), incorporated herein by reference.

More specifically, total RNA was isolated  
from tumor cells secured from three individuals,  
15 Patient 1 with melanoma, Patients 2 and 3 with thyroid  
tumors. The RNA from each patient was used to prepare  
a cDNA library, resulting in three cDNA libraries,  
named as Mel-N1, Thy-N1, and Thy-N2, respectively.  
Each of these cDNA libraries was cloned into  $\lambda$ ZAP phage  
20 vectors (Short et al., *Nucleic Acids Res.* 16: 7583,  
1988). Bacteria of the strain *E. Coli* XL1-Blue was  
then transfected with the recombinant phages derived  
from one of the described phage cDNA libraries, plated  
at a density of  $4-5 \times 10^3$  pfus (plaque forming units)  
25 per plate, and incubated for eight hours at 37°C. A  
nitrocellulose membrane was then placed on each plate,  
followed by overnight incubation.

The membrane was subsequently washed four  
times with TBS containing 0.05% Tween-20, and was  
30 immersed afterwards in TBS containing 5% non-fat dried  
milk. After one hour, the nitrocellulose membranes  
were washed three times with TBS, followed by the  
incubation with diluted human serum secured from the

autologous patient. The serum was pretreated, as described in detail by Sahin et al. (1995), U.S. Patent No. 5,698,396 and International Application WO 96/40209, to deplete interfering antibodies directed  
5 against antigens derived from *E. Coli* and phages. The stripped human serum was diluted 1:100 in TBS containing 0.5% milk powder (w/v). The membranes were incubated in the human serum overnight with gentle shaking, followed by three washes with TBS.  
10 Afterwards, the membranes were incubated with polyclonal goat anti-human IgG Fcγ conjugated with HRP. The conjugated antibodies were diluted 1:2000 in TBS-1% BSA. After incubation for one hour at room  
15 temperature, the membranes were washed three times with TBS. The positive clones were visualized using 30% solution of hydrogen peroxidase. Positive clones were further subcloned to monoclonality by repeated rounds of transfection and testing.

At the end of this screening procedure, ten  
20 cDNA clones (MEL 1-10) were obtained from the MEL-N1 library; three cDNA clones (Thy 1-3) were obtained from the Thy-N1 library; seven cDNA clones (Thy 5-6, 9, 11-12 and 14-15) were obtained from the Thy-N2 library.

## Example 2

### Sequencing the isolated cDNA clones.

5 The insert size of the isolated cDNA clones was determined using restriction enzymes and listed in Table I. The inserts of the cDNA clones were sequenced from the 3' end using standard techniques. See Sambrook et al. (1989), for example. SEQ ID NOS: 1-20 illustrate the sequences of the 3' portions of these  
10 isolated cDNA clones. Following nucleotide homology search of the databases, these sequences were resolved into known and unknown sequences. Table 1 summarizes the results. In Table 1, the "+" signs are used to indicate the relative strength of reactivity of each  
15 clone toward the corresponding patient serum.

SEQ ID NO: 1 (MEL 1) corresponds to a portion of the partial mRNA sequence for the repressor protein (SEQ ID NO: 21). SEQ ID NO: 2 (MEL 2) corresponds to a portion of the KIAA0201 gene (SEQ ID NO: 22, homologue to heat shock protein HSP). SEQ ID NOS: 4 and 8-10 (MEL 4 and MEL 8-10) correspond to portions of the Ki-67 nuclear antigen gene (SEQ ID NO: 23 and 24). SEQ ID NOS: 5-6 (MEL 5-6) correspond to portions of the CENP-B gene (SEQ ID NO: 25). SEQ ID NO: 3 (MEL 3) is matched  
20 by several EST sequences in Genbank. SEQ ID NO: 7 (MEL 7) does not find any sequence match in the databases.

SEQ ID NO: 11 (Thy 1) corresponds to a portion of the TAFII68 (TBP associated factor) gene (SEQ ID NO: 26). SEQ ID NO: 12 (Thy 2) corresponds to  
30 a portion of the lipocortin II gene (SEQ ID NO: 27). SEQ ID NO: 13 (Thy 3) corresponds to a portion of the thyroglobulin gene (SEQ ID NO: 28). SEQ ID NO: 16 (Thy 9) corresponds to a portion of the thymosin beta-4 gene



(SEQ ID NO: 29). SEQ ID NO: 17 (Thy 12) corresponds to a portion of the Acid ceramidase gene (SEQ ID NO: 30). SEQ ID NOS: 14,17 and 19-20 (Thy 5, Thy 11, Thy 14 and Thy 15) are only matched by EST sequences in the

5 databases.

Table II

SEQ ID NO	Clone	Serum react	Insert size (kb)	Access. No.	Identity
1	Mel 1	++	0.4	D30612	mRNA (partial) for repressor protein
2	Mel 2	+++++	0.7	D86956	KIAA0201, homolog to HSP
3	Mel 3	+	1.65	Novel	EST matches
4	Mel 4	++++	0.9	X65551/50	Ki-67 nuclear antigen, LONY-BR-8 (Breast SEREX)
8	Mel 8	+++	0.8		
9	Mel 9	++++	0.9		
10	Mel 10	++++	1.0		
5	Mel 5	++	1.25	X55039	CENP-B centromere autoantigen
6	Mel 6	+++	1.2		
7	Mel 7	+++	0.9	Novel	No EST match
11	Thy 1	+	0.8	X98893	TAF 1168
12	Thy 2	+	1.2	D000617	lipocortin II
13	Thy 3	+	1.7	X05615	thyroglobulin
14	Thy 5	+	2.7	Novel	Novel-EST matches
15	Thy 6	++	3.4	Novel	Novel-ESTs
16	Thy 9	+	0.6	M17733	thymosin beta-4
17	Thy 11	+	4.2	Novel	Novel-EST matches
18	Thy 12	++	0.8	U70063	Acid ceramidase
19	Thy 14	++	2.9	Novel	Novel-EST matches
20	Thy 15	++	2.5	Novel	Novel-EST matches

Table III

SEQ ID NO.	Accession NO.	Identity
21	D30612	Homo sapiens mRNA for repressor protein, partial cds
22	D86956	Human mRNA for KIAA0201 gene, complete cds
23	X65550	H.sapiens mki67a mRNA (long type) for antigen of monoclonal antibody Ki-67
24	X65551	H.sapiens mki67a mRNA (short type) for antigen of monoclonal antibody Ki-67
25	X55039	Human hCENP-B gene for centromere autoantigen B (CENP-B)
26	X98893	H.sapiens mRNA for TBP associated factor (TAFII68)
27	D00017	Homo sapiens mRNA for lipocortin II, complete cds
28	X05615	Human mRNA for thyroglobulin
29	M17733	Human thymosin beta-4 mRNA, complete cds
30	U70063	Human acid ceramidase mRNA, complete cds

**Example 3****Clone Reactivity with  
Sera from Allogeneic Cancer Patients**

5           The SEREX clones were tested for reactivity  
with 52 allogeneic sera from cancer patients (7 rectal,  
13 lung, 21 breast, 11 colon) and 10 allogeneic sera  
from normal individuals. The procedure was essentially  
10 as the SEREX method described in Example 1, except that  
'defined' cDNA molecules, i.e., the isolated clones  
were being expressed, blotted and screened with  
allogeneic sera rather than autologous sera. The  
allogeneic sera were treated in the same way the  
autologous sera were treated which as described in  
15 Example 1. Briefly, XL-1 E Coli cells were grown to OD  
1.0, spun down and suspended in 10 ml MgSO<sub>4</sub>. 20 ml of  
primary phage stock in SM-buffer were added to 100 ml  
of bacterial solution. Phage was sorbed for 15 min at  
28°C, then 0.5 ml of 2 YT medium and IPTG were added  
20 and samples were incubated at 42°C until lysis (6-7  
hrs). Afterwards, cell debris was spun down and 2 ml  
solution were transferred to Hybond-C filters,  
incubated with allogeneic sera samples overnight (sera  
1:100) and developed by standard method with anti-human  
25 anti-IgG horse radish peroxidase conjugate, stained  
with DAB. The level of immunoreactivity was estimated  
in arbitrary units, where 4=high signal level, 3=medium  
signal level, 2=weak signal, 1= absence of signal. An  
average mean of signals for each clone and type of  
30 cancer have been calculated, and mean of average signal  
for normal sera have been subtracted. Table IV  
summarizes the results.

35

**Table IV Dot Blot Analysis**

		C L O N E S																								
		ID NO	1	2	3	5	6	9	11	12	14	15	16	17	18	19	20	21	22	23	24	25				
		Rectal cancer																								
5	Rec1	1	2	1	4	3	1	1	2	1	2	2	3	3	3	2	2	2	2	2	2	2				
	Rec8	1	3	3	3	3	3	3	3	2	2	3	2	2	3	3	2	2	3	3	3	3				
	Rec3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	2	3	3	3				
	Rec4	2	2	3	3	3	2	3	3	3	2	3	2	2	2	2	2	2	2	3	3	3				
	Rec5	4	2	2	2	2	2	2	2	2	2	2	3	2	2	2	2	2	2	2	2	3				
10	Rec6	4	2	3	3	3	3	3	3	3	2	2	3	2	2	2	2	2	2	2	2	2				
	Rec2	3	2	3	3	3	2	3	3	3	3	3	3	4	3	3	3	2	2	2	3	3				
		18	16	18	21	20	16	18	19	17	16	18	20	17	18	16	14	14	17	18	20					
		Lung cancer																								
15	Lu2	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	3	3	3	3	3				
	Lu3	1	3	3	4	3	3	3	3	3	1	2	2	2	2	2	2	2	2	3	3	3				
	Lu46	1	2	3	3	3	2	1	1	1	3	2	3	3	3	3	3	3	3	2	2	4				
	Lu18	3	2	3	4	3	3	3	3	2	2	2	2	2	2	2	2	2	2	3	3	3				
	Lu24	1	1	1	3	3	3	3	2	2	3	2	2	2	2	3	3	3	2	3	3	4				
20	Lu26	3	2	3	3	3	2	2	2	2	2	2	2	2	2	2	2	2	2	2	2					
	Lu40	1	3	3	3	3	2	3	3	1	2	2	2	2	3	3	2	2	3	3	4					
	Lu44	1	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	2	2	3	4					
	Lu17	1	3	3	3	3	2	2	3	2	3	3	2	2	3	3	3	1	3	3	4					
	Lu49	3	2	2	3	3	2	3	3	3	2	2	3	2	3	3	3	3	2	2	3					
25	Lu4	2	2	2	3	3	2	2	3	2	1	2	3	1	2	2	2	2	2	2	2	3				
	Lu47	2	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	3					
	Lu50	2	1	1	3	3	1	1	2	2	1	2	2	3	3	3	3	1	2	2	2	3				
		22	30	33	41	39	31	32	34	29	29	30	32	30	35	34	34	28	33	34	42					
		Breast cancer																								
30	Br2	3	2	1	3	2	3	2	2	3	3	2	2	3	2	2	2	2	2	2	2	3				
	Br15	4	2	3	3	3	3	3	3	3	2	4	2	4	3	2	2	2	3	3	4					
	Br8	4	1	1	2	2	1	2	2	3	1	1	3	3	2	2	2	2	1	1	3					
	Br1	3	1	2	2	2	2	1	3	1	2	2	3	3	2	2	1	1	2	1	2					
	Br9	2	2	2	2	3	3	3	3	1	3	2	3	2	2	2	2	2	1	2	1					
35	Br3	2	1	3	2	3	3	3	2	2	2	1	3	2	2	2	2	2	2	3	3					
	Br10	3	2	4	3	3	3	1	4	2	2	3	4	4	3	3	3	2	2	2	2					
	Br17	3	3	3	3	3	2	3	3	3	2	3	3	3	3	3	1	1	3	3	3					
	Br16	1	1	1	1	2	2	1	2	1	2	1	1	1	1	1	1	1	1	2	1					
	Br4	2	2	2	1	2	2	2	2	1	1	1	2	2	2	2	1	1	1	1	2					
40	Br6	3	2	2	1	2	1	2	2	1	2	2	2	2	2	2	2	2	2	2	3					
	Br14	2	2	1	1	4	3	3	3	2	2	1	3	3	3	3	3	2	2	3	3					
	Br5	3	3	3	2	4	3	3	3	2	2	2	3	3	3	3	3	1	1	2	3					
	Br20	1	2	2	2	2	2	2	2	1	2	2	1	2	2	1	2	1	1	1	2					
	Br12	3	1	3	2	3	3	2	3	3	3	3	3	3	3	2	2	3	2	2	3					
45	Br19	3	3	3	2	3	3	2	3	2	2	2	3	3	1	3	3	1	1	1	2					
	Br18	3	3	3	2	3	3	2	2	1	1	2	2	2	2	2	3	1	1	1	3					
	Br11	2	1	2	1	3	2	2	2	1	1	2	2	2	2	2	2	2	1	1	2					
	Br248	1	1	2	2	2	2	3	2	4	2	3	3	2	3	3	1	1	3	3	4					
	Br257	1	2	3	3	3	3	3	3	4	1	3	2	3	4	4	3	3	3	4	4					
50	Br263	1	2	2	3	3	2	4	3	4	2	2	1	2	2	2	1	1	2	3	3					
		50	39	48	43	57	51	49	54	45	40	44	51	54	48	48	42	34	37	43	56					
	Colon cancer																									
55	Co5	4	3	3	3	3	3	3	3	3	2	2	3	3	3	3	3	1	3	3	3					
	Co30	3	2	3	3	3	3	3	3	3	2	2	3	3	3	3	3	2	3	3	3					
	Co17(?)	4	2	3	3	3	3	3	3	3	2	3	3	3	3	3	2	2	3	3	3					
	Co37	3	1	2	2	2	2	2	2	2	2	2	3	3	2	2	2	1	1	2	2					
	Co33	3	3	3	3	3	3	3	3	3	3	2	2	3	3	2	2	2	2	2	2					

**PCT/US00/04929**

-44-

All sera scoring 4 or 3 were classed as positive and the results of the dot blotting were summarized in Table V.

5

**Table V Clone Reactivity with Allogenic Sera**

	ID	Clone	SEQ ID NO	Allogenic cancer sera				
				Rectal (n=7)	Lung (n=13)	Breast (n=21)	Colon (n=11)	Normal (n=10)
10	1	Thy1	11	4	3	11	10	1
	2	Thy2	12	2	6	4	5	0
	3	Thy3	13	5	9	9	9	9
	5	Thy5	14	6	13	6	9	2
	6	Thy6	15	6	13	13	10	0
15	9	Thy9	16	3	6	11	10	0
	11	Thy11	17	5	8	9	9	3
	12	Thy12	18	5	9	11	9	1
	14	Thy14	19	4	5	8	8	0
	15	Thy15	20	2	6	3	4	1
20	16	Mel1	1	4	4	6	6	1
	17	Mel2	2	5	6	11	11	1
	18	Mel3	3	3	5	11	10	4
	19	Mel4	4	4	9	7	7	1
	20	Mel5	5	2	8	7	7	3
25	21	Mel6	6	0	8	6	2	0
	22	Mel7	7	0	4	2	0	3
	23	Mel8	8	3	7	4	8	0
	24	Mel9	9	4	8	7	8	0
	25	Mel10	10	6	11	13	10	0

Based on the data in Table V, the mean of the intensity values for each cancer sera type was calculated for each clone. The mean of the intensity values for each normal sera type was calculated For each clone. The difference between the cancer sera and normal sera is presented in Table VI. A value over 1.0 indicates a specific recognition of the clone by the type of cancer sera.

So for instance, SEQ ID No's 4, 8, 9, 10, which represent sequences of Ki-67, are specifically recognized by serum antibodies from rectal, lung, breast and colon cancer patients. Ki-67 is a marker of proliferation used in immunohistochemistry. The present invention has shown for the first time the association of this antigen with cancer.



**Table VI Specific Clone reactivity with allogenic cancer sera**

	ID	Clone	SEQ ID NO	Allogenic cancer sera			
				Rectal (n=7)	Lung (n=13)	Breast (n=21)	Colon (n=11)
5	1	Thy1	11	1.07	0.19	0.88	1.68
	2	Thy2	12	0.69	0.71	0.26	0.76
	3	Thy3	13	0.47	0.44	0.19	0.72
10	5	Thy5	14	1.2	1.35	0.24	1.02
	6	Thy6	15	1.55	1.7	1.41	1.61
	9	Thy9	16	0.59	0.68	0.73	1.21
	11	Thy11	17	0.47	0.36	0.23	0.72
	12	Thy12	18	1.01	0.92	0.87	1.12
15	14	Thy14	19	0.92	0.73	0.64	1.14
	15	Thy15	20	1.09	1.03	0.7	1.16
	16	Mel1	1	1.37	1.11	0.9	1.35
	17	Mel2	2	1.16	0.76	0.73	1.3
20	18	Mel3	3	0.32	0.21	0.47	0.81
	19	Mel4	4	1.37	1.49	1.09	1.44
	20	Mel5	5	0.91	0.52	0.19	0.54
	21	Mel6	6	0.6	1.22	0.6	0.6
	22	Mel7	7	0	0.05	0	0
25	23	Mel8	8	1.42	1.54	0.76	1.64
	24	Mel9	9	1.07	1.12	0.54	1.23
	25	Mel10	10	1.36	1.73	1.17	1.41

**Example 3**

Reactivity of a Fragment of Ki67  
Recombinantly Expressed in Bacteria  
With Allogenic Sera from Cancer Patients

5

A 0.5 kB sequence of Mel-9 clone was amplified by PCR, using Vent polymerase and a pair of specific primers. The primers used are:

10

Oligo N1, Ki67 sense, Nhe, 6His, 5610  
ATTGCTAGCCACCACCACCACCACAACTGGACCCAGCAGCAAGTGTAAAC  
(SEQ ID NO:31); and  
Oligo N2, Ki67 antisense, EcoRI, 6420  
CGGGAATTCCTATAGAGCCTCAGCCTTTTCCTTAGG (SEQ ID NO: 32)

15

Amplified cDNA fragment of Ki67 was subcloned into pET23d in a correct reading frame with the His-tag epitope. Expression of recombinant His-tag/Ki67 was carried out in DE3 pLysS cells in the presence of 1 mM IPTG. Recombinant protein had a predicted molecular weight (about 21 kDa) and was purified nearly to homogeneity by affinity chromatography on Talon Sepharose. Purified His-tag/Ki67 was used for heterologous screening of sera from healthy individuals and cancer patients.

25

Highly purified recombinant Ki67 was coupled to 96-well immunoassay plates (0.1-1 mkg per well). Non-specific binding of sera's IgG to plates was blocked by BSA. Binding of recombinant Ki-67 by specific antibodies present in normal and cancer sera was measured by ELISA using standard techniques. Four experiments were done. In each experiment, each sample of normal or cancer sera was tested against recombinant Ki-67. The mean values for corresponding sera types were calculated in each experiment and averages for normal and cancer sera were compared to determine differences. The difference in the measured intensity reflects the

30

difference in the amount of specific antibodies between cancer and normal sera.

Table VII presents the results. The results of this study indicate that sera from lung and breast cancer patients show increased immunoreactivity towards recombinant Ki67. The differences between the cancer sera and normal sera in immunoreactivity towards recombinant Ki67 were considered valid if p-value was less than 0.05. Statistical analysis indicated that significant differences were seen with lung and breast cancer sera, indicating that these cancer seras contained greater amounts of Ki-67 specific antibodies compared to normal sera.

**Table VII**

ELIZA: Recombinant Ki-67 screened with allogenic cancer and normal sera

	Exp	Sera Compared	Difference	Statistically Significant
20	exp 1	N1 vs. LU1	+	Yes
	exp 1	N1 vs. BR1	+	Yes
	exp 1	N1 vs. THY1	+	No
25	exp 2	N2 vs. LU2	+	Yes
	exp 2	N2 vs. CO2	+	No
	exp 3	N3 vs. LU3	+	Yes
	exp 3	N3 vs. BR3	+	Yes
30	exp 3	N3 vs. THY3	+	No
	exp 4	N4 vs. LU4	+	Yes
	exp 4	N4 vs. BR4	+	Yes

**WHAT IS CLAIMED IS:**

1. An isolated nucleic acid molecule or a part thereof, wherein said nucleic acid molecule has a sequence as set forth in any one of SEQ ID NOS: 3, 7, 14, 17, 19 or 20.

2. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 3.

3. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 7.

4. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 14.

5. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 15.

6. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 17.

7. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 19.

8. The isolated nucleic acid molecule or a part thereof of claim 1, wherein said nucleic acid molecule has a sequence as set forth in SEQ ID NO: 20.

9. An isolated nucleic acid molecule comprising a nucleotide sequence, the complementary sequence of which hybridizes under stringent conditions to at least one nucleic acid molecule of SEQ ID NOS: 3, 7, 14-15, 17 or 19-20.

10. An isolated protein encoded by the isolated nucleic acid molecule or a part thereof of claim 1.

11. An isolated antibody specific for a protein encoded by the nucleic acid molecule or a part thereof of claim 1.

12. An expression vector comprising the nucleic acid molecule or a part thereof of claim 1, operably linked to a promoter to effect the expression of a protein encoded by said nucleic acid molecule or a part thereof.

13. A cell, transformed or tranfected with the isolated nucleic acid molecule or a part thereof of claim 1.

14. A cell, transformed or tranfected with the expression vector of claim 12.

15. The cell of claim 14, wherein said cell is an antigen presenting cell having on the surface, a complex of an MHC molecule and a peptide, said peptide being encoded by a fragment of said nucleic acid molecule.

16. An isolated peptide/HLA complex, wherein said peptide is encoded by a fragment of any one of SEQ ID NOS: 3, 7, 14-15, 17 or 19-20.

17. A method for diagnosing a pathological condition in a patient, wherein said condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising the steps of:

- (i) obtaining a sample from said patient;
- (ii) assessing the expression of said nucleic acid molecule in said sample; and
- (iii) determining the expression of said nucleic acid molecule as abnormal thereby diagnosing said pathological condition.

18. The method of claim 17, wherein said pathological condition is selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

19. The method of Claim 18, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NO: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

20. The method of Claim 18, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

21. The method of Claim 18, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS:

21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

22. The method of Claim 18, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

23. The method of Claim 18, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

24. The method of Claim 18, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

25. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of mRNA of said nucleic acid molecule.

26. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of a protein encoded by said nucleic acid molecule or parts thereof.

27. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying the level of an antibody in the serum that is specific for a protein encoded by said nucleic acid molecule or parts thereof.

28. The method of claim 18, wherein the expression of said nucleic acid molecule is assessed by assaying a cell expressing an MHC/peptide complex and wherein said peptide is encoded by a fragment of said nucleic acid molecule.

29. A composition comprising a carrier and an antisense DNA of a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

30. A composition comprising a carrier and a protein encoded by a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

31. A composition comprising a carrier and an antibody directed against a protein encoded by a nucleic acid molecule or a part thereof, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30, or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20.

32. A composition comprising an immunogenic cell and a carrier, wherein said cell expresses a peptide complexed with an MHC molecule, said peptide being encoded by a fragment of a nucleic acid molecule, and wherein said nucleic acid molecule is any one of SEQ ID NOS: 14-15, 17 or 19-20.

33. A method for treating a patient afflicted with a pathological condition, wherein said



condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising any one of SEQ ID NO: 3, 7, 14-15, 17 or 19-20; said method comprising administering to said patient a therapeutically effective amount of at least one of: an antisense DNA of said nucleic acid molecule or part thereof, a protein encoded by said nucleic acid molecule or part thereof, an antibody specific for a protein encoded by said nucleic acid molecule or part thereof, or a cell expressing a MHC/peptide complex wherein said peptide is encoded by a fragment of said nucleic acid molecule.

34. The method of claim 33, wherein said pathological condition is selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

35. The method of claim 34, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

36. The method of claim 34, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleic acid sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

37. The method of Claim 34, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS:

21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

38. The method of Claim 34, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

39. The method of Claim 34, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

40. The method of Claim 34, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

41. A method for treating a subject afflicted with a pathological condition, wherein said condition is characterized by an abnormal expression of at least one nucleic acid molecule of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising:

(i) removing an immuno-reactive cell containing sample from said subject,

(ii) contacting the immuno-reactive cell containing sample with immunogenic cells expressing a peptide encoded by a fragment of said nucleic acid molecule complexed with an MHC molecule;

(iii) selecting the cytolytic T cells that are specific for said peptide; and

(iv) introducing a therapeutic effective amount of the cytolytic T cells produced from step (iii) to said subject thereby alleviating said condition.

42. The method of claim 41, wherein said pathological condition is one selected from the group consisting of melanoma, the presence of a thyroid tumor, rectal cancer, lung cancer, breast cancer and colon cancer.

43. The method of claim 42, wherein said pathological condition is melanoma and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-25, or a nucleic acid sequence comprising SEQ ID NO: 3 or 7.

44. The method of claim 42, wherein said pathological condition is characterized by the presence of a thyroid tumor and wherein said nucleic acid molecule is any one of SEQ ID NOS: 26-30, or a nucleic acid sequence comprising any one of SEQ ID NOS: 14-15, 17 or 19-20.

45. The method of Claim 42, wherein said pathological condition is rectal cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 30, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

46. The method of Claim 42, wherein said pathological condition is lung cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21 or 23-25, or a nucleotide sequence comprising any one of SEQ ID NOS: 14-15 or 20.

47. The method of Claim 42, wherein said pathological condition is breast cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 23-24, or a nucleotide sequence comprising SEQ ID NO: 15.

48. The method of Claim 42, wherein said pathological condition is colon cancer and wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-24, 26 or 29-30, or a nucleotide sequence comprising SEQ ID NO: 14-15 or 19-20.

49. A method of identifying the association of a pathological condition with an abnormal expression of a nucleic acid molecule, wherein said nucleic acid molecule is any one of SEQ ID NOS: 21-30 or a nucleic acid sequence comprising SEQ ID NO: 3, 7, 14-15, 17 or 19-20, said method comprising:

obtaining the serum from a patient suffering said pathological condition; and

detecting the presence of an antibody in said serum specific for an antigen encoded by said nucleic acid molecule, as indicative of an association of said pathological condition with the abnormal expression of said nucleic acid molecule.

50. The method of claim 49, wherein said nucleic acid molecule is SEQ ID NO: 23 or 24.

51. The method of claim 49, wherein said pathological condition is a cancer.

52. The method of claim 49, wherein the detection is carried out using a SEREX screening assay.

SEQ ID NO: 1 (Me11)

5 TGTNCAANGGGGNTNAGTGGTNACNGNCATGGGTACNNGCCTNTTCCC  
NNNGCNCCNGNNATATTGNGTGCANGNCGCANTNTTTNGNANANGCAGCN  
ACNGTGGACTGGTCCCTCNACAGGCCAGTTTNNNGGCCCCCAGAGTCANG  
NCCTCNACCANTGANNGATTNTGTTCCNGTTCATCCNCAGNGNAGAAGGG  
GCGAGGGAGAGNCNTTNTGCTTTTGAGGGTNANCNGTNAGGNGTNTNTTC  
CCNGCAGCAGCCGGTCAAGTGGATANTAGNGTNTGNGCNTCNGGNTNTCG  
TGCNNTGGGCCTCCCAATTGGNGGTATNTGNACTGCCCGTGNTCANGGAC  
10 NTGGCTACAGACCNTGNTGNGGCCANACCNTGCAGGCGCCTCGGGAAGCG  
CCCAAAGGATTCCCCTNNANGTTGGTGCACNTGATCCATAGNTCCGGGCG  
CTGNGTCCCGNGGGGGCCACAGTNNCCATNTCAGCGTCTTGCAATGGCNTGG  
CACCGGGTGGGGTGGTATGCCCCAGGACCCNTGNTTGTGNCAAAAATGAC  
TTTCCNTGCCCTTGCCGTGGGGCCGGGGTTCCTCCCANCCGGGATCACAG  
15 TGGGCAGCCGGCACCCGGCACCACCTTGGCGNGCGTCTGCTTCCGCCCT  
CGCCCTCATNTACGNTGNNCCGCTTTCCTCNGACCCCTTTTNCCTGTGA  
AAGGGAATTNTTGACATTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAA  
AAA

20

SEQ ID NO: 2 (Me12)

CTCCGGGAAGCGGCTCCCATTTGTTGTNGTACCCCGGAATTCGGCAGC  
AGGAGTTCAGANGACAAGCTGTGTGGACCATATGAAAAATTTATATGTGA  
25 GCAGGATCNTCAAAATTTTTTGGGACTCCTCACCAGAACTGAAGACTGG  
CTGTATGAAGAAGGAGAGGACCCAAGCTAAACAAGCATATGTTGACAAGT  
TGGAAGAATTAATGAAAATTGGCACTCCAGTTAAAGTTCGGTTTCAGGAA  
GCTGAAGAACGGCCAAAATGTTTGAAGAACTAGGACAGAGGCTGCAGCA  
TTATGCCAAGATAGCAGCTGACTTCAGAAATAAGGATGAGAAATACANCC  
30 ATATTGATGAGTCTGAAATGAAAAAGTGGAGAAGTCTGTAAATGAAGTG  
ATGGAATGGATGAATAATGTCATGAATGCTCAGGCTAAAAGAGTCTTGA  
TCAGGATCCAGTTGTACGTGCTCAGGAAATTAAACAAAAATCAAGGAAT  
TGAACAACACATGTGAACCCGTTGTAACACAACCGAAACCAAAATTGAA  
TCACCCAAANTGGAAAGAACTCCAAATGGCCCAAATATTGNTAAAAAAA

AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 3 (Me13)

5 TGGGNTTTTCCCCCTTTTTTNGNAACCCCNNTTTCNTNCCCCCNNTTG  
CCNTTNGGGTCTCGGGGGCCCCANTTTGGGNGNTTGGGGNGTTNCCGGG  
NGGTTTCCCAACCGTGCCCCNCCGTGGGTNACCCCCCGNGGCNNCCAGG  
GGTNGGCCNTGGGGGTTTCCGGCCGGGGGGTGCTTTTCCCNTTNNCANN  
CNAGTNAGGNTTTTTNTNGGGGGGGCCCCAANCCCTTTTTGGGAGGGGTC  
10 CCGNNGNAGGTCCNCNNTTGGCCCCCTNCAAGGGTNGGNGCCCCNCCCC  
CACCCCCCGGNCCCCCTTGGGAGNCCCGTTTAAATCNNTNGGGGGTCNT  
NGGCCTGGTTTTTNCCTGGTTTNCNCTNCCCCGTNCCCTTTTTTGGCCCN  
TTCCCTTTGGNTTTTGCCCCTNGGTTTTTTTCCCGGTTTGGGGNTTNCCA  
GGGGCCCCCCCCCTNGGAGTTNCCCAGGGGGGTTCNTTTNGGNCNNTN  
15 CCGNCCCCCTNCCTTTCCTCCCNNTTNGNNGGNCCCCCTTTTGGCCGG  
GGGGCCTTGGGGTTGGCCCCGGGNCCCCCNCCCGNTNNCCNTTNCCC  
NNTTNGTTTTNNATNAANTTTNCCNTCCCCCTTTTTNGGGGNGACNTTT  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
20 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
A

SEQ ID NO: 4 (Me14)

25 TTGTGTTGGAATTNTTGAGCGGATTAACANTTTTNACACNGGNAAACAGN  
TTTTGNNCCNTTGATTACNCCAANGTTATTTTAGGGTTGACANTTTTGGA  
ATTACTCAAGGTAGGNTNTTGGTTTAACATTGGCAAGGGTGTCTGGCATAG  
CCGANGATATTCGGTAGAGTTATATTGAGCAGATCCCCCGGTGAAGGATT  
TAACCGTGTTATCTCGTTGGAATATTCATGGCGTATTTTTGGATGATAAC  
30 GAGGCGCAAAAAATGAAAAGTACTNTAGCAATTGTGAGCGGACAACAATT  
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCCGAGATCTGG  
ACGAGCTTTTTTTTTTTTCTCGGGAAGCGCGCCATTGTGTTGGTACCCG  
GGAATTCGGCACGAGGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAC  
TGGTAGCAAGAGGCAGCCAAGAACTCCTAAGGAAAAGCCCAACCCCTAG

AAGACTTGGCTGGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGAC  
AAGCCCACGACTCATGAGAAAATAACCAAATAGCCTGCAGATCTCCACA  
ACCAGACCCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAA  
GTCTCAGGAAAGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGA  
5 ACACCATCAGTAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGA  
TGAGAAAGACATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACC  
TGCCAGGAAATTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAA  
AAGGCCCAGGC

10

SEQ ID NO: 5 (Me15)

ACCCCCAGGGGCAGGGGGAATTTTTTTGGGAAACCCGTTTNTGCATGGAG  
CCCAGNATTGNAGGGCCCCCANATCCCTTTNAGTAATTGNTTTCCCTTG  
15 GTCCTTGNAACAGGCCCCGGTTNACTTTGGCCGGGGCCCNGGGGTTGA  
GTTTCAGCCTTNANTTGCCTTGTTAATTGCNTCTTTTTTCAGAATCCTCTT  
TCTTCCCAATTTGNCCTTGGGTTTCAGGGGACCAGTTGGGGCGGNTGGGGA  
GTTGTCCGGTGTTACCACACNGTGCCNTCAGTGGANTAACCACAGCAGCA  
GCCAGGGATGGGCCTTGGAGGTTCCCGGCCGGAGAGTGCTTTCCCTTNT  
20 GCCATCCACGTACAGTCTTTGGTGGGGGGACCCCAAAGCCATTTTGGGAA  
GGGCTCCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGNTGGCAGCCCC  
CACCCCCACCCCCAGGCCGCTTGAGAAGCACAGTTTAACTCANTGCGG  
GCTCNTGAGCCTGCTTCTGCCGTGCTTTCCACNTCCCCAGTCCCTTTCTNT  
GGCCCTGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGT  
25 TTCCAAGAGGCCCCCACCGTGGAAGTAACCAAGGGCGNTTCCTTGTGGG  
CAGNTGCAGGCCCCATGCCNTNTCCTCCCTCTNTGGCAGGGCCCCATCNTG  
GGCAGAGGGGCCTGGGGNTGGGCCAGAGTCCAGCCGTCCAGNTGCTCCT  
TTCCAGTTTGATTTCAATAAATNTGTCCANTCCCCTTTTGTGGGGGTGA  
ACGTTTAAACAGCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
30 AA

SEQ ID NO: 6 (Me16)

TTTGAACATAAAAGGTTGNGTCANTTGAACNTAGTTNTGCCCCCAAACCT  
TGGATTGGCAGCAACAACCCAGGGGCAGGAGAATTTTTTGGGCAACCNG  
TTGTGCATGGAGCCAGATTGCAGAGCCCCANATCCTTTTAGTAATGCTTT  
CCCTTGNTCTTGAACAGGCCCCGGTAAC TTCGGCCGGGCCGGGGNTGAG  
5 GTCAGCCTCATTGCNTGCTTATTGCNTCTTCTCAGAATCCTCTTCNTC  
CCCATTTGGCCTTGGGCTCAGGGGACCAGGTGGGGCGGGTGGGAGCTTGT  
CCGGTGCTACCACACCGTGCCCTCAGTGGACTAACCACAGCAGCAGCCAG  
GGATGGGCCCTGGAGGTTCCCGGCCGGAGAGTGCTCTCCCTCTGCCAT  
CCACGTCAGGTCTTTGGTGGGGGGACCCCAAAGCCATTCTGGGAAGGGCT  
10 CCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGCTGGCAGCCCCACCC  
CCACCCNCAGGCCGCCTTGAGAAGCACAGTTTAACTCACTGCGGGCTCC  
TGAGCCTGCTTCTGCCTGCTTTCCACCTCCCCAGTCCCTTCTCTGGCCC  
TGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGTTTCCA  
AGAGGCCCCCACCGTGGAAGTAACCAAGGGCGCTTCTTGTGGGCAGCT  
15 GCAGGCCCCATGCCTCTCCTCCCTCTCTGGCAGGGCCCCATCCTGGGCAG  
AGGGGCCTGGGGCTGGGCCCAGAGTCCAGCCGTCCAGCTGCTCCTTTCCC  
AGTTTGATTTCAATAAATCTGTCCACTCCCCTTTTGTGGGGGTGAACGTT  
TTAACAGCCAAAAA

20

SEQ ID NO: 7 (Mel7)

CCCCNNNTCCCTNGNACNTNGGNCNTTTTNTTGGAATNNGGGGGGCNT  
CTTTTTTNTNGCCNTNNGGNNNNNGCCNTTTGNGGANTGGGGTTTTTT  
25 NTCGTTTTNNGCNCTCNGTTTTNTTTTTTGGGGGGGNTTCTNNTTGG  
GGGNCCTGTTNACCCCGGTTTTNNGGGGGCCNTGGTNTCTTNTTCCCT  
NGTTNNGGGGGACCCGTNCCCTTTTCNCCNNTTNGACCNGGGTNGCG  
GGGCCNCNTNNNCTCANNATTGGGACNNAANTTNGNTCNNTTGTNCCCG  
GGGGNNCCCCNCCGGGCNNGGGGGGGTNTNGGGTTTTTGNNTCNAAGN  
30 TNGGTNCCTTNGGCCNNGGTTNCCCCCNCCCTTGNTTGGGGNCCCCC  
CCCGGGGGGGGGCTTTTTNNGNNCCCCNTTTNNTTNGNNCCCGGTNNN  
GGGCCCCAATCCNTTTGGNATGGTTNCCCTNGTCCTTGAANCGNCCNG  
TNNCTNNGCCGGGGCCNNGGNTTGGGTTGGGGTTTCCCNGGGGGCCCC  
CCCCNTNGGNGTTNCCCAGGGGGGTTCNTTTNGGCCGNTTCNGGGCCCC



TNCCTTTCTCCCCNTTTGGNCGGGCCCCCTTNTNGGCCGGGGGGCCTTG  
GGGTNGGCCCCGGGNCCCNCCNCCCGNTNGNCCNTTNCCCGNTTNGT<sup>5</sup>TT  
NCNTNAANTTNTCCCCNCCCCCTTTTTGGGGGNNNANGTTTTTNCCCCC  
NAAA  
AAA  
AAA  
AAAAA

10 SEQ ID NO: 8 (Me18)

TGAAAAGGGGCNTTNAANGGCNTTTAAGGAATTTTGCAAAAGCCAGATTG  
TTTGGACCCAGCAAAANTNTTGAANTTGGGATGGAGANGTTGNCCAAGG  
AACACCTTAGGGANGAGGGCCCAATTCACTNGAAGACCTTGCCCGGNTTC  
15 AAAGGAGTTNTTCCAGACACCGGACCCACATTGAGGAATCAACAACTGAT  
GACAAACTACCAAAACAGCNTGCAATCTTCCACCACCCAGAATCAATG  
GACACTCCAACAAGCACAAGAGGCGGCCAAAACACCTTTGGGGAAAAGG  
GATATAGTGGAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCACACA  
CACAGACAAAGTACCAGGAGATGAGGATAAGGCATCAACGTGTTTAGGGA  
20 AACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGCAAGA  
GGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTTGGCT  
GGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCCACGAC  
TCATGAGAAAAC<sup>25</sup>TACCAAAATAGCCTGCAGATCTCCACAACCAGACCCAG  
TGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAAA  
GCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAGT  
AGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGACA  
TGAAAGCATTTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGGAAAT  
TTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCCCAGGC

30

SEQ ID NO:9 (Me19)

TTTTGGGCACCCCCAGGGTTTTAANANNTTATTGNTTNCCGGGNTTNGT  
AATTNTTGTNNTGAAATTTTTTGAGCCGNATAAACAANTTNCANCACAG

WO 00/50595

5 GGAAACAGGTNTTGNCCNATTGATTACNCCCAAGGTATTTTNGGTTGAC  
AATTATTGANTACTTCAAGTTNNCTNTTAGCTTTACATTGCAAAGGGTGT  
CGGCNTAAGCCGAAGATATCGGGTNGAGTTATATTGAGCAGAATCCCCC  
GTTGAAGGATTTAACCGTGTTATCTNGNTGGAATATTCATGGCGTATTTT  
TGGATGATAACGAGGCGCAAAAANTGAAAAGTACTTCTTGCAATTGTGAG  
CGGACAACAATTTACACAGGAAACAGCTATGACCATGATTACGCCAAGC  
TCCGAGATCTGGACGAGCTTTTTTTTTTTTCTCGGGAAGCGCGCCATTG  
TGTTGGTACCCGGGAATTCGGCACGAGGAAAGACATCAACACATTTGTGG  
GGACTCCAGTGGAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGCAAG  
10 AGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTTGGC  
TGGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCCACGA  
CTCATGAGAAAACACAAAATAGCCTGCAGATCTCCACAACCAGACCCA  
GTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAA  
AGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAG  
15 TAGGGAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGAC  
ATGAAAGCATTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGGAAA  
TTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCCCAGG

20 SEQ ID NO: 10 (Mel10)

CCGGAAGTTCAGGGGAAGGGCCANNACCGGACAACCACCGGGGGGACC  
GCCAGNGATTGGAAAGGGGCTTCAAGGCGTTTTAAGGAATCTTGCAA  
AGCCGGATGTTGGACCCAGCAAANTATTGGAANTGGGATTGAGAGGTTG  
25 GCCCAAGAACACNTAAGGAAGAGGCCCCAATCANTAGANGACCTTGCCGG  
CTTCAAAGAGCTNTTCCAGACACCAGGACCACATTGAGGAATCAACAAC  
TGATGACAAAACACTACCAAAACAGCNTGCAAATCTCCACCACCAGAATCAA  
TGGACACTCCAACAAGCACAAGGAGGCGGCCCAAAACACCTTTGGGGAAA  
AGGGATATAGTGGAAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCAC  
30 ACACACAGACAAAGTACCAGGAGATGAGGATAAAGGCATCAACGTGTTCA  
GGGAAACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAAGTGGTAGC  
AAGAGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTT  
GGCTGGCTTGAAAGAGCTCTTCCAGACACCAATATGCACTGACAAGCCCA  
CGACTCATGAGAAAACACTACCAAAATAGCCTGCAGATCTCCACAACCAGAC

CCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAG  
GAAAGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCAT  
CAGTAGGGAAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAA  
GACATGAAAGCATTATGGGAACTCCAGTGCAGAAATTGGACCTGCCAGG  
5 AAATTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCCC  
AGGC

SEQ ID NO: 11 (Thy1)

10 TGTGTGGAATTTTGGACCGGATACAATTTTACCCCGGGAACCAGNTNTA  
CCCTTGATTACCCCAAGCTATTTAGGTGACACTNTTGGATTACTCAAGC  
TGCTNTAGCTTTACATCGCAAGGGTGTCTGGCATAAGCCGAAGNATATCCG  
GAGAGTTATATTGAGCANATCCCCCGGTGAAGGATTTAACCGTGTATC  
15 TCGTTGGAATATTCATGGCGTATTTTGGATGATAACGAGGCGCAAAAAT  
GAAAAGTACTCTAGCAATTGTGAGCGGACAACAATTTACACAGGAAACA  
GCTATGACCATGATTACGCCAAGCTCCGAGATCTGGACGAGCTTTTTTTT  
TTTTTCTCGGGAAGCGCGCCATTGTGTTGGTACCCGGGAATTCGGCACGA  
GGGAGATCGAGGAGCTATGGAGGAGACAGAAGCCGGGGGGCTATGGAGG  
20 AGACCGTGTTGGTGGCAGTGGCTACGGTGGAGACCGAAGTGGAGNNTATG  
GAGGAGACAGGAGTGGTGGCGGCTATGGAGGAGACCGAGGTGGGGGCTAC  
GGAGGAGACCGAGGTGGCTATGGAGGCAAAATGGGAGGAAGAAACGACTA  
CAGAAATGATCAGCGCAACCGACCATACTGATGACTGTTTTGAATGTTCC  
TTTGTCTCTGACATGATCCATAGTGAAATTGCCAGAGTTTGCCTGCTGC  
25 TTTCCCTCGTGGCCTCTTCTTGGGTGTGAAATTAAGTGACATTTGGATTTT  
TATTTGGGTGGGAGGGCTGGGACAGTTTTTCT

30 SEQ ID NO: 12 (Thy2)

TTCCCTTTNGCCTNCCCGGGGGAAGGGCCCAAAAAGGAANTTGCATTNG  
CAATTGAAGTTCACCCNTTATTTTGCCCCACTTGGGAACGGTGATTTTTG  
GCCNTATTGAGAACACCTTGNTCAGTATGAGGCTTTTGAGCTAAANGCTT  
NCCATGAAGGGGCTGGGAACCGACGAGGATTCTCTCATTGAGATCATCTG

CTCCAGAACCAACCAGGAGTGCAGGAAATTAACAGAGTCTACAAGGAAAT  
GTACAGACTGATCTGGAGAAGGACATTATTTTCGGACACATCTGGTGA CTT  
CCGCAAGCTGATGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCT  
CTGTCAATTGATTATGAACTGATTGACCAAGATGCTCGGATCTCTATGACG  
5 CTGGAGTGAAGAGGAAAGGAAC TGATGTTCCCAAGTGGATCAGCATCATG  
ACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAG  
TTACAGCCCTTATGACATGTTGGAAA GCATCAGGAAAGAGGTTAAAGGAG  
ACCTGGAAAATGCTTTCCCTGAACCTGGTTCAGTGCATTCAGAACAAGCCC  
CTGTATTTTGCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCG  
10 AGATAAGGTCTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGT  
TGAAAATTAGGTCTGAATTCAAGAGAAAGTACGGCAAGTCCCTGTACTAT  
TATATCCAGCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCT  
GTGTGGTGGAGATGACTGAAGCCCCGACACGGCCTGAGCGTCCAGAAATGG  
TGCTCACCATGCTTCCAGCTAACAGG

15

SEQ ID NO: 13 (Thy3)

AGGGNTTNTAAACGGGGCNAAGGTTTTAAAGCAATTTTGGGNAAATGGAG  
20 CCCGNCCCCGTTGGAAAAACAN CCTTTTACAGGCATTCAGAATTTNTCTG  
GTTGGGGAGGATTCAGATGCCCCGCTTGGAGGCTGTTGNTACATGGTATTA  
TTCTTTGNGCACTCCACGGATGATTATGCCTCCTTNTTCCCGGGCTNTGG  
AGAATGCCACCCGGGATTACTTTATCATTTGCCCTATAATCGACATGNCC  
AGTGCTTGGCAAAGAGGGCCCGAGGAAACGTCTTCATGTACCATGCTCNT  
25 GAAAAC TACGGCCATGGCAGCCTGGAGCTGCTGGCGGATGTT CAGTTTGC  
CTTGGGGCTTCCCTTCTACCCAGCCTACGAGGGGCAGTTTCTCTGGAGG  
AGAAGAGCCTGTCGCTGAAAATCATGCAGTACTTTTCCCACTTCATCAGA  
TCAGGAAATCCCAATTACCCTTATGAGTTCTCACGAAAGTACCCACATT  
TGCAACCCCCCTGGCCTGACTTTGTACCCCGTGCTGGTGGAGAGAACTACA  
30 AGGAGTTCAGTGAGCTGCTCCCCAATCGACAGGGCCTGAAGAAAGCCGAC  
TGCTCCTTCTGGTCCAAGTACATCTCGTCTCTGAAGACATCTGCAGATGG  
AGCCAAGGGCGGGCAGTCAGCAGAGAGTGAAGAGGAGGAGTTGACGGCTG  
GATCTGGGCTAAGAGAAGATCTCCTAAGCCTCCAGGAACCAGGCTCTAAG  
ACTACAGCAAGTGACCAGCCCTTGAGCTCCCCAAAAACCTCACCCGAGGC

TGCCCCACTATGGTCATCTTTTTCTCTAAAATAGCCACTTACCTTCAATAA  
AGTATCTACATGCGGGAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 14 (Thy5)

5  
CGCCTGACTATCTTATATGATCTGCNGAACTGNATGTATCCAAGTAAGT  
AGTTAGCTAAGGAAGGTTNTTCATGCTTTNCTGTTTACAGNTGTGNNCTG  
TTTTTTAAGAATGTAACCTGTTTTAGNGTANAATGCATCTGGGNNTTNNT  
NCCNGCCACGGTGACANNAAACCGGGTNTNGGTCNNGGNANGTTGGNTCN  
10 TTCNCTTNCGNCAGAATCCCTTNTTCATTCCTCTTCTCTGTGTTTCAATCC  
TCTTCTGTGCTGTTCTGAAGCTTCTACCAATACTCTTCCATATTGTCTT  
TTTCAGTGAAGAGAAATGCATTCAAGATTAGGTCCCTCCTGTCTATCCAG  
TTTCAGGATTTTATGTTGTTTTATACACAGTTATTTTTCAGTATAGAACTG  
GCTTTATTGCCAAGTGTTTTTTTAAACATGTTTTTAACTCTCATATGAGCA  
15 AACTGTCCAACCTTCAGTTTTTTCATAAGATTAACTTCTTACGATCAAATT  
TGTCTCTTGCAATGATGTGATGAGTTGCCAAATAATTGAGATTATTTTAA  
AATGTTTTGTTTCATATTCTTGTTTTATAATTAAAATTTACATTCAGTGTG  
AAAAAAAAAAAAAAAAAAAAAAAAAAAA

20

SEQ ID NO: 15 (Thy6)

CANCTAAGCCGNTTNGGAAGGGATACACTCGGAAGTTTGCCAATTTTAAC  
GATCTTGCAGAACTTCGGCAACCATTTCCCTCTTTGAAGAGNGGACANCCA  
25 GCNGCAGNTTTNNTCNGAAAGGCGGCTCCAGGATNTTTGGCAAAGTTTG  
NAGNTNGGAAGAANCNACTTGTTTGGGGTTATNGCCCAGGCATTCAGGGT  
TTTNCAGGNTGAATTGGAAANCCGTTCTAATCAGGTGCGATGTGCAGAGA  
AAAATTACAACACAAGGAATTGGAGTCACAGGAACAGATAACTTACATAC  
GACAAGAATATGAAACAAAATTGAAAGGATTGATGCCAGCATCCCTAAGA  
30 CAAGAACCTGAAGACACCATTTCCCTCCCTAAAATCACAGGTTAATTTTCT  
GCAAAAGAGAGCTTCCATCCTTCAGGAAGAACTGACTACATATCAAGGCA  
GAAGGTAACCTGCACGAGAGAATGCAACGGATGCAATTTCCAGGCTGTGCT  
GTGGACTTCTTCCAGCAGGTTTGAAGATTGGATATTGTAACTGTGAGA  
TCAGTGGCATTTTTTTAAATCCTTAAATGTAATTAAGATCATAAAAACATG

CATCATTCATAAAAAAAAAAAAAAAAAA

SEQ ID NO: 16 (Thy9)

5 CCGGAATNTCGNTANGTCGAACTGAGGAGACAGAGACGCAAGAGAAAAAT  
CCACTGCCTTCCAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATC  
GTAATGAGGCGTGCGCCGCAATATGCACTGTACATTCCACAAGCATTGC  
CTTCTTATTTTACTTCTTTTAGCTGTTTAACTTTGTAAGATGCAAAGAGG  
TTGGATCAAGTTTAAATGACTGTGCTGCCCCTTTCACATCAAAGAACTAC  
10 TGACAACGAAGGCCGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTG  
GCAGGGAAGGAAAGAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGGAA  
GAAGTGGGGTGGGACGACAGTGAAA

15 SEQ ID NO: 17 (Thy11)

TCGGAACAGCNAACAAAGACCATGTCAAGGTCCCAAAGCCCACGGGGGTG  
AAGAAGGGATGGCAGNGNGNATATGCAGTCGTCTGTGACTGCAAGCTCTT  
CNTGTATGATCTGCNTGAAGGAAAATCCACCCAGCCTGGTGTCATTGCGA  
20 GCCAAGTCTTGATCTCAGAGATGACGAGTTTCCGTGAGNTCAGTCCTG  
GCCTCAGATGCATTCATGNTACACGCCGAGATATTCCATGTATATTCAGG  
GTGACGGCCTCTCTCTTAGGTGCACCTTNTAAGACCAGCTCTNTGCTCAT  
TNTGACNGAAAATGAGAATGAAAAGAGGAAGTGGG

25

SEQ ID NO: 18 (Thy12)

GCTCCGGAAATTTTGGACGGGNCTTTTTTTTTTTTTTCTCGGGGAAGCG  
30 GCNCCCATTTGTGTTTGTACCCCGGAATTTCCGCNACGGGGACCAAAA  
TTGAAGTTGGACAAACGGTTCTTTGCACAAATTGACGTACCATTTTCACA  
GTTTAATTCGTGAAGGTTTGGAAAGGTTAACCANGTTCTTATTAGTACTT  
TTCATAAGCAGTTGGATTTTCTGAAAAATACAGTAACATAATTTTGTAGTA  
ACTTACTTAAAATTTCTTTAAAACTCCCTATCAATCTGAAGAACAACAACTA

5 AAAACCTGTTTATTACATGAATGCTACTTATGAGAATTTAAAATATGGGT  
TCACTTCCTATTTTCCACAAGTCTTTGACTTGTTTATTTACTAAATTAAC  
AGAACGTGGGATGCAGTTTTTTAAGTTAGCAACTTCCTTAGGGTTACTGG  
GAAGTAGAGTAATTATGAAAAAGGGAACACTTCAATTATTGTATAAAAGA  
TTGCTTTGCATACTGATTACTTCTTGAACCCCAAAAAGTGCTATTTAGAG  
GCAAGGGCCCATTTTGTGCCCATTA AAAAGAAATATACAGGTGAATGTCTG  
TCTCATCCCTCTAATCATATGTAATAAAATTATATCGCTGTCAATAACAG  
CAAAGATAATGATATATTAATTTTAACAGCAGTTAGAACCAGAAGGAAAA  
GGCTGTTATACAGAAAAACATACAAATATGTAGGTAGAAGTGAAAACTG  
10 AAGAATGTGGAGTGTTTACTGTCCCGTTACTCACACAGACGTGCTGGATT  
CAACACCCACGCTGAATCTCCATTTATTCCACGGAGGTGGAGTTCACCAT  
GGTTCGACTGCCCAACAGATCCCCAAATGTCAAAGTGAAACAAAACCTCAG  
TGAAT

15

SEQ ID NO: 19 (Thy14)

CACTTGAAATTTTNGTTAGGNCCCTTTGGGNTTCCCTTNTTTCTTGTNNT  
TAAANTGGTTNTTGCAGCTTGTCCTTTTGGCCAACATAGGNCCTAATT  
20 TCAATGGAAGTGTAGTTTNNCTCTGGGGATTCTTTAACTTTAGAGCCAT  
TTNCTTTTCTTCAAAANTGATGAACTTTTGGTTTGAAAGGCTTANGGA  
GTGAAAAGCTCCTTGAAAATCCAGGCGGGTATGGAAGGTGCTGCTACCCA  
TATCTTTTGTACTTTCTTTGTTTTCATGACTTTAACTTCATGGCATCTCC  
TTTGTAGTAAAAGGAGACAGACCATTAAATTCAGCATTTCTTTGTGATTT  
25 ATAAGTACTGAGCATGAAGTACTTGTCTGCCCCTCATTTCAAGGCCAGAG  
TTATTTTCTATTTATGTATTAGTCTAGGCTGATCTTTTAGGGCACAATAG  
AAACCATGGGGCGTGGAGCATGAGTTGTGAATGGCAGGGATCATCTCTGGG  
TAAAAAAAACCTAGAAATCATTTCTGATGTGCAACATTGTCAAGTGAAGAA  
GCTAACAGTTCAACTACCGAGATTATTTGATAACCTGGGTTTCTCATTC  
30 ATCCATCAAGCACCATCAACCAGTCAGCCATTATTATTTATATATGTATT  
ACCAAAAAGCAGTCTATCTGCCTGTGACCTCCAATGTACACTGCCAAACAC  
AAGAGTAGGACACATCTGTTCTGGGTTCTTGACCTATCTGTCTCCAATTC  
ATCTCCCCTTTTAGCCATTTCAACAACTACTCTTTGGAGCTCTGAGAT  
GACATCTTGTGTTTTATATAGATGTATCTTTTAAAATAGTTCACGTTT

GGAGAATTCTTTTGTACTCATTTGCTTTTGTCTGAGAACCATGTCTATT  
TTTATAACTGGAGTGTGAGTTCTGTATCTTCTCACATTCTGTATACTGTA  
TCCATTT

5

SEQ ID NO: 20 (Thy15)

GGCGGCTTTGTNGCAGNNAAAGGCNGGNTNNCNAGGGATNGTTNGGACAN  
AAAGGTTTTGAAGGATTGCGGAAGGAAGCAGNTTGATTNGGNGGNTANTG  
10 ACCCAAGCCAATCCAAGGTTTTNANCACGGNTGAAATTTGGAAACCN GTT  
NCTAAATNCAGGTGCGGATGTGCAGGAGAAAAAATTACCAACCNCAAGGA  
NTTTGGAGTCACAGGAACNGGTTAACTTACATANGACAAGACTNNTGAAA  
CCAAAATTGAAAGGATTGATGCCAGCATCCCTAAGACAAGAACTTGAGAC  
ACCATTTCCCTCCCCTAAAGTCACAGNTTAATTTTCTGCAAAAGAGAGCTT  
15 CCATCNTTCAGGAAGAACTTGANTACATATCAAGGCAGAAGGTAAGTCA  
CGAGAGANTGCAACGGATGCAATTTCCAGGCTGTGCTGTGGACTTCTTCC  
AGCAGGTTTGAAGATTTGGATATTGTAAACTGTGAGATCAGTGGCATT  
TTAAATCCTTAAATGTANTTAAGATCATAAAAACATGCATCATTCATACA  
CTAGTGGGGTGGATTATTTGTGTCNTGCCTAAGTTATTTTTTTAACATTC  
20 CTTTATTTCCGATTTTCATGTTTGTGTGCATTTGAGTATGTGCTGAGAAC  
TGCTTATATTGGGCAAAGTGATTTCCCTATGATATGCCTTGTTAATCCTTT  
TGCATAGAATTTTACCAGTTGCGTACGATCAAAATCACGTTTGTAGTATC  
ATATCAAAAATTCTAACCTGTTTACATTGTTTTCATGTTTCATGTTTCCTAT  
GTTATTAAATATTATTTTGTAAAAA

25

SEQ ID NO: 21

gi|2723456|dbj|D30612|D30612 Homo sapiens mRNA for repressor protein  
, partial cds

30

ACCCACGCGTCCGGCCGCCGAAGGGGACTGTTTGCTCCTACGGGCTGTAGATGGAGCTGTCCGGCCCCGG  
AGAGGGGGAAGGCGCTGGAAAACGTTCTTCTTCTCCCTGGCCGACCCGAGCGGGGAACAGCACTCCCAG  
GATGCAGTTTGTGTCAACACGGCCGCAGCCTCAGCAGCTGGGCATCCAGGGCTTGGGGCTGGACAGCGGG  
AGCTGGAGCTGGGGCCAGGCTCTGCCCCCGAGCAGGTCTGCCACCAGGAGCCGGCGCTGCGCGGGGAAA  
TGCGCCGAGGGAATGCCGCCATGCAGGCTCAAGAATGGGACATGGACGCCCGGGCGGCAATGCCTTTTCA  
GTTCCCACCCTTTCCAGATAGGGCACCTGTCTTCCCGACCGCATGATGCGAGAGCCCCAGTTGCCACACA  
35 GCAGAGATCTCACTCTGGACTGTGGTGGCTGCCATTGAGGCTGTGGAGAGGAAGGTGGATGCCAGGCCA  
GCCAGCTGCTGAACCTGGAGGGGCGCACGGGGACAGCCGAGAAGAAGCTGGCCGACTGTGAAAAGACGGC



CGTGGAATTTGGGAACCATGGAGAGCAAGTGGGCCGTGCTGGGGACCCCTGCTGCAGGAGTACGGGCTG  
CTGCAGAGGGCGGCTGGAGAACTTGGAGAACTTGTGCGCAACAGGAATTCTGGGTCTGCGGCTGCCCC  
CGGGCAGCAAGGGGGAGGCCCCAAGGTTCCAGTGACTTTTGTGACATTGCTGTGTACTTCTCCGAAGA  
CGAGTGGAAGAACTTGGACGAATGGCAGAAGGAGCTTTATAACAACCTTGTTAAGGAGAACTACAAAACC  
5 CTCATGTCCCTGGACGCGGAGGGCTCAGTCCCCAAGCCAGATGCTCCAGTCCAGGCTGAGCCCAGGGAAG  
AACCTTGTGTGTGGGAGCAGCGCACCCCGAAGAGAGAGAAATCCCAATGGATCCCGAAGCAGGAGCAGA  
GCCCCGTGGTGCCTGCGCAGGATGCGTCTCTCCAGGTGAAGCGTGAGGACACCCCTGTGTGTCCGGGGTCAG  
CGGGGCTGGAGGAAAGAGCCATCCCTACGGAATCCATTACCGACTCCCCAATTTCTGCCCAGGACCTCT  
TGTCCCGGATTAAACAGGAGGAGCATCAGTGGGTGTGGGATCAGCAGGATTTGGCAGACAGAGATATTCC  
10 CACGGATCCCAATTTCAGAGTCTCTCATCTCAGCACATGACATTTTGTTCATGGATCAAGCAGGAGGAGCAG  
CCATACCCATGGGGACCACGCGACTCAATGGACGGAGAGCTTGGATTAGACTCTGGCCCTAGTGACAGCC  
TGCTGATGGTGAAGAACCACCCCCGGCCCCGCCACAGCCCCAGCCCCAGCGCCAGCCACCGCAGCCGCA  
GCTGCAGTCGCAGCCCCAGCCCCAGAGCCTGCCCCCATCGCGGTGGCCGAGAACC CGGGCGGCCCCCG  
AGCCGAGGGCTGCTGGACGACGCTTTCCAGGTGCTGCCCGGGAGCGTGGCTCCGGCGAGGCGCCGCGCG  
15 GTGGGGACCGCAGCACCGGGGGCGGGGGGGCGATGGGGGGCGGTGGGGGGCGGGCGCGGAGGCGGGGAC  
GGGGGCAGGCGGCGGCTGTGGCAGCTGCTGCCCTGGCGGGCTGCGGCGGAGCCTCCTCCTGCACGGCGCC  
CGCAGCAAGCCCTACTCGTGCCCCGAGTGCGGCAAGAGCTTCGGCGTGCGCAAGAGCCTCATCATCCACC  
ACCGCAGCCACACCAAGGAGCGGCCCTACGAGTGCGCTGAGTGCGAGAAGAGCTTCAACTGCCACTCGGG  
CCTCATCCGCCACCAGATGACGCACCGCGGAGCGGCCCTACAAGTGCTCGGAGTGCGAGAAGACCTAC  
20 AGCCGTAAGGAGCACCTGCAGAACCAACAGCGGCTGCACACGGGCGAGCGGCCTTTCCAATGTGCACTGT  
GCGGCAAGAGCTTCATCCGCAAGCAGAACCTGCTCAAGCACCAGCGCATCCACACGGGCGAGCGCCCCCTA  
CACGTGCGGGCAGTGCGGCAAGAGCTTCCGCTACAAGGAGTCGCTCAAGGACCACCTGCGCGTGACAGC  
GGCGGCCCCGGGCCCCGGCGCCCCACGGCAGCTCCCGCGCCTCCTGAGCGAGACTAGGGCTGGGCTGGGG  
GAGGGCAGGGCCGACGGAGTGGATCGGGGGCGGCCGTGAGCACCAACCACCTTGCCGGGTGCCTCAGCC  
25 ACCGTCTGGAAATCGGCAACAGGCATTGCACTCCGGTTGGGGGTCCCCCAGGGTGGGGCAGGGATCCCCC  
AGATCTGTCTGGTCTGAATGGACGCCCAGCTCATCTAGGGTGGACCCAGCTGCTGGGGAAGAGCCAGGGG  
GACCGCGAGGAGCCGAGCGTCTCGGGCACCGCCCTCACACCTCCTCGAGTGCCCTGGGACCCTGGGCC  
ACAGATGGTCATCAGGGGAAGCCACCAGGGAGTCCCGAAGCCCTTCTGAGATCAGGAAATCAGGTCCCAA  
GGTTAGGAGACGCCCTGAAAAAAGTGAAGCCGAGGGATGTGCTAAGGGTAACACCTTCATGATGACAA  
30 CACTGCCTCGCGTTTCAATAGCGCTTTATACTTTTTTAAGTGTTTTCTATCCGTTATCCATTTCACCCCTT  
GGCCTATCCCTCTCAGATAGGTGGGGTAGGATTTTCCTGGTGACCGAGTAAAGTGAGAGGCAGGTGAGAC  
GGTTACCCAATCACACGGGAAGGGGCGCGCTGCCCAACCGCGCTCTCCGCTACCTCGCTGCTCGGG  
AAGCTGCTGGCCTGGCCCTCCTGGTCTCTCTTCTTTCTGGTCTCTCTCCTTTCTTCTGCTCTCACCAC  
GGATAAAACCAGAAGCGACAGGAGCCAGCTCCTGGGGTTCCTGGGACCGGGAACAGATTGGCTACGGAA  
35 CGCCCCAGGTTGTACATTTCAGAGGGCTCTTTCTCCATGGGAGCTCCTGGTGCCGCCTTCGGCCCCAGCCT  
GTCCCCAGCCCCCAATCTGGTGCAGCAGCATCTTGTCACTGCACAACAGTGGCCTGGTCCCCCAGAGC  
AGTTAGGGCCCCAGGTCAGACCTCACCATGATGATTTGTTCAGTTCTCCAGGGCAGAGGGGCGAGGGA  
GAGGCTTTTGTGTGAGAGTAGCCGTACGTGTCTCTTCCCAGCAGCGCCGGGCAAGTGGGTGCTAGAGT  
CTGAGCCTCAGGCTCTCCTGCCCTGGGCCTCCCAATTGGTGCTATCTGTACTGCCCGTGCTCACGGACA  
40 TGGATACAGACCCTGCTGTGCTCCACACCTGCAGGCGCCTCGGGAAGCGCCCAAAGGATTCCCTTCAC  
GTTGGTGACCTGCTCCATAGCTCCGGGCGCTGCGTCCCGAGGGGCCACAGTCTCCATTTCAGCGTCTTG

5

CATGGCCTGGCACC GGGTGGGGTGGTATGCCCCCTTGTTTGTGTCAAAAATGACTTTCCTGCCCTTGCC  
GTGGGTCCGGCGTTCCCTCCCAGCCGGGATCACAGTGGGCAGCCGGCACC CGGCACCACTTTGGCGAGCGT  
CCTGCTTCGCCCCTCGCCCTCATCTACGCTGCTCCGCTTTCCTCAGACCCCTTTTGGCCGTGCAAAGGAA  
TTCTTGACATTAAATAAAAGGTATCCAGATTGCAGACTGCATGTTACAGAGCTGGGGGTCTCCAGCTT  
GCCTACAGTAAAGCCTCAATGAACTGG

SEQ ID NO: 22

>gi|1503985|dbj|D86956|D86956 Human mRNA for KIAA0201 gene, complete cds

5 CTGAGGAAGTGGGACCTCCCCCTTTTGGGTCTGGTAGTTCAGCGCCGCGCGCGGTGTGCGAGCCGCGGCAGA  
GTGAGGCAGGCAACCCGAGGTGCGGAGCGACCTGCGGAGGCTGAGCCCCGCTTTCTCCAGGGTTTCTTA  
TCAGCCAGCCGCGCTGTCCCCGGGGAGTAGGAGGCTCCTGACAGGCCGCGGCTGTCTGTGTCTCTTC  
TGAGTGTCTAGAGGAACGGCCAGACCCCGGGGCCGAGCAGAACGCGCCAGGGCAGAAAGCGGCGGCAG  
GAGAAGCAGGCAGGGGGCCGGAGGACGACAGACCCGAGGCGGAGGCGGACCGCGAGCCGGCCATG  
10 TCGGTGGTGGGGTTGGACGTGGGCTCGCAGAGCTGCTACATCGCGGTAGCCCGGCCGGGGGCATCGAGA  
CCATCGCCAATGAGTTCAGCGACCGGTGCACCCCGTCAGTCATATCATTTGGATCAAAAAATAGAACAAT  
CGGAGTTGCAGCCAAAAATCAGCAAACTCACTCATGCAAAACAATACGGTGTCTAACTTCAAAAGATTTTCAT  
GGCCGAGCATTTCAATGACCCCTTCATTTCAAAGGAGAAGGAAACTTGAGTTACGATTTGGTTCCATTGA  
AAAATGGTGGAGTTGGAATAAAGGTAATGTACATGGGTGAAGAACATCTATTTAGTGTGGAGCAGATAAC  
15 AGCCATGTTGTTGACTAAGCTGAAGGAACTGCTGAAAACAGCCTCAAGAAACCAGTAACAGATTGTGTT  
ATTTTCAGTCCCCCTCTTCTTTACAGATGCTGAGAGCGCATCTGTGTTAGATGCTGCACAGATTGTTGGCC  
TAAACTGTTTAAAGACTTATGAATGACATGACAGCTGTTGCTTTGAATTACGGAATTTATAAGCAGGATCT  
CCCAAGCCTGGATGAGAAACCTCGGATAGTGGTTTTGTGTTGATATGGGACATTCAGCTTTTCAAGTGTCT  
GCTTGTGCTTTTAAACAAGGAAAATTGAAGGTACTGGGAACAGCTTTTGATCCTTTCTTAGGAGGAAAAA  
20 ACTTCGATGAAAAGTTAGTGGAACATTTTTGTGCAGAATTTAAACTAAGTACAAGTTGGATGCAAAATC  
CAAAATACGAGCACTCCTACGTCTGTATCAGGAATGTGAAAACTGAAAAAGCTAATGAGCTCTAACAGC  
ACAGACCTTCCACTGAATATCGAATGCTTTATGAATGATAAAGATGTTTCCGGAAGATGAACAGGTCAC  
AATTTGAAGAACTCTGTGCTGAACCTTCTGCAAAAGATAGAAGTACCCCTTTATTCAGTGTGGAACAAAC  
TCATCTCAAAGTAGAAGATGTGAGTGCAGTTGAGATTGTTGGAGGCGCTACACGAATTCAGCTGTGAAG  
25 GAAAGAATTGCCAAATTCTTTGGAAAAGATATTAGCACAACTCAATGCAGATGAAGCAGTAGCCAGAG  
GATGTGCATTACAGTGTGCAATACTTTCCCCGCATTTAAAGTTAGAGAATTTCCGTCACAGATGCAGT  
TCCTTTTCCAATATCTCTGATCTGGAACCATGATTCAGAAGATACTGAAGGTGTTTCATGAAGTCTTTAGT  
CGAAACCATGCTGCTCCTTTCTCCAAAGTTCTCACCTTTCTGAGAAGGGGGCCTTTTGAGCTAGAAGCTT  
TCTATTCTGATCCCCAAGGAGTTCATATCCAGAAGCAAAAATAGGCCGCTTTGTAGTTCAGAATGTTTC  
30 TGCACAGAAAGATGGAGAAAAATCTAGAGTAAAGTCAAAGTGGAGTCAACACCCATGGCATTTTCACC  
ATCTCTACGGCATCTATGGTGGAGAAAGTCCCAACTGAGGAGAATGAAATGTCTTCTGAAGCTGACATGG  
AGTGTCTGAATCAGAGACCACCAGAAAACCCAGACACTGATAAAAATGTCCAGCAAGACAACAGTGAAGC  
TGGAACACAGCCCCAGGTACAACTGATGCTCAACAAACCTCACAGTCTCCCCCTTCACCTGAACTTACC  
TCAGAAGAAAACAAAATCCCAGATGCTGACAAAGCAAATGAAAAAAAAGTTGACCAGCCTCCAGAAGCTA  
35 AAAAGCCCCAAAATAAAGGTGGTGAATGTTGAGCTGCCTATTGAAGCCAAC TTGGTCTGGCAGTTAGGGAA  
AGACCTTCTTAACATGTATATTGAGACAGAGGCTAAGATGATAATGCAAGATAAATTGGAAAAAGAAAGG  
AATGATGCTAAAAATGCAGTTGAGGAATATGTGTATGAGTTCAGAGACAAGCTGTGTGGACCATATGAAA  
AATTTATATGTGAGCAGGATCATCAAAATTTTTTGAGACTCCTCACAGAACTGAAGACTGGCTGTATGA  
AGAAGGAGAGGACCAAGCTAAACAAGCATATGTTGACAAGTTGGAAGAATTAATGAAAATTGGCACTCCA  
40 GTTAAAGTTCGGTTTCAGGAAGCTGAAGAACGGCCAAAAATGTTTGAAGAACTAGGACAGAGGCTGCAGC  
ATTATGCCAAGATAGCAGCTGACTTCAGAAATAAGGATGAGAAATACAACCATATTGATGAGTCTGAAAT

GAAAAAAGTGGAGAAGTCTGTTAATGAAGTGATGGAATGGATGAATAATGTCATGAATGCTCAGGCTAAA  
AAGAGTCTTGATCAGGATCCAGTTGTACGTGCTCAGGAAATTAAAAACAAAAATCAAGGAATTGAACAACA  
CATGTGAACCCGTTGTAACACAACCGAAACCAAAATTTGAATCACCCAACTGGAAAGAACTCCAAATGG  
CCCAAATATTGATAAAAAGGAAGAAGATTTAGAAGACAAAAACAATTTTGGTGCTGAACCTCCACATCAG  
5 AATGGTGAATGTTACCCTAATGAGAAAAATTTCTGTTAATATGGACTTGGACTAGATAACCTTAAATTGGC  
CTATTCCTTCAATTAATAAAATATTTTGGCCATAGTATGTGACTCTACATAACATACTGAAACTATTTAT  
ATTTTCTTTTTTAAGGATATTTAGAAATTTTGTGTATTATATGGAAAAAGAAAAAGCTTAACTCTGTA  
GTCTTTATGATCCTAAAAGGGAAAATTGCCTTGTTAACTTTCAGATTCTGTGGAATTGTGAATTCATAC  
TAAGCTTTCTGTGCAGTCTCACCATTTGCATCACTGAGGATGAACTGACTTTTGTCTTTTGGAGAAAAA  
10 AACTGTACTGCTTGTTCAAGAGGGCTGTGATTAAAATCTTTAAGCATTTGTTCTGCCAAGGTAGTTTT  
CTTGCATTTTGTCTCCATTTCAGCATGTGTGTGGGTGTGGATGTTTATAACAAGACTAAGTCTGACTTC  
ATAAGGGCTTTCTAAAACCATTTCTGTCCAAGAGAAAATGACTTTTTTGCTTTGATATTAAAAATTCAATG  
AGTAAAAACAAAGCTAGTCAAATGTGTTAGCAGCATGCAGAACAAAACTTTAACTTTCTCTCTCACTA  
TACAGTATATTGTCATGTGAAAGTGTGGAATGGAAGAAATGTGATCCTGTTGTAAGTGAATGTGAACAC  
15 TTTTATGAGCTTTAAAATAAAGTTCATCTTATGGTGTCAATTTCT

SEQ ID NO: 23

>gi|415818|emb|X65550|HSMKI67 H.sapiens mki67a mRNA (long type) for  
antigen of monoclonal antibody Ki-67

5 CTACCGGGCGGAGGTGAGCGCGGCGCGGCTCCTCCTGCGGCGGACTTTGGGTGCGACTTGACGAGCGGT  
GGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGAAGAGTTGTAAATTTGCTTCTGGCCTTCCC  
CTACGGATTATACCTGGCCTTCCCCTACGGATTATACTCAACTTACTGTTTAGAAAATGTGGCCACGAG  
ACGCCCTGGTTACTATCAAAAGGAGCGGGGTCGACGGTCCCCACTTTCCCCTGAGCCTCAGCACCTGCTTG  
TTTGAAGGGGTATTGAATGTGACATCCGTATCCAGCTTCCTGTTGTGTCAAAACAACATTGCAAAATTG  
10 AAATCCATGAGCAGGAGGCAATATTACATAATTTAGTTCCACAAATCCAACACAAGTAAATGGGTCTGT  
TATTGATGAGCCTGTACGGCTAAACATGGAGATGTAATAACTATTATTGATCGTTCCTTCAGGTATGAA  
AATGAAAGTCTTCAGAATGGAAGGAAGTCAACTGAATTTCCAAGAAAAATACGTGAACAGGAGCCAGCAC  
GTCGTGTCTCAAGATCTAGCTTCTCTTCTGACCCTGATGAGAAAGCTCAAGATTCCAAGGCCTATTCAAA  
AATCACTGAAGGAAAAGTTTCAGGAAATCCTCAGGTACATATCAAGAAATGTCAAAGAAGACAGTACCGCA  
15 GATGACTCAAAAGACAGTGTGCTCAGGGAACAATAATGTTTCATTCCCTCAGAACATGTGAGCGTAATG  
GCAGAAATGCAGCTGATCCCATTTCTGGGGATTTTAAAGAAATTTCCAGCGTTAAATTAGTGAGCCGTTA  
TGGAGAATTGAAGTCTGTTCCCACTACACAATGTCTTGACAATAGCAAAAAAATGAATCTCCCTTTTGG  
AAGCTTTATGAGTCAGTGAAGAAAGAGTTGGATGTAAATCACAAAAAGAAAATGTCCTACAGTATTGTA  
GAAATCTGGATTACAACTGATTACGCAACAGAGAAAGAAAGTGCCTGATGGTTTACAGGGGGAGACCCA  
20 ACTGTTGGTCTCGCGTAAGTCAAGACCAAAATCTGGTGGGAGCGGCCACGCTGTGGCAGAGCCTGCTTCA  
CCTGAACAAGAGCTTGACCAGAACAAGGGAAGGGAAGAGACGTGGAGTCTGTTTCAGACTCCCAGCAAGG  
CTGTGGGCGCCAGCTTTCCTCTCTATGAGCCGGCTAAATGAAGACCCCTGTACAATATTACAGCAACA  
AAATTCCTCCACAAAACATAAGAACAAGACCTGTATACTACTGGTAGAAGAGAATCTGTGAATCTGGGT  
AAAAGTGAAGGCTTCAAGGCTGGTGATAAACTCTTACTCCCAGGAAGCTTTCAACTAGAAATCGAACAC  
25 CAGCTAAAGTTGAAGATGCAGCTGACTCTGCCACTAAGCCAGAAAATCTCTCTTCCAAAACCAGAGGAAG  
TATTCCTACAGATGTGAAGTTCTGCCTACGGAACTGAAATTCACAATGAGCCATTTTAACTCTGTGG  
CTCACTCAAGTTGAGAGGAAGATCCAAAAGGATTCCCTCAGCAAGCCTGAGAAATTGGGCACTACAGCTG  
GACAGATGTGCTCTGGGTTACCTGGTCTTAGTTTCAGTTGATATCAACAACCTTTGGTGATTCCATTAATGA  
GAGTGAGGGAATACCTTTGAAAAGAAGGCGTGTGTCTTTGGTGGGCACCTAAGACCTGAACTATTGAT  
30 GAAAATTCCTCCTAATACGCCTCTCAAAAGGGGAGAAGCCCCAACCAAAAGAAAGTCTCTGGTAATGC  
ACACTCCACCTGTCTGAAGAAAATCATCAAGGAACAGCCTCAACCATCAGGAAAACAAGAGTCAGGTTC  
AGAAATCCATGTGGAAGTGAAGGCACAAAGCTTGGTTATAAGCCCTCCAGCTCCTAGTCCTAGGAAAAT  
CCAGTTGCCAGTGATCAACGCCGTAGGTCTGCAAAACAGCCCCTGCTTCCAGCAGCAAATCTCAGACAG  
AGGTTCCCTAAGAGAGGAGGAGAAAGAGTGGCAACCTGCCTTCAAAGAGAGTGTCTATCAGCCGAAGTCA  
35 ACATGATATTTTACAGATGATATGTTCCAAAAGAAGAAGTGGTGCTTCGGAAGCAAATCTGATTGTTGCA  
AAATCATGGGCAGATGTAGTAAACTTGGTGCAAAACAAACACAACTAAAGTCATAAAACATGGTCTCTC  
AAAGGTCAATGAACAAAAGGCAAAGAAGACCTGTACTCCAAAGAAGCCTGTGGGCGAAGTTCACAGTCA  
ATTTAGTACAGGCCACGCAAACTCTCCTTGTACCATAATAATAGGGAAAGCTCATACTGAAAAAGTACAT  
GTGCCTGCTCGACCTACAGAGTGCTCAACAACCTCATTTCCAACCAAAAAATGGACTTTAAGGAAGATC  
40 TTTCAGGAATAGCTGAAATGTTCAAGACCCAGTGAAGGAGCAACCGCAGTTGACAAGCACATGTCACAT  
CGCTATTTCAAATTCAGAGAATTTGCTTGGAACAGTTTCAAGGAAGTATTGAGGAGAAGAACCTCTG

CTCCCCACCTCAGAGAGTTTGGAGGAAATGTGTCTTCAGTGCACAGAATGCAGCAAAACAGCCATCTG  
ATAAATGCTCTGCAAGCCCTCCCTTAAGACGGCAGTGTATTAGAGAAAATGGAACGTAGCAAAAACGCC  
CAGGAACACCTACAAAATGACTTCTCTGGAGACAAAACCTTCAGATACTGAGACAGAGCCCTTCAAAAACA  
GTATCCACTGTAAACAGGTCAGGAAGGTCTACAGAGTTCAGGAATATACAGAAGCTACCTGTGGAAAGTA  
5 AGAGTGAAGAAACAAATACAGAAATTGTTGAGTGCATCTTAAAAAGAGGTGAGAAGGCAACACTACTACA  
ACAAAGGAGAGAAGGAGAGATGAAGGAAATAGAAAGACCTTTTGAGACATATAAGGAAAATATGAAATTA  
AAAGAAAACGATGAAAAGATGAAAGCAATGAAGAGATCAAGAACTTGGGGGCAGAAATGTGCACCAATGT  
CTGACCTGACAGACCTCAAGAGCTTGCCCTGATACAGAACTCATGAAAGACACGGCACGTGGCCAGAATCT  
CCTCCAAACCCAAGATCATGCCAAGGCACCAAGAGTGAGAAAGGCAAAATCACTAAAATGCCCTGCCAG  
10 TCATTACAACCAGAACCAATAAACACCCCAACACACAAAAACAACAGTTGAAGGCATCCCTGGGGAAAG  
TAGGTGTGAAAGAAGAGCTCCTAGCAGTCGGCAAGTTCACACGGACGTCAGGGGAGACCACGCACACGCA  
CAGAGAGCCAGCAGGAGATGGCAAGAGCATCAGAACGTTTAAGGAGTCTCCAAGCAGATCCTGGACCCA  
GCAGCCCGTGTAAGTGAAGAGTGGCCAAGAAGCCTAAGGAAGAGGCCAGTCACTAGAAGACC  
TGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGTCCTCTGAGGAATCAATGACTGATGAGAAAACCTAC  
15 CAAAATAGCCTGCAATCTCCACCACCAGAATCAGTGGACACTCCAACAAGCACAAAGCAATGGCCTAAG  
AGAAGTCTCAGGAAAGCAGATGTAGAGGAAGAATTCTTAGCACTCAGGAACTAACACCATCAGCAGGGA  
AAGCCATGCTTACGCCCAAACAGCAGGAGGTGATGAGAAAGACATTAAAGCATTTATGGGAACTCCAGT  
GCAGAACTGGACCTGGCAGGAACCTTACCTGGCAGCAAAAGACAGCTACAGACTCCTAAGGAAAAGGCC  
CAGGCTCTAGAAGACCTGGCTGGCTTTAAAGAGCTCTTCCAGACTCCTGGTCACACCGAGGAATTAGTGG  
20 CTGCTGGTAAACCCTAAAATACCTGCGACTCTCCACAGTCAGACCCAGTGGACACCCCAACAAGCAC  
AAAGCAACGACCCAAGAGAAGTATCAGGAAAGCAGATGTAGAGGGAGAACTCTTAGCGTGCAGGAATCTA  
ATGCCATCAGCAGGCAAAGCCATGCACACGCCTAAACCATCAGTAGGTGAAGAGAAAGACATCATCATAT  
TTGTGGGAACTCCAGTGCAGAACTGGACCTGACAGAGAACTTAACCGGCAGCAAGAGACGGCCACAAAC  
TCCTAAGGAAGAGGCCAGGCTCTGGAAGACCTGACTGGCTTTAAAGAGCTCTTCCAGACCCCTGGTCAT  
25 ACTGAAGAAGCAGTGGCTGCTGGCAAACTACTAAAATGCCCTGCGAATCTTCTCCACCAGAATCAGCAG  
ACACCCCAACAAGCACAGAAGGCAGCCCAAGACACCTTTGGAGAAAAGGGACGTACAGAAGGAGCTCTC  
AGCCCTGAAGAAGCTCACACAGACATCAGGGGAAACCACACACAGATAAAGTACCAGGAGGTGAGGAT  
AAAAGCATCAACGCGTTTAGGGAACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAACTGGTAGCA  
AGAGGCACCCAAAACCTAAGGAAAAGGCCAACCCCTAGAAGACCTGGCTGGCTGGAAGAGCTCTTCCA  
30 GACACCAGTATGCACTGACAAGCCCACGACTCACGAGAAAACCTACCAAAATAGCCTGCAGATCACAACCA  
GACCCAGTGGACACACCAACAAGCTCCAAGCCACAGTCCAAGAGAAGTCTCAGGAAAGTGGACGTAGAAG  
AAGAATCTTTCGCACTCAGGAAACGAACACCATCAGCAGGCAAAGCCATGCACACACCCAAACAGCAGT  
AAGTGGTGAGAAAAACATCTACGCATTTATGGGAACTCCAGTGCAGAACTGGACCTGACAGAGAACTTA  
ACTGGCAGCAAGAGACGGCTACAACTCCTAAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTTA  
35 AAGAGCTCTTCCAGACACGAGGTCACTGAGGAATCAATGACTAACGATAAACTGCCAAAGTAGCCTG  
CAAATCTTCACAACCAGACCTAGACAAAACCCAGCAAGCTCCAAGCGACGGCTCAAGACATCCCTGGGG  
AAAGTGGGCGTGAAAGAAGAGCTCCTAGCAGTTGGCAAGCTCACACAGACATCAGGAGAGACTACACACA  
CACACACAGAGCCAACAGGAGATGGTAAGAGCATGAAAGCATTTATGGAGTCTCCAAGCAGATCTTAGA  
CTCAGCAGCAAGTCTAACTGGCAGCAAGAGGCAGCTGAGAACTCCTAAGGAAAAGTCTGAAGTCCCTGAA  
40 GACCTGGCCGGCTTCATCGAGCTCTTCCAGACACCAAGTCACACTAAGGAATCAATGACTAATGAAAAAA  
CTACCAAAGTATCCTACAGAGCTTCACAGCCAGACCTAGTGGACACCCCAACAAGCTCCAAGCCACAGCC

CAAGAGAAGTCTCAGGAAAGCAGACACTGAAGAAGAATTTTATAGCATTTAGGAAACAAACGCCATCAGCA  
GGCAAAGCCATGCACACACCCAAACCAGCAGTAGGTGAAGAGAAAGACATCAACACGTTTTTGGGAACTC  
CAGTGCAGAAACTGGACCAGCCAGGAAATTTACCTGGCAGCAATAGACGGCTACAAACTCGTAAGGAAAA  
GGCCCAGGCTCTAGAAGAACTGACTGGCTTCAGAGAGCTTTTCCAGACACCATGCACTGATAACCCACACA  
5 GCTGATGAGAAAACTACCAAAAAAATACTCTGCAAAATCTCCGCAATCAGACCCAGCGGACACCCCAACAA  
ACACAAAGCAACGGCCCAAGAGAAGCCTCAAGAAAGCAGACGTAGAGGAAGAATTTTATAGCATTCAGGAA  
ACTAACACCATCAGCAGGCAAAGCCATGCACACGCCTAAAGCAGCAGTAGGTGAAGAGAAAGACATCAAC  
ACATTTGTGGGGACTCCAGTGGAGAAACTGGACCTGCTAGGAAATTTACCTGGCAGCAAGAGACGGCCAC  
AAACTCCTAAAGAAAAGGCCAAGGCTCTAGAAGATCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGG  
10 TCACACTGAGGAATCAATGACCGATGACAAAATCACAGAAGTATCCTGCAAAATCTCCACAACCAGACCCA  
GTCAAAACCCCAACAAGCTCCAAGCAACGACTCAAGATATCCTTGGGGAAAGTAGGTGTGAAAGAAGAGG  
TCCTACCAGTCGGCAAGCTCACACAGACGTCAGGGAAGACCACACAGACACACAGAGAGACAGCAGGAGA  
TGGAAAGAGCATCAAAGCGTTTAAGGAATCTGCAAAAGCAGATGCTGGACCCAGCAAACTATGGAAGTGGG  
ATGGAGAGGTGGCCAAGAACACCTAAGGAAGAGGGCCCAATCACTAGAAGACCTGGCCGGCTTCAAAGAGC  
15 TCTTCCAGACACCAGACCACACTGAGGAATCAACAATGATGACAAAATACCAAAATAGCCTGCAAAATC  
TCCACCACCAGAATCAATGGACACTCCAACAAGCACAAGGAGGCGGCCCAAAACACCTTTGGGGAAAAGG  
GATATAGTGGAAAGAGCTCTCAGCCCTGAAGCAGCTCACACAGACCACACACAGACAAAAGTACCAGGAG  
ATGAGGATAAAGGCATCAACGTGTTTCAAGGAAACTGCAAAACAGAAACTGGACCCAGCAGCAAGTGTAAAC  
TGGTAGCAAGAGGCAGCCAAGAACTCCTAAGGGAAAAGCCCAACCCCTAGAAGACTTGGCTGGCTTGAAA  
20 GAGCTCTTCCAGACACCAGTATGCACTGACAAGCCCACGACTCACGAGAAAACTACCAAAATAGCCTGCA  
GATCTCCACAACCAGACCCAGTGGGTACCCCAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAA  
AGCAGACGTAGAGGAAGAATCCTTAGCACTCAGGAAACGAACACCATCAGTAGGGAAAGCTATGGACACA  
CCCAAACCAGCAGGAGGTGATGAGAAAGACATGAAAGCATTTATGGGAACTCCAGTGCAGAAATTTGGACC  
TGCCAGGAAATTTACCTGGCAGCAAAAGATGGCCACAACTCCTAAGGAAAAGGCCCAGGCTCTAGAAGA  
25 CCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGCACTGACAAGCCCACGACTGATGAGAAAACTACC  
AAAATAGCCTGCAAAATCTCCACAACCAGACCCAGTGGACACCCAGCAAGCACAAGCAACGGCCCAAGA  
GAAACCTCAGGAAAGCAGACGTAGAGGAAGAATTTTATAGCACTCAGGAAACGAACACCATCAGCAGGCAA  
AGCCATGGACACCCCAAAACCAGCAGTAAGTGATGAGAAAAATATCAACACATTTGTGGAAACTCCAGTG  
CAGAACTGGACCTGCTAGGAAATTTACCTGGCAGCAAGAGACAGCCACAGACTCCTAAGGAAAAGGCTG  
30 AGGCTCTAGAGGACCTGGTTGGCTTCAAAGAACTCTTCCAGACACCAGGTACACTGAGGAATCAATGAC  
TGATGACAAAATCACAGAAGTATCCTGTAAATCTCCACAGCCAGAGTCATTCAAAACCTCAAGAAGCTCC  
AAGCAAAGGCTCAAGATACCCCTGGTGAAAGTGGACATGAAAGAAGAGCCCTAGCAGTCAGCAAGCTCA  
CACGGACATCAGGGGAGACTACGCAACACACACAGAGCCAACAGGAGATAGTAAGAGCATCAAAGCGTT  
TAAGGAGTCTCCAAAGCAGATCCTGGACCCAGCAGCAAGTGTAAGTGGTAGCAGGAGGCAGCTGAGAACT  
35 CGTAAGGAAAAGGCCGTGCTCTAGAAGACCTGGTTGACTTCAAAGAGCTCTTCTCAGCACCAGGTCACA  
CTGAAGAGTCAATGACTATTGACAAAAACAAAAATTCCTTGCATAATCTCCCCACCAGAACTAACAGA  
CACTGCCACGAGCACAAAGAGATGCCCCAAGACACGTCCCAGGAAAGAAGTAAAAGAGGAGCTCTCAGCA  
GTTGAGAGGCTCAGCAAAACATCAGGGCAAAGCACACACACACAAAGAACCAGCAAGCGGTGATGAGG  
GCATCAAAGTATTGAAGCAACGTGCAAAGAAGAAACCAACCCAGTAGAAGAGGAACCCAGCAGGAGAAG  
40 GCCAAGAGCACCTAAGGAAAAGGCCCAACCCCTGGAAGACCTGGCCGGCTTCACAGAGCTCTCTGAAACA  
TCAGGTACACTCAGGAATCACTGACTGCTGGCAAAGCCACTAAAATACCCCTGCGAATCTCCCCCACTAG

AAGTGGTAGACACCACAGCAAGCACAAAGAGGCATCTCAGGACACGTGTGCAGAAGGTACAAGTAAAAGA  
AGAGCCTTCAGCAGTCAAGTTCACACAAACATCAGGGGAAACCACGGATGCAGACAAAGAACAGCAGGT  
GAAGATAAAGGCATCAAAGCATTGAAGGAATCTGCAAAACAGACACCGGCTCCAGCAGCAAGTGTAAGTGA  
GCAGCAGGAGACGGCCAAGAGCACCCAGGGAAAGTGCCCAAGCCATAGAAGACCTAGCTGGCTTCAAAGA  
5 CCCAGCAGCAGGTCACTGAAGAATCAATGACTGATGACAAAACCTAAAATACCTGCAAATCATCA  
CCAGAAGTAGAAGACACCGCAACAAGCTCAAAGAGACGGCCAGGACACGTGCCAGAAAGTAGAAGTGA  
AGGAGGAGCTGTTAGCAGTTGGCAAGCTCACACAAACCTCAGGGGAGACCACGCACACCGACAAAGAGCC  
GGTAGGTGAGGGCAAAGGCACGAAAGCATTAAAGCAACCTGCAAAGCGGAACGTGGACGCAGAAGATGTA  
ATTGGCAGCAGGAGACAGCCAAGAGCACCTAAGGAAAAGGCCCAACCCCTGGAAGACCTGGCCAGCTTCC  
10 AAGAGCTCTCTCAAACACCAGGCCACACTGAGGAACTGGCAAATGGTGCTGCTGATAGCTTTACAAGCGC  
TCCAAAGCAAACACCTGACAGTGGAACCTCTAAAAATATCCAGAAGAGTTCTTCGGGGCCCTAAAGTA  
GAACCCGTGGGAGACGTGGTAAGCACCAGAGACCTGTAAAATCACAAAGCAAAGCAACACTTCCCTGC  
CCCCACTGCCCTTCAAGAGGGGAGGTGGCAAAGATGGAAGCGTCACGGGAACCAAGAGGTGCGCTGCAT  
GCCAGCACCAGAGGAAATTGTGGAGGAGCTGCCAGCCAGCAAGAAGCAGAGGGTTGCTCCAGGGCAAGA  
15 GGCAAATCATCCGAACCCGTGGTTCATCATGAAGAGAAGTTTGAAGACTTCTGCAAAAAGAAATTGAACCTG  
CGGAAGAGCTGAACAGCAACGACATGAAAACCAACAAAGAGGAACACAAATTACAAGACTCGGTCCCTGA  
AAATAAGGGAATATCCCTGCGCTCCAGACGCCAAGATAAGACTGAGGCAGAACAGCAAATAACTGAGGTC  
TTTGTATTAGCAGAAAGAATAGAAATAAACAGAAATGAAAAGAAGCCCATGAAGACCTCCCCAGAGATGG  
ACATTGAGATCCAGATGATGGAGCCCGGAAACCCATACCTAGAGACAAAGTCACTGAGAACAAAAGGTG  
20 CTTGAGGTCTGCTAGACAGAATGAGAGCTCCCAGCCTAAGGTGGCAGAGGAGAGCGGAGGGCAGAAGAGT  
GCGAAGGTTCTCATGCAGAATCAGAAAGGGAAAGGAGAAGCAGGAAATTCAGACTCCATGTGCCTGAGAT  
CAAGAAAGACAAAAAGCCAGCCTGCAGCAAGCACTTTGGAGAGCAAATCTGTGCAGAGAGTAACGCGGAG  
TGTCAGAGGTGTGCAGAAATCCAAAGAAGGCTGAGGACAATGTGTGTGTCAAGAAAATAACAACCAGA  
AGTCATAGGGACACTGAAGATATTTGACAGAAAAATCGAACTGGGAAAAATATAATAAAGTTAGTTTTGT  
25 GATAAGTTCTAGTGCAGTTTTTGTGCATAAATTACAAGTGAATTCTGTAAGTAAGGCTGTGAGTCTGCTTA  
AGGGAAGAAAACTTTGATTGTGCTGGGTCTGAATCGGCTTCATAAACTCCACTGGGAGCACTGCTGGGCT  
CCTGGACTGAGAATAGTTGAACACCGGGGGCTTTGTGAAGGAGTCTGGGCCAAGGTTTGCCTCAGCTTT  
GCAGAATGAAGCCTTGAGGTCTGTCAACACCCACAGCCACCCTACAGCAGCCTTAACTGTGACACTTGCC  
ACACTGTGTGCTGCTTTGTTTGCTATGTTCTCCAGGGCACGGTGGCAGGAACAACATCCTCGTCTGTC  
30 CCAACACTGAGCAGGCACTCGGTAAACACGAATGAATGGATAAGCGCACGGATGAATGGAGCTTACAAGA  
TCTGTCTTTCCAATGGCCGGGGCATTTGGTCCCAAAATTAAGGCTATTGGACATCTGCACAGGACAGTC  
CTATTTTTGATGTCCTTTCTTTCTGAAAATAAAGTTTTGTGCTTTGGAGAATGACTCGTGAGCACATCT  
TTAGGGACCAAGAGTGACTTTCTGTAAGGAGTGACTCGTGGCTTGCTTGGTCTCTTGGGAATACTTTTC  
TAACTAGGGTTGCTCTCACCTGAGACATTCTCCACCCGCGGAATCTCAGGGTCCCAGGCTGTGGGCCATC  
35 ACGACCTCAAACCTGGCTCCTAATCTCCAGCTTTCTGTGCTATTGAAAGCTTCGGAAGTTTACTGGCTCTGC  
TCCCGCTGTTTTCTTTCTGACTCTATCTGGCAGCCGATGCCACCCAGTACAGGAAGTGACACCAGTAC  
TCTGTAAAGCATCATCATCTTGGAGAGACTGAGCACTCAGCACCTTCAGCCACGATTTAGGATCGCTT  
CCTTGTGAGCCGCTGCCTCCGAAATCTCCTTTGAAGCCAGACATCTTTCTCCAGCTTCAGACTTGTAGA  
TATAACTCGTTCATCTTCACTTTTCCACTTTGCCCCCTGTCTCTGTGTCCCCAAATCAGAGAA  
40 TAGCCCGCCATCCCCAGATCACCTGTCTGGATTCTCCCATTCACCCACCTTGCCAGGTGCAGGTGAG  
GATGGTGCACCAGACAGGGTAGCTGTCCCCCAAATGTGCCCTGTGCGGGCAGTGCCCTGTCTCCACGTT



5 TGTTCCTCCAGTGTCTGGCGGGGAGCCAGGTGACATCATAAATACTTGCTGAATGAATGCAGAAATCAGC  
GGTACTGACTTGACTATATTGGCTGCCATGATAGGGTTCTCACAGCGTCATCCATGATCGTAAGGGAGA  
ATGACATTCTGCTTGAGGGAGGGAATAGAAAGGGGCAGGGAGGGGACATCTGAGGGCTTCACAGGGCTGC  
AAAGGGTACAGGGATTGCACACAGGGCAGAACAGGGGAGGGTGTTCAGGAAGAGTGGCTCTTAGCAGAGG  
10 CACTTTGGAAGGTGTGAGGCATAAATGCTTCCTTCTACGTAGGCCAACCTCAAACTTTTCAGTAGGAATG  
TTGCTATGATCAAGTTGTTCTAACACTTTAGACTTAGTAGTAATTATGAACCTCACATAGAAAAATTTCA  
TCCAGCCATATGCCTGTGGAGTGAATATTCTGTTTAGTAGAAAAATCCTTTAGAGTTCAGCTCTAACCA  
GAAATCTTGCTGAAGTATGTCAGCACCTTTTCTCACCTGGTAAGTACAGTATTTCAAGAGCACGCTAAG  
GGTGGTTTTTCATTTTACAGGGCTGTTGATGATGGGTAAAAATGTTTCATTTAAGGGCTACCCCGTGTTT  
15 AATAGATGAACACCACTTCTACACAACCTCCTTGGTACTGGGGGAGGGAGAGATCTGACAAATACTGCC  
CATTCCCTTAGGCTGACTGGATTTGAGAACAAATACCCACCATTTCCACCATGGTATGGTAACCTCTCT  
GAGCTTCAGTTTCCAAGTGAATTTCCATGTAATAGGACATTCCCATTAATAACAAGCTGTTTTTACTTTT  
TCGCCTCCAGGGCCTGTGCGATCTGGTCCCCCAGCCTCTCTTGGGCTTTCTTACACTAATCTGTACCT  
ACCATCTCCTGCCTCCCTTAGGCAGGCACCTCCAACCACCACACACTCCCTGCTGTTTTCCCTGCCTGGA  
20 ACTTTCCACCAGCCCCACCAAGATCATTTTCATCCAGTCTTGAGCTCAGCTTAAGGGAGGCTTCTTGCT  
GTGGGTTCCTCACCCTCATGCTGTCTCCAGGCTGGGGCAGGTTCTTAGTTTGCTGGAATTGTTCTG  
TACCTCTTTGTAGCACGTAGTGTGTGAACTAAGCCACTAATTGAGTTTCTGGCTCCCTCCTGGGGTT  
GTAAGTTTTGTTTCATTCATGAGGGCCGACTGTATTTCTGGTTACTGTATCCAGTGACCAGCCACAGGA  
GATGTCCAATAAAGTATGTGATGAAATGGTCTTAAAAAAAAAAAAAAAAAAAAA

20

SEQ ID NO: 24

25 >gi|415820|emb|X65551|HSMKI67A H.sapiens mki67a mRNA (short type) for  
antigen of monoclonal antibody Ki-67  
CTACCGGGCGGAGGTGAGCGCGCGCGGCTCCTCCTGCGGGGACTTTGGGTGCGACTTGACGAGCGGT  
GGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGAAGAGTTGTAAATTTGCTTCTGGCCTTCCC  
CTACGGATTATACCTGGCCTTCCCCTACGGATTATACTCAACTTACTGTTAGAAAATGTGGCCACGAG  
ACGCCGTGGTTACTATCAAAAGGAGCGGGGTGACGGTCCCCACTTTCCCTGAGCCTCAGCACCTGCTTG  
30 TTTGGAAGGGGTATTGAATGTGACATCCGTATCCAGCTTCTGTGTGTCAAAACAACATTGCAAAATTG  
AAATCCATGAGCAGGAGGCAATATTACATAATTTAGTTCCACAAATCCAACACAAGTAAATGGGTCTGT  
TATTGATGAGCCTGTACGGCTAAACATGGAGATGTAATAACTATTATTGATCGTTCTTCAGGTATGAA  
AATGAAAGTCTTCAGAAATGGAAGGAAGTCAACTGAATTTCCAAGAAAAATACGTGAACAGGAGCCAGCAC  
GTCGTGTCTCAAGATCTAGCTTCTTCTGACCCTGATGAGAGTGAGGGAATACCTTTGAAAAGAAGGCG  
35 TGTGTCTTTTGGTGGGCACCTAAGACCTGAACTATTTGATGAAAACCTGCCTCCTAATACGCTCTCAAA  
AGGGGAGAAGCCCCAACCAAAAGAAAGTCTCTGGTAATGCACACTCCACCTGTCTGAAGAAAATCATCA  
AGGAACAGCCTCAACCATCAGGAAAACAAGAGTCAGGTTTCAGAAATCCATGTGGAAGTGAAGGCACAAAG  
CTTGGTTATAAGCCCTCCAGCTCCTAGTCTTAGGAAAACCTCAGTTGCCAGTGATCAACGCCGTAGGTCC  
TGCAAAACAGCCCTGCTTCCAGCAGCAAAATCTCAGACAGAGGTTCCCTAAGAGAGGAGGAGAAAGAGTGG  
40 CAACCTGCCTTCAAAAGAGAGTGTCTATCAGCCGAAGTCAACATGATATTTTACAGATGATATGTTCCAA  
AAGAAGAAGTGGTGCTTCGGAAGCAATCTGATTGTTGCAAAATCATGGGCAGATGTAGTAAACTTGGT

GCAAAACAAACACAACTAAAGTCATAAAACATGGTCTCAAAGGTCAATGAACAAAAGGCAAAGAAGAC  
CTGCTACTCCAAAGAAGCCTGTGGGCGAAGTTCACAGTCAATTTAGTACAGGCCACGCAAACTCTCCTTG  
TACCATAATAATAGGGAAAGCTCATACTGAAAAAGTACATGTGCCTGCTCGACCCTACAGAGTGCTCAAC  
AACTTCATTTCCAACCAAAAAATGGACTTTAAGGAAGATCTTTCAGGAATAGCTGAAATGTTCAAGACCC  
5 CAGTGAAGGAGCAACCGCAGTTGACAAGCACATGTACATCGCTATTTCAAATTCAGAGAATTTGCTTGG  
AAAACAGTTTCAAGGAAGTATTGAGGAGAAGAACCTCTGCTCCCCACCTCAGAGAGT"TT"TTGGAGGAAAT  
GTGTTCTTCAGTGACAGAAATGCAGCAAAACAGCCATCTGATAAATGCTCTGCAAGCCCTCCCTTAAGAC  
GGCAGTGTATTAGAGAAAATGGAAACGTAGCAAAAACGCCAGGAACACCTACAAAATGACTTCTCTGGA  
GACAAAAACTTCAGATACTGAGACAGAGCCTTCAAAAACAGTATCCACTGTAAACAGGTCAGGAAGGTCT  
10 ACAGAGTTTCAGGAATATACAGAAGCTACCTGTGAAAGTAAGAGTGAAGAAAACAAATACAGAAATTGTTG  
AGTGCATCCTAAAAAGAGGTGAGAAGGCAACACTACTACAACAAAGGAGAGAAGGAGAGATGAAGGAAAT  
AGAAAGACCTTTTGAGACATATAAGGAAAATATTGAATTAAAAAGAAAACGATGAAAAGATGAAAGCAATG  
AAGAGATCAAGAACTTGGGGGCAGAAATGTGCACCAATGTCTGACCTGACAGACCTCAAGAGCTTGCCTG  
ATACAGAAGTCAAGAGACACGGCAGTGGCCAGAATCTCCTCCAAACCAAGATCATGCCAAGGCACC  
15 AAAGAGTGAGAAAGGCAAAATCACTAAATGCCCTGCCAGTCATTACAACCAGAACCAATAAACACCCCCA  
ACACACACAAAACACAGTTGAAGGCATCCCTGGGGAAAGTAGGTGTGAAAGAAGAGCTCCTAGCAGTCG  
GCAAGTTACACGGACGTGAGGGGAGACCACGCACACGACAGAGAGCCAGCAGGAGATGGCAAGAGCAT  
CAGAACGTTTAAGGAGTCTCAAAGCAGATCCTGGACCCAGCAGCCCGTGTAACTGGAATGAAGAAGTGG  
CCAAGAAGCGCTAAGGAAGAGGCCAGTCACTAGAAGACCTGGCTGGCTTCAAAGAGCTCTTCCAGACAC  
20 CAGGTCCCTCTGAGGAATCAATGACTGATGAGAAAACTACCAAAATAGCCTGCAAAATCTCCACCACCAGA  
ATCAGTGGACACTCCAACAAGCACAAAGCAATGGCCTAAGAGAAGTCTCAGGAAAGCAGATGTAGAGGAA  
GAATCTTTAGCACTCAGGAACTAACACCATCAGCAGGGAAAGCCATGCTTACGCCCCAACCCAGCAGGAG  
GTGATGAGAAAGACATTAAAGCATTATGGAAGTCCAGTGCAGAACTGGACCTGGCAGGAACTTTACC  
TGGCAGCAAAAGACAGCTACAGACTCCTAAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTTAAA  
25 GAGCTCTTCCAGACTCCTGGTCACACCGAGGAATTAGTGGCTGCTGGTAAAACCACTAAAATACCCTGCG  
ACTCTCCACAGTCAGACCCAGTGGACACCCCAACAAGCACAAAGCAACGACCCAAGAGAAGTATCAGGAA  
AGCAGATGTAGAGGGAGAAGTCTTAGCGTGCAGGAATCTAATGCCATCAGCAGGCAAAGCCATGCACACG  
CCTAAACCATCAGTAGGTGAAGAGAAAGACATCATCATATTTGTGGGAAGTCCAGTGCAGAACTGGACC  
TGACAGAGAACTTAACCGGCAGCAAGAGACGGCCACAACTCCTAAGGAAGAGGCCAGGCTCTGGAAGA  
30 CCTGACTGGCTTTAAAGAGCTCTTCCAGACCCCTGGTCATACTGAAGAAGCAGTGGCTGCTGGCAAACT  
ACTAAAATGCCCTGCGAATCTTCTCCACCAGAATCAGCAGACACCCCAACAAGCACAAAGAGGACGCCCA  
AGACACCTTTGGAGAAAAGGGACGTACAGAAGGAGCTCTAGCCCTGAAGAAGCTCACACAGACATCAGG  
GGAAACCACACACACAGATAAAGTACCAGGAGGTGAGGATAAAAGCATCAACGCGTTTAGGGAACTGCA  
AAACAGAACTGGACCCAGCAGCAAGTGTAACTGGTAGCAAGAGGCACCCAAAACTAAGGAAAAGGCC  
35 AACCCTTAGAAGACCTGGCTGGCTGGAAAGAGCTCTTCCAGACACCAGTATGCACTGACAAGCCCACGAC  
TCACGAGAAAATACCAAAATAGCCTGCAGATCACAAACCAGACCCAGTGGACACACCAACAAGCTCCAAG  
CCACAGTCCAAGAGAAGTCTCAGGAAAGTGGACGTAGAAGAAGAATTCTTCGCACTCAGGAAACGAACAC  
CATCAGCAGGCAAAGCCATGCACACACCCAAACCAGCAGTAAGTGGTGAGAAAAACATCTACGCATTTAT  
GGGAAGTCCAGTGCAGAACTGGACCTGACAGAGAACTTAACTGGCAGCAAGAGACGGCTACAACTCCT  
40 AAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTTAAAGAGCTCTTCCAGACACGAGGTCACTG  
AGGAATCAATGACTAACGATAAACTGCCAAAGTAGCCTGCAATCTTCACAACCAGACCTAGACAAAA

CCCAGCAAGCTCCAAGCGACGGCTCAAGACATCCCTGGGGAAAGTGGGCGTGAAAGAAGAGCTCCTAGCA  
GTTGGCAAGCTCACACAGACATCAGGAGAGACTACACACACACACAGAGCCAACAGGAGATGGTAAGA  
GCATGAAAGCATTATGGAGTCTCCAAAGCAGATCTTAGACTCAGCAGCAAGTCTAACTGGCAGCAAGAG  
GCAGCTGAGAACTCCTAAGGGAAAGTCTGAAGTCCCTGAAGACCTGGCCGGCTTCATCGAGCTCTTCCAG  
5 ACACCAAGTCACACTAAGGAATCAATGACTAATGAAAAAATAACCAAAGTATCCTACAGAGCTTCACAGC  
CAGACCTAGTGGACACCCCAACAAGCTCCAAGCCACAGCCCAAGAGAAGTCTCAGGAAAGCAGACACTGA  
AGAAGAATTTTATAGCATTTAGGAAACAAACGCCATCAGCAGGCAAAGCCATGCACACACCCAAACCAGCA  
GTAGGTGAAGAGAAAGACATCAACACGTTTTTGGGAACTCCAGTGCAGAACTGGACCAGCCAGGAAATT  
TACCTGGCAGCAATAGACGGCTACAACTCGTAAGGAAAAGGCCAGGCTCTAGAAGAACTGACTGGCTT  
10 CAGAGAGCTTTTCCAGACACCATGCACTGATAACCCACAGCTGATGAGAAAATAACCAAAAAATACTC  
TGCAAACTCTCCGCAATCAGACCCAGCGACACCCCAACAAACACAAAGCAACGGCCCAAGAGAAGCCTCA  
AGAAAGCAGACGTAGAGGAAGAATTTTAGCATTCAGGAACTAACACCATCAGCAGGCAAAGCCATGCA  
CACGCCTAAAGCAGCAGTAGGTGAAGAGAAAGACATCAACACATTTGTGGGGACTCCAGTGGAGAACTG  
GACCTGCTAGGAAATTTACCTGGCAGCAAGAGACGGCCACAACTCCTAAAGAAAAGGCCAAGGCTCTAG  
15 AAGATCTGGCTGGCTTCAAAGAGCTCTTCCAGACACCAGGTCACTGAGGAATCAATGACCGATGACAA  
AATCACAGAAGTATCCTGCAAATCTCCACAACCAGACCCAGTCAAAACCCCAACAAGCTCCAAGCAACGA  
CTCAAGATATCCTTGGGGAAAGTAGGTGTGAAAGAAGAGGTCTTACCAGTCGGCAAGCTCACACAGACGT  
CAGGGAAGACCACACAGACACACAGAGACAGCAGGAGATGGAAGAGCATCAAAGCGTTTAAGGAATC  
TGCAAAAGCAGATGCTGGACCCAGCAAATATGGAAGTGGGATGGAGAGGTGGCCAAGAACCTAAGGAA  
20 GAGGCCCAATCACTAGAAGACCTGGCCGGCTTCAAAGAGCTCTTCCAGACACCAGACCACACTGAGGAAT  
CAACAACTGATGACAAAATAACCAAAATAGCCTGCAAATCTCCACCACCAGAATCAATGGACACTCCAAC  
AAGCACAAGGAGGCGGCCCAAAACACCTTTGGGGAAAAGGGATATAGTGAAGAGCTCTCAGCCCTGAAG  
CAGCTCACACAGACCACACACACAGACAAAGTACCAGGAGATGAGGATAAAGGCATCAACGTGTTTCAGGG  
AACTGCAAAACAGAACTGGACCCAGCAGCAAGTGTAACTGGTAGCAAGAGGCAGCCAAGAACTCCTAA  
25 GGGAAAAGCCCAACCCCTAGAAGACTTGGCTGGCTTGAAAGAGCTCTTCCAGACACCAGTATGCACTGAC  
AAGCCCACGACTCAGAGAAAATAACCAAAATAGCCTGCAGATCTCCACAACCAGACCCAGTGGGTACCC  
CAACAATCTTCAAGCCACAGTCCAAGAGAAGTCTCAGGAAAGCAGACGTAGAGGAAGAATCCTTAGCACT  
CAGGAAACGAACACCATCAGTAGGGAAGCTATGGACACACCCAAACCAGCAGGAGGTGATGAGAAAGAC  
ATGAAAGCATTATGCGAACTCCAGTGCAGAAATTGGACCTGCCAGGAAATTTACCTGGCAGCAAAAGAT  
30 GGCCACAACTCCTAAGGAAAAGGCCAGGCTCTAGAAGACCTGGCTGGCTTCAAAGAGCTCTTCCAGAC  
ACCAGGCACTGACAAGCCCACGACTGATGAGAAAATAACCAAAATAGCCTGCAAATCTCCACAACCAGAC  
CCAGTGGACACCCAGCAAGCACAAAGCAACGGCCCAAGAGAAACCTCAGGAAAGCAGACGTAGAGGAAG  
AATTTTATGCACTCAGGAAACGAACACCATCAGCAGGCAAAGCCATGGACACCCCAAAACCAGCAGTAAG  
TGATGAGAAAAATATCAACACATTTGTGGAACTCCAGTGCAGAACTGGACCTGCTAGGAAATTTACCT  
35 GGCAGCAAGAGACAGCCACAGACTCCTAAGGAAAAGGCTGAGGCTCTAGAGGACCTGGTTGGCTTCAAAG  
AACTCTTCCAGACACCAGGTCACTGAGGAATCAATGACTGATGACAAAATCACAGAAGTATCCTGTAA  
ATCTCCACAGCCAGAGTCATTCAAACCTCAAGAAGCTCCAAGCAAAGGCTCAAGATACCCCTGGTGAAA  
GTGGACATGAAAGAAGAGCCCCTAGCAGTCAGCAAGCTCACACGGACATCAGGGGAGACTACGCAACAC  
ACACAGAGCCAACAGGAGATAGTAAGAGCATCAAAGCGTTTAAGGAGTCTCAAAGCAGATCCTGGACCC  
40 AGCAGCAAGTGTAAGTGGTAGCAGGAGGAGCTGAGAACTCGTAAGGAAAAGGCCGTGCTCTAGAAGAC  
CTGGTTGACTTCAAAGAGCTCTTCTCAGCACCAGGTCACTGAAGAGTCAATGACTATTGACAAAAACA

CAAAAATTCCCTGCAAATCTCCCCACCAGAACTAACAGACACTGCCACGAGCACAAAGAGATGCCCCAA  
GACACGTCCCAGGAAAGAAGTAAAAGAGGAGCTCTCAGCAGTTGAGAGGCTCACGCAAACATCAGGGCAA  
AGCACACACACACAAAGAACCAGCAAGCGGTGATGAGGGCATCAAAGTATTGAAGCAACGTGCAAAGA  
AGAAACCAAACCCAGTAGAAGAGGAACCCAGCAGGAGAAGGCCAAGAGCACCTAAGGAAAAGGCCCAACC  
5 CCTGGAAGACCTGGCCGGCTTCACAGAGCTCTCTGAAACATCAGGTCACACTCAGGAATCACTGACTGCT  
GGCAAAGCCACTAAAATACCCCTGCGAATCTCCCCACTAGAAGTGGTAGACACCACAGCAAGCACAAAGA  
GGCATCTCAGGACACGTGTGCAGAAGGTACAAGTAAAAGAAGAGCCTTCAGCAGTCAAGTTCACACAAAC  
ATCAGGGGAAACCACGGATGCAGACAAAGAACCAGCAGGTGAAGATAAAGGCATCAAAGCATTTGAAGGAA  
TCTGCAAAACAGACACCGGCTCCAGCAGCAAGTGTAACTGGCAGCAGGAGACGGCCAAGAGCACCCAGGG  
10 AAAGTGGCCAAGCCATAGAAGACCTAGCTGGCTTCAAAGACCCAGCAGCAGGTCACTGAAGAATCAAT  
GACTGATGACAAAACCACTAAAATACCCCTGCAATCATCACCAGAACTAGAAGACACCGCAACAAGCTCA  
AAGAGACGGCCCAGGACACGTGCCAGAAAGTAGAAGTGAAGGAGGAGCTGTTAGCAGTTGGCAAGCTCA  
CACAAACCTCAGGGGAGACCACGCACACCGACAAAGAGCCGGTAGGTGAGGGCAAAGGCACGAAAGCATT  
TAAGCAACCTGCAAAGCGGAACGTGGACGCAGAAGATGTAATTGGCAGCAGGAGACAGCCAAGAGCACCT  
15 AAGGAAAAGGCCAACCCCTGGAAGACCTGGCCAGCTTCCAAGAGCTCTCTCAAACACCAGGCCACACTG  
AGGAACTGGCAAATGGTGCTGCTGATAGCTTTACAAGCGCTCCAAAGCAAACACCTGACAGTGAAAACC  
TCTAAAAATATCCAGAAGAGTTCTTCGGGCCCCCTAAAGTAGAACCCGTGGGAGACGTGGTAAGCACCAGA  
GACCTGTAAAATCACAAAGCAAAGCAACACTTCCCTGCCCCACTGCCCTTCAAGAGGGGAGGTGGCA  
AAGATGGAAGCGTCACGGGAACCAAGAGGCTGCGCTGCATGCCAGCACCAGAGGAAATTGTGGAGGAGCT  
20 GCCAGCCAGCAAGAAGCAGAGGGTTGCTCCCAGGGCAAGAGGCAAATCATCCGAACCCGTGGTCATCATG  
AAGAGAAGTTTGAGGACTTCTGCAAAAAGAATTGAACCTGCGGAAGAGCTGAACAGCAACGACATGAAAA  
CCAACAAAGAGGAACACAAATTACAAGACTCGGTCCCTGAAAATAAGGGAATATCCCTGCGCTCCAGACG  
CCAAGATAAGACTGAGGCAGAACAGCAAATAACTGAGGTCTTTGTATTAGCAGAAAGAATAGAAATAAAC  
AGAAATGAAAAGAAGCCCATGAAGACCTCCCCAGAGATGGACATTGAGATCCAGATGATGGAGCCCGGA  
25 AACCCTACCTAGAGACAAAGTCACTGAGAACAAAAGGTGCTTGAGGTCTGCTAGACAGAATGAGAGCTC  
CCAGCCTAAGGTGGCAGAGGAGAGCGGAGGGCAGAAGAGTGCGAAGGTTCTCATGCAGAATCAGAAAGGG  
AAAGGAGAAGCAGGAAATTCAGACTCCATGTGCCTGAGATCAAGAAAGACAAAAAGCCAGCCTGCAGCAA  
GCACTTTGGAGAGCAAATCTGTGCAGAGAGTAACGCGGAGTGTCAAGAGGTGTGCAGAAAATCCAAAGAA  
GGCTGAGGACAATGTGTGTGTCAAGAAAAATAACAACCAGAAGTCATAGGGACAGTGAAGATATTTGACAG  
30 AAAAATCGAACTGGGAAAAATATAATAAAGTTAGTTTTGTGATAAGTTCTAGTGCAGTTTTTGTCTATAAA  
TTACAAGTGAATTCTGTAAGTAAGGCTGTGAGTCTGCTTAAGGGAAGAAAACTTTGGATTGTGCTGGGTCT  
GAATCGGCTTCATAAACTCCACTGGGAGCACTGCTGGGCTCCTGGACTGAGAATAGTTGAACACCGGGGG  
CTTTGTGAAGGAGTCTGGGCCAAGGTTTGCCCTCAGCTTTGCAGAATGAAGCCTTGAGGTCTGTCAACCAC  
CCACAGCCACCCTACAGCAGCCTTAACGTGACACTTGCCCACTGTGTGTCGTTTGTGCTTATGTT  
35 CTCCAGGGCACGGTGGCAGGAACAACATCCTCGTCTGTCCCAACACTGAGCAGGCACTCGGTAAACACG  
AATGAATGGATAAGCGCACGGATGAATGGAGCTTACAAGATCTGTCTTTCCAATGGCCGGGGGCAATTTGG  
TCCCCAAATTAAAGCTATTGGACATCTGCACAGGACAGTCTATTTTGTATGTCTTTCTCTGAAAA  
TAAAGTTTTGTGCTTTGGAGAATGACTCGTGAGCACATCTTTAGGGACCAAGAGTGACTTTCTGTAAGGA  
GTGACTCGTGGCTTGCCTTGGTCTCTTGGGAATACTTTTCTAACTAGGGTTGCTCTCACCTGAGACATTC  
40 TCCACCCGCGGAATCTCAGGCTCCAGGCTGTGGGCCATCAGGACCTCAAACCTGGCTCCTAATCTCCAGC  
TTTCTGTGATTGAAAGCTTCGGAAGTTTACTGGCTCTGCTCCCGCCTGTTTTCTTTCTGACTCTATCTG

GCAGCCCCGATGCCACCCAGTACAGGAAGTGACACCAGTACTCTGTAAAGCATCATCATCCTTGGAGAGAC  
TGAGCACTCAGCACCTTCAGCCACGATTTTCAGGATCGCTTCCTTGTGAGCCGCTGCCTCCGAAATCTCCT  
TTGAAGCCCAGACATCTTTCTCCAGCTTCAGACTTGTAGATATAAATCGTTCATCTTCATTTACTTTCCA  
CTTTGCCCCCTGTCTCTCTGTGTTCCCCAAATCAGAGAATAGCCCGCCATCCCCCAGATCACCTGTCTG  
5 GATTCCTCCCCATTACCCACCTTGCCAGGTGCAGGTGAGGATGGTGCACCAGACAGGGTAGCTGTCCCC  
CAAAATGTGCCCTGTGCGGGCAGTGCCCTGTCTCCACGTTTGTTCCTCCAGTGTCTGGCGGGAGCCAGG  
TGACATCATAAATACTTGCTGAATGAATGCAGAAATCAGCGGTACTGACTTGTACTATATTGGCTGCCAT  
GATAGGGTTCACACAGCGTCATCCATGATCGTAAGGGAGAATGACATTCTGCTTGAGGGAGGGAAATAGAA  
AGGGGCAGGGAGGGGACATCTGAGGGCTTCACAGGGCTGCAAAGGGTACAGGGATTGCACCAGGGCAGAA  
10 CAGGGGAGGGTGTTCAGGAAGAGTGGCTCTTAGCAGAGGCACTTTGGAAGGTGTGAGGCATAAATGCTT  
CCTTCTACGTAGGCCAACCTCAAACTTTTCAGTAGGAATGTGCTATGATCAAGTTGTTCTAACACTTTA  
GACTTAGTAGTAATTATGAACCTCACATAGAAAAATTTTCATCCAGCCATATGCCTGTGGAGTGGAAATATT  
CTGTTTAGTAGAAAAATCCTTTAGAGTTCAGCTCTAACCAGAAATCTTGCTGAAGTATGTCAGCACCTTT  
TCTCACCTGGTAAGTACAGTATTTCAAGAGCACGCTAAGGGTGGTTTTTCATTTTACAGGGCTGTGATG  
15 ATGGGTAAAAATGTTCAATTAAGGGCTACCCCGTGTTTAATAGATGAACACCACTTCTACACAACCCCT  
CCTTGGTACTGGGGGAGGGAGAGATCTGACAAATACTGCCCATTCCTTAGGCTGACTGGATTTGAGAAC  
AAATACCCACCCATTTCCACCATGGTATGGTAACTTCTCTGAGCTTCAGTTTCCAAGTGAATTTCCATGT  
AATAGGACATTTCCATTAAATACAAGCTGTTTCTTACTTTTTCGCCTCCCAGGGCCTGTGCGATCTGGTCC  
CCCAGCCTCTCTTGGGCTTTCTTACACTAACTCTGTACCTACCATCTCCTGCCTCCCTTAGGCAGGCACC  
20 TCCAACCACCACACACTCCCTGCTGTTTCCCTGCCTGGAACCTTTCCACCAGCCCCACCAAGATCATTT  
CATCCAGTCTCTGAGCTCAGCTTAAGGGAGGCTTCTTGCCCTGTGGGTTCCTCACCCCCATGCCTGTCTC  
CAGGCTGGGGCAGGTTCCTAGTTTGCTGGAATTGTTCTGTACCTCTTTGTAGCACGTAGTGTGTGAAA  
CTAAGCCACTAATTGAGTTTCTGGCTCCCCCTCGGGGTGTAAAGTTTGTTCATTTCATGAGGCGGACT  
GTATTTCTGGTTACTGTATCCCAGTGACCAGCCACAGGAGATGTCCAATAAAGTATGTGATGAAATGGT  
25 CTTAAAAAAAAAAAAAAAAAAAAA

SEQ ID NO: 25

>gi|29860|emb|X55039|HSCENPB Human hCENP-B gene for centromere  
autoantigen B (CENP-B)

5 TAGATTTACAACGTGAATGCTGATTTTAAAAATAACTTAAGTGTGTAACAATAGGTTACATACGCTAGTG  
TTCAATTCATAGCTGGAATGCTACACAATCATTAAAAAGCGTGTGGCAATGATACTTACCGATATGGCAA  
AATTCTCACTACTTGATGCCAGGTAAAACAGCAGGAGATGCCAGATATACAGTCTATACAGTCTGATGCC  
AGTTTATATAATAAAATTTTAAAAAGAAAACGACATGCATCTAGAGAAAAGACTGGAAGGAAATGTATC  
AAAATGTTACCTGTGCATCTCTCCAGGTGACGTGAAAAGCGTTTTTCAACTTCTTGAATTTTTCAGGTTT  
10 CGCAAAAAAAGTGCCTTATTTTACCTTAATTAATAAAAAAAAAAAAAACAAACAAAAACCTGGTTCTT  
ATTCTTTTGTAGCAGCAAGTCGCTGTCCGCCGGGCGCAGTAGCGATGCACCGCGTCCCCGCCCGCGTCCG  
TGCCGGGTGCGCCGAGGCCGCGCAGCACGGGCAGGTCCAGCAGGCCGCGAGCGCCCCCGCGGTATGTGCC  
CGGCGGCGGGAAGGGGTGGGCGCGGAGGGCGGGAGGAGGCGCGGGCGTCCCCGCGCTTCCCGCGAGA  
TCCCCGCTCCGCCCGCTCGCCGCGCGTCCCGCTCCCCGCGCGGCCACTTCTGCCTTCCGCGCCCGCG  
15 CCGCCCGCCCTCGTCTGCGCCCGTGCCTGCGCCCGCGCGCCCGCGGACGCGGCCCGCGGCGTCCCCGGA  
GGTGGCCCGCCCGCGCGGTGCTCGCCCGCGCGCGCGCGCGAGCCGCTTGTCTCGGGCGGGCGCGCG  
GGGAGAGGCCGCCAGGTGCCCCCGCCACGGGCCCGGGCCCCCGCGGGCGGCGGCGGCGCGCGCG  
GCCCCGGGGCGGGGGCGCGCGGGATGGGCCCCAAGAGGCGACAGCTGACGTTCCGGGAGAAGTCAAGG  
ATCATCCAGGAGGTGGAGGAGAATCCGGACCTGCGCAAGGGCGAGATCGCGCGCGCTTCAACATCCCGC  
20 CGTCCACGCTGAGCACGATCCTGAAGAACAAGCGCGCCATCCTGGCGTGGAGCGCAAGTACGGGGTGGC  
CTCCACCTGCCGAAGACCAACAAGCTGTCTCCCTACGACAAGCTCGAGGGCTTGTCTCATCGCCTGGTTT  
CAGCAGATCCGCGCCCGCGCTGCGGGTCAAGGGCATCATCTCAAGGAGAAGGCGCTGCGCATAGCCG  
AGGAGCTGGGCATGGACGACTTCACCGCTCCAACGGCTGGCTGGACCGCTTCCGCCGCGCCACGGCGT  
GGTGTCTGACAGCGCGTGGCCCGCGCCCGCGCGGAAACGCTGCCCCCGCACCCCGCGGCGCCTGCC  
25 AGTCCGGCCGCGGTGCCCTCGGAGGGCAGTGGCGGGAGCACTACTGGTTGGCGCGCTCGGGAGGAGCAGC  
CGCGTGGTGGCCGAGGGCTACGCCTCGCAGGACGTGTTACAGCGCCACCGAGACCACTATGGTACGA  
CTTCTGCCCCGACCAGGCCGCGGGGTGTGCGGAGGCGACGACGGCCGCGTCAAGCCACCCAGCGCCTG  
AGCGTCTGTATGCGCCAATGCCGACGCGCAGCAGAGAAGCTGCCCCGCTGGTGGCCGCAAGTCGGCCA  
AGCCCCGCGCAGGCCAAGCCGGCTGCCCTGCGACTACACCGCCAACCTCAAGGGTGGTGTACACCCCA  
30 GGCCCTGGCCAAGTACTTGAAGGCCTTGGACACCCGAATGGCTGCAGAGTCTCGCCGGTCTCTGTGTG  
GCCCGCGCTTGGCTGCCAGTCTTGGACACCTCGGGCTGCGGCATGTGCAGCTGGCCTTCTTCCCTC  
CCGGCACCGTGCATCCGCTGGAGAGGGGAGTGGTCCAGCAGGTGAAGGGCCACTACCGCCAGGCCATGCT  
GCTCAAGGCCATGGCCGCGCTAGAGGGCCAGGATCCCTCAGGCCTGCAGCTGGGTCTCACGGAGGCCCTG  
CACTTTGTGGCTGCCGCTGGCAGGCAGTGGAGCCTTCGGACATAGCCGCTGCTTTCGTGAGGCTGGCT  
35 TTGGGGGTGGCCCTAATGCCACCATCACCCTTCCCTCAAGAGTGAGGGAGAGGAAGAGGAGGAGGAGGA  
GGAAGAAGAGGAGGAGGAAGAGGTTGAAGGAGAGGAAGAGGAGGAGGAAGGGGAGGAGGAGGAGGAA  
GGGGGGAAGGAGAGGAATTGGGGGAGGAAGAGCAGGTGGAGGAGGAGGTTGATGTTGATAGTGATGAAG  
AAGAGGAGGAAGATGAGGAGAGCTCCTCGGAGGGCTTGGAGGCTGAGGACTGGGCCAGGGAGTAGTGGA  
GGCCGTGGCAGCTTCGGGGCTTATGGTGGCCAGGAGGAAGCCAGTGGCCCTACTCTGCATTTCTTGGAA  
40 GGTGGGGAGGACTCTGATTGAGACAGTGAGGAAGAGGACGATGAGGAAGAGGATGATGAAGATGAAGACG  
ACGATGATGATGAGGAGGATGGTGTGAGGTGCCTGTACCCAGCTTTGGGGAGGCCATGGCTTACTTTGC

CATGGTCAAGAGGTACCTGACCTCCTTCCCCATTGATGACCGCGTGCAGAGCCACATCCTCCACTTGGA  
CACGATCTGGTTCATGTGACCAGGAAGAACCACGCCAGGCAGGCGGGAGTTCGAGGTCTTGGACATCAAA  
GCTGAGTCACTGGACCTAGCTGTGCCCCAACCTAGATTGGCAGCACCACCCAGGGCAGAGGACTCTCT  
GGGCACCCGCTGTGCATGGAGCCAGAGTGCAGAGCCCCAGATCCTTTAGTAATGCTTCCCCTGGTCTGC  
5 AACAGGCCCGGTCACCTCGGCCGGGCCCCGGGGCTGAGGTCAGCCTCACTGCCTGCTTATTGCCCTCTTTCT  
CAGAATCCTCTTTCTCCTCCCCATTGGGCCCTGGGCTCAGGGGACCAGGTGGGGCGGGTGGGGAGCTGTCCG  
GTGCTACCACACCGTGCCCTCAGTGGACTAACCACAGCAGCAGCCAGGGATGGGCCCTGGAGGTTCCCGG  
CCGGAGAGTGCTCTCCCCCTTGCCATCCACGTCAGGTCCTTTGGTGGGGGACCCCAAAGCCATTCTGGG  
AAGGGCTCCAGAAGAAGGTCCAGCCTAGGCCCCCTGCAAGGCTGGCAGCCCCACCCCCACCCCCAGGC  
10 CGCCTTGAGAAGCACAGTTTAACTCACTGCGGGCTCCTGAGCCTGCTTCTGCCTGCTTTCCACCTCCCCA  
GTCCCTTTCTCTGGCCCTGTCCATGTGACTTTGGCCCTTGGTTTTCTTTCCAGATTGGAGGTTTCCAAGA  
GGCCCCCACCGTGGAAGTAACCAAGGGCGCTTCCTTGTTGGGCAGCTGCAGGCCCCATGCCTCTCCTCCC  
TCTCTCTGGCAGGGCCCATCCTGGGCAGAGGGCCTGGGGCTGGGCCCAGAGTCCAGCCGTCCAGCTGCT  
CCTTTCCAGTTTGATTTCATAAATCTGTCCACTCCCCCTTTGTGGGGTGAACGTTTTAACAGCCAAG  
15 GGTGCATCCTTCATGGTCTGGGCTTGCGTCTGTCTTGGGGACTTATTCGTCTGGCTCTCTTTGGTCTT  
TGCTCTGGTGGGACATGGAGGCAAGTGTGAGAGGGTTGCCCTGACCGGAAGAGGGCAGGAGGAGACCT  
CAAGCTT

SEQ ID NO: 26

>gi|1628402|emb|X98893|HSTAFII68 H.sapiens mRNA for TBP associated factor, TAFII68

5 GTTGTTCCTCGGCGGGCTGTGGGGCCTCCGCGCCGCGGCCGTTAGTCATGTCGGATTCTGGAAGTTACGGT  
CAGTCTGGGGGTGAGCAGCAAAGTTATTCTACCTATGGAAATCCAGGCAGCCAAGGCTATGGACAAGCAT  
CACAAAGCTATTCTGGCTATGGGCAAACGACTGATTCCTCTTATGGACAGAACTACAGCGGTTACTCCAG  
TTATGGACAAAGTTATTACAGTCCTATGGTGGTTATGAGAATCAAAAGCAGAGCTCATATAGCCAGCAA  
CCATATAATAACCAGGGACAGCAGCAAAACATGGAATCATCAGGAAGCCAAGGTGGAAGAGCACCTTCCT  
10 ATGACCAGCCAGACTATGGTCAACAAGATTTCATATGACCAGCAGTCAGGCTATGATCAACATCAAGGCTC  
ATATGATGAGCAGTCAAATTATGATCAGCAGCATGATTCCTATAGTCAAACCAGCAGTCCTATCATTCA  
CAAAGGGAAACTACAGCCACCACACACAAGATGACCGTCGTGATGTGAGTAGGTATGGAGAAGATAATA  
GAGGATATGGCGGGTCACAGGGAGGAGGTAGAGGGCGTGGGGGATATGACAAGGATGGAAGAGGTCTTAT  
GACAGGATCAAGTGGTGGTGACCGCGGTGGCTTCAAAAATTTTGGTGGTCACAGGGATTATGGACCCAGA  
15 ACAGATGCTGATTGAGAACTCTGATAATTCAGATAACAACACAATCTTTGTGCAAGGACTTGGGGAGGGTG  
TGTCTACAGATCAAGTTGGGGAGTTCCTTAAACAAATAGGAATTATCAAGACAAATAAGAAGACCGGAAA  
ACCAATGATAAATCTTTATACAGACAAGGACACAGGAAAGCCAAAGGGGGAGGCAACAGTGTCAATTTGAT  
GACCCTCCTTCAGCTAAGGCAGCCATTGACTGGTTTGTATGGAAAAGAATTCCATGGCAACATCATTAAG  
TGTCTTTGCCACTAGAAGACCTGAATTCATGAGAGGAGGTGGAAGTGGAGGTGGGCGGCGAGGCCGTGG  
20 AGGATATAGAGGTCGTGGAGGCTTTCAAGGGAGAGGTGGAGACCCCAAAAGTGGGGATTGGGTPTGCCCT  
AATCCGTCATGCGGAAATATGAACTTTGCTCGAAGGAATTCCTGCAATCAGTGCATGAGCCTAGACCAG  
AGGACTCTCGTCCCTCAGGAGGAGATTTCGGGGGAGAGGCTACGCTGGAGAGAGGGGCTACAGAGGTCTG  
CGGGGGCAGAGGTGGAGACCGAGGCGGCTATGGTGGAGACAGAAGTGGGGGTGGCTATGGTGGAGACAGA  
AGCAGCGGTGGTGGCTACAGCGGAGATAGAAGTGGGGGCGGCTATGGTGGAGACAGAAGTGGGGGTGGCT  
25 ATGGTGGGACAGAGGCGGCGGCTATGGTGGGGACAGAGGAGGCGGCTATGGAGGAGACCGAGGAGGTGG  
CTATGGAGGAGATCGAGGTGGCTATGGAGGAGACCGAGGTGGAGGCTATGGTGGAGACCGAGGAGGCTAT  
GGAGGAGATCGAGGAGGTACCGAGGAGATCGAGGAGGTATGGAGGAGATCGAGGAGGCTATGGAGGAG  
ACAGAAGCCGGGGGGGCTATGGAGGAGACCGTGGTGGTGGCAGTGGCTACGGTGGAGACCGAAGTGGAGG  
CTATGGAGGAGACAGGAGTGGTGGCGGCTATGGAGGAGACCGAGGTGGGGGCTACGGAGGAGACCGAGGT  
30 GGCTATGGAGGCAAAATGGGAGGAAGAAACGACTACAGAAATGATCAGCGCAACCGACCATACTGATGAC  
TGTTTTGAATGTTCTTTGTCTCTGACATGATCCATAGTGAAATTGCCAGAGTTTTGCCTGGTGTCTCC  
TCGTGGCCTCTTCTTGGGTAGTGAAATTAAGTGACATTTGGATTTTTATTTGGGTGGGAGGGCTGGGACA  
GTTTTTCTTCTAGAAATGTCTGTTGAGATTTCCCCCTTTAGTTTCCAACCTTCTCCCCAACCTTGGAGC  
TAAATGCGTTGTAAAATATTGCCAAAATGAAAAGTGTTTTGTAACTGCAATAAAGGCTGCTTGTTTTT  
35 GTGGAAAAAAAAAAAAAAAAAAAAA



SEQ ID NO: 27

>gi|219909|dbj|D00017|HUMLIC Homo sapiens mRNA for lipocortin II,  
complete cds

5 CATTGTTGGGACGCTCTCAGCTCTCGGCGCACGGCCAGCTTCCTTCAAAATGTCTACTGTTACGAAATC  
CTGTGCAAGCTCAGCTTGGAGGGTGATCACTCTACACCCCAAGTGCATATGGGTCTGTCAAAGCCTATA  
CTAACTTTGATGCTGAGCGGGATGCTTTGAACATTGAAACAGCCATCAAGACCAAAGGTGTGGATGAGGT  
CACCATTGTCAACATTTTGACCAACCGCAGCAATGCACAGAGACAGGATATTGCCTTCGCCTACCAGAGA  
10 AGGACCAAAAAGGAACTTGCATCAGCACTGAAGTCAGCCTTATCTGGCCACCTGGAGACGGTGATTTTGG  
GCCTATTGAAGACACCTGCTCAGTATGACGCTTCTGAGCTAAAAGCTTCCATGAAGGGGCTGGGAACCGA  
CGAGGACTCTCTCATTGAGATCATCTGCTCCAGAACCAACCAGGAGCTGCAGGAAATTAACAGAGTCTAC  
AAGGAAATGTACAAGACTGATCTGGAGAAGGACATTATTTCCGACACATCTGGTGACTTCCGCAAGCTGA  
TGGTTGCCCTGGCAAAGGGTAGAAGAGCAGAGGATGGCTCTGTCAATTGATTATGAACTGATTGACCAAGA  
TGCTCGGGATCTCTATGACGCTGGAGTGAAGAGGAAAGGAACTGATGTTCCAAGTGGATCAGCATCATG  
15 ACCGAGCGGAGCGTGCCCCACCTCCAGAAAGTATTTGATAGGTACAAGAGTTACAGCCCTTATGACATGT  
TGGAAGCATCAGGAAAGAGGTTAAAGGAGACCTGGAAAATGCTTTCCTGAACCTGGTTCAGTGCATTCA  
GAACAAGCCCCGTGATTTTGTCTGATCGGCTGTATGACTCCATGAAGGGCAAGGGGACGCGAGATAAGGTC  
CTGATCAGAATCATGGTCTCCCGCAGTGAAGTGGACATGTTGAAAATTAGGTCTGAATTCAAGAGAAAGT  
ACGGCAAGTCCCTGTACTATTATATCCAGCAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCT  
20 GTGTGGTGGAGATGACTGAAGCCCGACACGGCCTGAGCGTCCAGAAATGGTGCTCACCATGCTTCCAGCT  
AACAGGTCTAGAAAACCAGCTTGCGAATAACAGTCCCCGTGGCCATCCCTGTGAGGGTGACGTTAGCATT  
ACCCCCAACCTCATTTTAGTTGCCTAAGCATTGCCTGGCCTTCCTGTCTAGTCTCTCCTGTAAGCCAAAG  
AAATGAACATTCCAAGGAGTTGGAAGTGAAGTCTATGATGTGAAACACTTTGCCTCCTGTGTACTGTGTC  
ATAAACAGATGAATAAACTGAATTTGTACTTT

25

SEQ ID NO: 28

>gi|37173|emb|X05615|HSTHYRR Human mRNA for thyroglobulin

5 GCAGTGGTTTCTCCTCCTTCCTCCCAGGAAGGGCCAGGAAAATGGCCCTGGTCCTGGAGATCTTCACCCCT  
GCTGGCCTCCATCTGCTGGGTGTCGGCCAATATCTTCGAGTACCAGGTTGATGCCCAGCCCCTTCGTCCC  
TGTGAGCTGCAGAGGGAAACGGCCTTTCTGAAGCAAGCAGACTACGTGCCCCAGTGTGCAGAGGATGGCA  
GCTTCCAGACTGTCCAGTGCCAGAACGACGGCCGCTCCTGCTGGTGTGTGGGTGCCAACGGCAGTGAAGT  
GCTGGGCAGCAGGCAGCCAGGACGGCCTGTGGCTTGTCTGTCATTTTGTGCTACAGAAAACAGCAGATC  
TTACTGAGTGGCTACATTAACAGCACAGACACCTCCTACCTCCCTCAGTGTGAGGATTCAGGGGACTACG  
10 CGCCTGTTTCAGTGTGATGTGCAGCATGTCCAGTGTGCTGGTGTGTGGACGCAGAGGGGATGGAGGTGTATGG  
GACCCGCCAGCTGGGGAGGCCAAAGCGATGTCCAAGGAGCTGTGAAATAAGAAATCGTCGTCTTCTCCAC  
GGGGTGGGAGATAAGTCACCACCCAGTGTCTGCGGAGGGAGAGTTTATGCCTGTCCAGTGCAAAATTTG  
TCAACACCACAGACATGATGATTTTTGATCTGGTCCACAGCTACAACAGGTTTCCAGATGCATTTGTGAC  
CTTCAGTTCCTTCCAGAGGAGGTTCCCTGAGGTATCTGGGTATTGCCACTGTGCTGACAGCCAAGGGCGG  
15 GAACTGGCTGAGACAGGTTTGGAGTTGTTACTGGATGAAATTTATGACACCATTTTTGCTGGCCTGGACC  
TTCTTCCACCTTCACTGAAACCACCTGTACCGGATACTGCAGAGACGGTTCCCTCGCAGTTCAATCAGT  
CATCTCTGGCAGATTCCGATGCCCCACAAAATGTGAAGTGGAGCGGTTTACAGCAACCAGCTTTGGTCAC  
CCCTATGTTCCAAGCTGCCGCCGAAATGGCGACTATCAGCGGTTGCAGTGCCAGACGGGAGGGCCCTGCT  
GGTGTGTGGACGCCCAGGGGAAGGAAATGCATGGAACCCGGCAGCAAGGGGAGCCGCCATCTTGTGCTGA  
20 AGGCCAATCTTGTGCCTCCGAAAGGCAGCAGGCCTTGTCCAGACTCTACTTTGGGACCTCAGGCTACTTC  
AGCCAGCACGACCTGTTCTCTTCCCCAGAGAAAAGATGGGCCTCTCCAAGAGTAGCCAGATTTGCCACAT  
CCTGCCCCACCCACGATCAAGGAGCTCTTTGTGGACTCTGGGCTTCTCCGCCCAATGGTGGAGGGACAGAG  
CCAACAGTTTTCTGTCTCAGAAAATCTTCTCAAAGAAGCCATCCGAGCAATTTTTCCCTCCCCAGGGCTG  
GCTCGTCTTGCCCTTCAGTTTACCACCAACCCAAAGAGACTCCAGCAAAACCTTTTTTGGAGGGAAATTTT  
25 TGGTGAATGTTGGCCAGTTTAACTTGTCTGGAGCCCTTGGCACAAGAGGCACATTTAACTTCAGTCAATT  
TTTCCAGCAACTTGGTCTTGCAAGCTTCTTGAATGGAGGGAGACAAGAAGATTTGGCCAAGCCACTCTCT  
GTGGGATTAGATTCAAATCTTCCACAGGAACCCCTGAAGCTGCTAAGAAGGATGGTACTATGAATAAGC  
CAACTGTGGGCAGCTTTGGCTTTGAAATTAACCTACAAGAGAACCAAAATGCCCTCAAATTCCTTGCTTC  
TCTCCTGGAGCTTCCAGAATTCCTTCTCTTCTGCAACATGCTATCTCTGTGCCAGAAGATGTGGCAAGA  
30 GATTTAGGTGATGTGATGGAACGGTACTCGACTCCCAGACCTGTGAGCAGACACCTGAAAGGCTATTTG  
TCCCATCATGCACGACAGAAGGAAGCTATGAGGATGTCCAATGCTTTTCCGGAGAGTGCTGGTGTGTGAA  
TTCTTGGGGCAAAGAGCTTCCAGGCTCAAGAGTCAGAGATGGACAGCCAAGGTGCCCCACAGACTGTGAA  
AAGCAAAGGGCTCGCATGCAAAGCCTCATGGGCAGCCAGCCTGCTGGCTCCACCTTGTTTGTCCCTGCTP  
GTACTAGTGAGGGACATTTCTGCCTGTCCAGTGCTTCAACTCAGAGTGCTACTGTGTTGATGCTGAGGG  
35 TCAGGCCATTCTTGAACTCGAAGTGCAATAGGGAAGCCCAAGAAATGCCCCACGCCCTGTCAATTACAG  
TCTGAGCAAGCTTTCTCAGGACGGTGCAGGCCCTGCTCTCTAACTCCAGCATGCTACCCACCCCTTTCCG  
ACACCTACATCCCACAGTGCAGCACCGATGGGCAGTGGAGACAAGTGCAATGCAATGGGCCTCCTGAGCA  
GGTCTTCGAGTTGTACCAACGATGGGAGGCTCAGAACAAGGGCCAGGATCTGACGCCTGCCAAGCTGCTA  
GTGAAGATCATGAGCTACAGAGAAGCAGCTTCCGGAACCTTCAGTCTCTTTATTCAAAGTCTGTATGAGG  
40 CTGGCCAGCAAGATGTCTTCCCGGTGCTGTCAATACCCTTCTCTGCAAGATGTCCCACTAGCAGCACT  
GGAAGGGAACGGCCCCAGCCAGGGAGAATATCCTCCTGGAGCCCTACCTCTTCTGGCAGATCTTAAAT

GGCCAACTCAGCCAATACCCGGGTCCTACTCAGACTTCAGCACTCCTTTGGCACATTTTGATCTTCGGA  
ACTGCTGGTGTGTGGATGAGGCTGGCCAAGAAGCTGGAAGGAATGCGGTCTGAGCCAAGCAAGCTCCCAAC  
GTGTCCTGGCTCCTGTGAGGAAGCAAAGCTCCGTGTACTGCAGTTCATTAGGGAAACGGAAGAGATTGTT  
5 TCAGCTTCCAACAGTTCTCGGTTCCCTCTGGGGGAGAGTTTCTGCTGGCCAAGGGAATCCGGCTGAGGA  
ATGAGGACCTCGGCCTTCTCCGCTCTTCCGCCCCGGGAGGCTTTCGCGGAGTTTCTGCGTGGGAGTGA  
TTACGCCATTTCGCTGGCGGCTCAGTCTACCTTAAGCTTCTATCAGAGACGCCGCTTTTCCCCGGACGAC  
TCGGCTGGAGCATCCGCCCTTCTGCGGTGGGGCCCTACATGCCACAGTGTGATGCGTTTGAAGTTGGG  
AGCCTGTGCAGTGCCACGCTGGGACTGGGCACCTGCTGGTGTGTAGATGAGAAAGGAGGGTTTCATCCCTGG  
10 CTTACTGACTGCCCCGCTCTCTGCAGATTCCACAGTGGCCGACAACCTGCGAGAAATCTCGAACCAGTGGG  
CTGCTTTCCAGTTGGAAACAGGCTAGATCCCAAGAAAACCCATCTCCAAAAGACCTGTTTCGTCCCAGCCT  
GCCTAGAAACAGGAGAATATGCCAGGCTGCAGGCATCGGGGGCTGGCACCTGGTGTGTGGACCTGCATC  
AGGAGAAGAGTTGCGGCCTGGCTCGAGCAGCAGTGGCCAGTGGCCAAGCCTCTGCAATGTGCTCAAGAGT  
GGAGTCTCTCTAGGAGAGTCAGCCCAGGCTATGTCCAGCCTGCAGGGCAGAGGATGGGGGCTTTTCCC  
CAGTGCAATGTGACCAGGCCCAGGGCAGCTGCTGGTGTGTGTCATGGACAGCGGAGAAGAGGTGCCTGGGAC  
15 GCGCGTGACCGGGGCCAGCCCCCTGTGAGAGCCCCGCGGTGTCCGCTGCCATTCAACGCGTCGGAGGTG  
GTTGGTGGAACAATCCTGTGTGAGACAATCTCGGGCCCCACAGGCTCTGCCATGCAGCAGTGGCAATTGC  
TGTGCCGCCAAGGCTCCTGGAGCGTGTTCACCAGGGCCATTGATATGTAGCCTGGAGAGCGGACGCTG  
GGAGTCAAGCTGCCTCAGCCCCGGGCCTGCCAACGGCCCCAGCTGTGGCAGACCATCCAGACCCAAGGG  
CACTTTTCAGCTCCAGCTCCCGCCGGGCAAGATGTGCAGTGTGACTACGCGGGTTTGTGTCAGACTTTCC  
20 AGGTTTTTCATATTGGATGAGCTGACAGCCCCGCGGCTTCTGCCAGATCCAGGTGAAGACTTTTGGCACCTT  
GGTTTTCCATTCTGTCTGCAACAACCTCCTCTGTGCAGGTGGGTGTCTGACCAGGGAGCGTTTAGGAGTG  
AATGTTACATGGAAATCACGGCTTGAGGACATCCAGTGGCTTCTCTTCTGACTTACATGACATTGAGA  
GAGCCTTGGTGGCAAGGATCTCCTTGGGCGCTTACAGATCTGATCCAGAGTGGCTCATTCCAGCTTCA  
TCTGGACTCCAAGACGTTCCAGCGGAAACCATCCGCTTCTCCAAGGGGACCACTTTGGCACCTCTCCT  
25 AGGACACGGTTTGGGTGCTCGGAAGGATTCTACCAAGTCTTGACAAGTGAGGCCAGTCAGGACGGACTGG  
GATGCGTTAAGTGCCATGAAGGAAGCTATTCCCAAGATGAGGAATGCATTCTTGTCTGTGTTGGATTCTA  
CCAAGAACAGGCAGGGAGCTTGGCCTGTGTCCATGTCTGTGGGCAGAACGACCATTCTGCCGGAGCT  
TTCAGCCAGACTCACTGTGTCACTGACTGTGAGAGGAACGAAGCAGGCCTGCAATGTGACCAGAATGGCC  
AGTATCGAGCCAGCCAGAAGGACAGGGGCAGTGGGAAGGCCTTCTGTGTGGACGGCGAGGGGCGGAGGCT  
30 GCCATGGTGGGAAACAGAGGCCCTCTTGAGGACTCACAGTGTGTTGATGATGCAGAAGTTTGAGAAGGTT  
CCAGAATCAAAGGTGATCTTCGACGCCAATGCTCCTGTGGCTGTGAGATCCAAAGTTTCTGATTTCTGAGT  
TCCCCGTGATGCAGTGTGACAGATTGCACAGAGGACGAGGCCTGCAGCTTCTTACCGTGTCCACGAC  
GGAGCCAGAGATTTCTGTGATTTCTATGCTTGGACAAGTGACAATGTTGCTGTCATGACTTCTGACCAG  
AAACGAGATGCACTGGGGAACCAAAGGCCACCAGCTTTGGAAGTCTTCGCTGCCAGGTGAAAGTGAGGA  
35 GCCATGGTCAAGATTCTCCAGCTGTGTATTTGAAAAAGGGCCAAGGATCCACCACAACACTTCAGAAACG  
CTTTGAACCCACTGGTTTCCAAAACATGCTTTCTGGATTGTACAACCCCATTTGTGTTCTCAGCCTCAGGA  
GCCAATCTAACCAGTGTCTACCTCTTCTGTCTTCTTGCATGCGACCGTGATCTGTGTTGCGATGGCTTCG  
TCCTCACACAGGTTCAAGGAGGTGCCATCATCTGTGGGTTGCTGAGCTCACCCAGTGTCTGCTTTGTAA  
TGTCAAAGACTGGATGGATCCCTCTGAAGCCTGGGCTAATGCTACATGTCTGGTGTGACATATGACCAG  
40 GAGAGCCACCAGGTGATATTGCGTCTTGGAGACCAGGAGTTCATCAAGAGTCTGACACCCCTTAGAAGGAA  
CTCAAGACACCTTTACCAATTTTCAGCAGGTTTATCTCTGGAAGATTTCTGACATGGGGTCTCGGCCTGA

GTCTATGGGATGTAGAAAAACACAGTGCCAAGGCCAGCATCTCCAACAGAAGCAGGTTTGACAACAGAA  
CTTTTCTCCCTGTGGACCTCAACCAGGTCAATTGTCAATGGAAATCAATCACTATCCAGCCAGAAGCACT  
GGCTTTTCAAGCACCTGTTTTTCAGCCCAGCAGGCAAACCTATGGTGCCTTTCTCGTTGTGTGCAGGAGCA  
CTCTTTCTGTACAGCTCGCAGAGATAACAGAGAGTGCATCCTTGTACTTCACCTGCACCCTCTACCCAGAG  
5 GCACAGGTGTGTGATGACATCATGGAGTCCAATACCCAGGGCTGCAGACTGATCCTGCCTCAGATGCCAA  
AGGCCCTGTTCCGGAAGAAAGTTATACTGGAAGATAAAGTGAAGAACTTTTACACTCGCCTGCCGTTCGA  
AAAAGTATGGGGATATCCATTAGAAATAAAGTGCCCATGTCTGAAAAATCTATTTCTAATGGGTTCTTT  
GAATGTGAACGACGGTGCGATGCGGACCCATGCTGCACTGGCTTTGGATTCTAAATGTTTCCAGTTAA  
AAGGAGGAGAGGTGACATGTCTCACTCTGAACAGCTTGGGAATTCAGATGTGCAGTGAGGAGAATGGAGG  
10 AGCCTGGCGCATTTTGGACTGTGGCTCTCCTGACATTGAAGTCCACACCTATCCCTTCGGATGGTACCAG  
AAGCCCATTTGCTCAAAATAATGCTCCAGTTTTTGGCCCTTGGTTGTCTGCCTTCCCTCACAGAGAAAG  
TGTCTCTGGAATCGTGGCAGTCCCTGGCCCTCTCTTCAGTGGTTGTTGATCCATCCATTAGGCACTTTGA  
TGTGCCCATGTACAGACTGCTGCCACCAGCAATTTCTCTGCTGTCCGAGACCTCTGTTTGTCCGAATGT  
TCCCAACATGAGGCCCTGTCTCATCACCCTCTGCAAACCAACTCGGGGCTGTGAGATGTATGTTCTATG  
15 CTGATACTCAAAGCTGCACACATAGTCTGCAGGGTCGGAACGCCGACTTCTGCTTCGTGAAGAGGCCAC  
CCACATCTACCGGAAGCCAGGAATCTCTCTGCTCAGCTATGAGGCATCTGTACCTTCTGTGCCATTTCC  
ACCCATGGCCGGCTGTGGGCAGGTCCCAGGCCATCCAGGTGGGTACCTCATGGAAGCAAGTGGACCAGT  
TCCTTGGAGTTCCATATGCTGCCCCGCCCTGGCAGAGAGGCACTTCCAGGCACCAGAGCCCTTGAAGT  
GACAGGCTCCTGGGATGCCAGCAAGCCAAGGGCCAGCTGCTGGCAGCCAGGCACCAGAACATCCACGTCT  
20 CCTGGAGTCAGTGAAGATTGTTTGTATCTCAATGTGTTTCATCCCTCAGAATGTGGCCCCCTAACCGCTCTG  
TGCTGGTGTCTTCCACAACACCATGGACAGGGAGGAGTGAAGGATGGCCGGCTATCGACGGCTCCTT  
CTTGGCTGTGTTGGCAACCTCATCGTGGTCACTGCCAGTACCGAGTGGGTGTCTTCGGCTTCTGAGT  
TCTGGATCCGGAGAGGTGAGTGGCAACTGGGGGCTGCTGGACCAGGTGGCGGCTCTGACCTGGGTGCAGA  
CCCACATCCGAGGATTTGGCGGGGACCCTCGGCGCTGTCCCTGGCAGCAGACCCTGGCGGGGCTGATGT  
25 GGCCAGCATCCACCTTCTCACGGCCAGGGCCACCAACTCCCAACTTTTCCGGAGAGCTGTGCTGATGGGA  
GGCTCCGCACTCTCCCCGGCCGGCTCATCAGCCATGAGAGGGCTCAGCAGCAGGCAATTGCTTTGGCAA  
AGGAGGTCAAGTGGCCCCATGTATCCAGCCAAGAAGTGGTGTCTGCCTCCGCCAGAAGCCTGCCAATGT  
CCTCAATGATGCCAGACCAAGCTCCTGGCCGTGAGTGGCCCTTTCCACTACTGGGGTCTGTGATCGAT  
GGCCACTTCTCCGTGAGCCTCCAGCCAGAGCACTGAAGAGGTCTTTATGGGTAGAGGTGATCTGCTCA  
30 TTGGGAGTTCTCAGGACGACGGGCTCATCAACAGAGCAAAGGCTGTGAAGCAATTGAGGAAAGTCGAGG  
CCGGACCAGTAGCAAAACAGCCTTTTACCAGGCACCTGCAGAATCTCTGGGTGGCGAGGACTCAGATGCC  
CGCGTCGAGGCTGCTGCTACATGGTATTACTCTCTGGAGCACTCCACGGATGACTATGCCTCCTTCTCCC  
GGGCTCTGGAGAATGCCACCGGGACTACTTTATCATCTGCCCTATAATCGACATGGCCAGTGCCTGGGC  
AAAGAGGGCCCCGAGGAAACGTCTTCATGTACCATGCTCCTGAAAACCTACGGCCATGGCAGCCTGGAGCTG  
35 CTGGCGGATGTTTCAGTTTGCTTGGGGCTTCCCTTCTACCCAGCCTACGAGGGGAGTTTCTCTGGAGG  
AGAAGAGCCTGTGCTGAAAATCATGCAGTACTTTTCCCACTTCATCAGATCAGGAAATCCCAACTACCC  
TTATGAGTTCTCACGGAAGTACCCACATTTGCAACCCCTGGCCTGACTTTGTACCCCGTGTGGTGA  
GAGAACTACAAGGAGTTCAAGTGTGCTCCCCAATCGACAGGGCCTGAAGAAAGCCGACTGCTCCTTCT  
GGTCCAAGTACATCTCGTCTCTGAAGACATCTGCAGATGGAGCCAAGGGCGGGCAGTCAGCAGAGAGTGA  
40 AGAGGAGGAGTTGACGGCTGGATCTGGGCTAAGAGAAGATCTCCTAAGCCTCCAGGAACCAGGCTCTAAG  
ACCTACAGCAAGTGACCAGCCCTTGAGCTCCCCAAAACCTCACCCGAGGCTGCCACTATGGTCATCTT

TTTCTCTAAAATAGTTACTTACCTTCAATAAAGTATCTACATGCGGTG

SEQ ID NO: 29

5

10

15

>gi|339688|gb|M17733|HUMTHYB4 Human thymosin beta-4 mRNA, complete cds  
ACAACTCGGTGGTGGCCACTGCGCAGACCAGACTTCGCTCGTACTCGTGCGCCTCGCTTCGCTTTTCCTC  
CGCAACCATGTCTGACAAACCCGATATGGCTGAGATCGAGAAATTCGATAAGTCGAAACTGAAGAAGACA  
GAGACGCAAGAGAAAAATCCACTGCCCTTCCAAAGAAACGATTGAACAGGAGAAGCAAGCAGGCGAATCGT  
AATGAGGCGTGCGCCGCAATATGCACTGTACATTCACAAGCATTCGCTTCTTATTTTACTTCTTTTAG  
CTGTTTAACTTTGTAAGATGCAAAGAGGTTGGATCAAGTTTAAATGACTGTGCTGCCCCCTTTCACATCAA  
AGAACTACTGACAACGAAGGCCGCGCTGCCCTTCCCATCTGTCTATCTATCTGGCTGGCAGGGAAGGAAA  
GAACTTGCATGTTGGTGAAGGAAGAAGTGGGGTGAAGAAGTGGGGTGGGACGACAGTGAAATCTAGAGT  
AAAACCAAGCTGGCCCAAGTGTCTGCAGGCTGTAATGCAGTTTAAATCAGAGTGCCATTTTTTTTTT

SEQ ID NO: 30

20

25

30

35

40

>gi|1743866|gb|U70063|HSU70063 Human acid ceramidase mRNA, complete  
cds  
GGCAGGAGGCTAGAGCGATGCCGGGCCGAGTTGCGTCGCCTTAGTCCTCCTGGCTGCCGCCGTCAGCTG  
TGCCGTCGCGCAGCACGCGCCGCGCTGGACAGAGGACTGCAGAAAATCAACCTATCCTCCTTCAGGACCA  
ACGTACAGAGGTGCAGTTCCATGGTACACCATAAATCTTGACTTACCACCCTACAAAAGATGGCATGAAT  
TGATGCTTGACAAGGCACCAATGCTAAAGGTTATAGTGAATTCTCTGAAGAATATGATAAATACATTCGT  
GCCAAGTGGAAAAGTTATGCAGGTGGTGGATGAAAAATTCGCTGGCCTACTTGGCAACTTTTCCTGGCCCT  
TTTGAAGAGGAAATGAAGGGTATTGCCGCTGTTACTGATATACCTTTAGGAGAGATTATTTTCATTCAATA  
TTTTTTTATGAATTATTTACCATTGTACTTCAATAGTAGCAGAAGACAAAAAAGGCATCTAATACATGG  
GAGAAACATGGATTTTGGAGTATTTCTTGGGTGGAACATAAATAATGATACCTGGGTGATAACTGAGCAA  
CTAAAACCTTTAACAGTGAATTTGGATTTCCAAAGAAACAACAAACTGTCTTCAAGGCTTCAAGCTTTC  
CTGGCTATGTGGGCATGTTAACAGGATTCAAACCAGGACTGTTTCAGTCTTACACTGAATGAACGTTTCAG  
TATAAATGGTGGTTATCTGGGTATTCTAGAATGGATTCTGGGAAAGAAAGATGCCATGTGGATAGGGTTC  
CTCACTAGAACAGTTCTGGAAAATAGCACAAGTTATGAAGAAGCCAAGAATTTATTGACCAAGACCAAGA  
TATTGGCCCCAGCCTACTTTATCCTGGGAGGCAACCAGTCTGGGGAAGGTTGTGTGATTACACGAGACAG  
AAAGGAATCATTTGGATGTATATGAACTCGATGCTAAGCAGGGTAGATGGTATGTGGTACAAACAAATTAT  
GACCGTTGGAAACATCCCTTCTTCCCTTGATGATCGCAGAACGCCTGCAAAGATGTGTCTGAACCGCACCA  
GCCAAGAGAATATCTCATTTGAAACCATGTATGATGTCTGTCAACAAAACCTGTCTCAACAAGCTGAC  
CGTATACACAACCTTGATAGATGTTACCAAAGGTCAATTCGAAACTTACCTGCGGGACTGCCCTGACCCCT  
TGTATAGGTTGGTGAACACAGTCTGGCCTACAGAATCGGCCTCTGAGACATGAAGACACCATCTCCAT  
GTGACCGAACACTGCAGCTGTCTGACCTTCCAAAGACTAAGACTCGCGGCAGGTTCTCTTTGAGTCAATA  
GCTTGTCTTCGTCCATCTGTTGACAAATGACAGATCTTTTTTTTTTCCCCCTATCAGTTGATTTTTCTT  
ATTTACAGATAACTTCTTTAGGGGAAGTAAAACAGTCATCTAGAATTCAGTGGTTTGTTCACCTTGA

5 CATTGTTGGGATCTGGTGGGCACTCGAACCATGGTGAACCTCCACCTCCGTGGAATAAATGGAGATTCAGCG  
TGGGTGTTGAATCCAGCACGTCTGTGTGAGTAACGGGACAGTAAACACTCCACATTCCTCAGTTTTTCAC  
TTCTACCTACATATTTGTATGTTTTCTGTATAACAGCCTTTTCCTTCTGGTTCTAACTGCTGTTAAAT  
TAATATATCATTATCTTTGCTGTTATTGACAGCGATATTATTTATTACATATCATTAGAGGGATGAGAC  
AGACATTCACCTGTATATTTCTTTTAATGGGCACAAAATGGGCCCTTGCCTCTAAATAGCACTTTTTCCG  
GTTCAAGAAGTAATCAGTATGCAAAGCAATCTTTTATACAATAATTGAAGTGTCCCTTTTTCATAATTA  
CTCTACTTCCCAGTAACCCTAAGGAAGTTGCTAACTTAAAAAACTGCATCCCACGTTCTGTTAATTTAGT  
AAATAAACAAAGTCAAAGACTTGTGGAAAATAGGAAGTGAACCCATATTTTAAATTCTCATAAGTAGCATT  
GATGTAATAAACAGGTTTTTAGTTTGTCTTCAGATTGATAGGGAGTTTTAAAGAAATTTTAGTAGTTAC  
10 TAAAATTATGTTACTGTATTTTTCAGAAATCAAACCTGCTTATGAAAAGTACTAATAGAACCTGTTAACCT  
TTCTAACCTTCACGATTAACGTGTGAAATGTACGTCATTTGTGCAAGACCGTTTGTCCACTTCATTTTGTA  
TAATCACAGTTGTGTTCTTGACACTCAATAAACAGTCACTGGAAAGAGTGCCAGTCAGCAGTCATGCACG  
CTGATAAAAAAAAAAAAAAAAAA

15

SEQ ID NO:31 -- Oligo N1, Ki67 sense, Nhe, 6His, 5610:  
ATTGCTAGCCACCACCACCACCACCAAACTGGACCCAGCAGCAAGTGTAAC

20

SEQ ID NO: 32 -- Oligo N2, Ki67 antisense, EcoRI, 6420:  
CGGGAATTCCTATAGAGCCTCAGCCTTTTCCTTAGG

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**